<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001302.pub3" GROUP_ID="MENSTR" ID="376299092817002632" MERGED_FROM="" MODIFIED="2016-11-04 03:30:12 +0000" MODIFIED_BY="Helen Nagels" NOTES="&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): IV albumin for prevention of severe OHSS&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-11-04 14:39:20 +1300" NOTES_MODIFIED_BY="Helen E Nagels" REVIEW_NO="PMA481" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2016-11-04 03:30:11 +0000" MODIFIED_BY="Helen Nagels">
<TITLE MODIFIED="2015-11-30 14:27:11 +1300" MODIFIED_BY="[Empty name]">Volume expanders for the prevention of ovarian hyperstimulation syndrome</TITLE>
<CONTACT MODIFIED="2016-11-04 03:30:11 +0000" MODIFIED_BY="Helen Nagels"><PERSON ID="30E89DD682E26AA200E3043B171C4937" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>MA</FIRST_NAME><LAST_NAME>Youssef</LAST_NAME><POSITION>Assistant professor</POSITION><EMAIL_1>mohamedyoussef1973@gmail.com</EMAIL_1><EMAIL_2>m.a.youssef@amc.uva.nl</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>Faculty of Medicine, Cairo University</ORGANISATION><CITY>Cairo</CITY><COUNTRY CODE="EG">Egypt</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-11-04 03:30:11 +0000" MODIFIED_BY="Helen Nagels"><PERSON ID="30E89DD682E26AA200E3043B171C4937" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>MA</FIRST_NAME><LAST_NAME>Youssef</LAST_NAME><POSITION>Assistant professor</POSITION><EMAIL_1>mohamedyoussef1973@gmail.com</EMAIL_1><EMAIL_2>m.a.youssef@amc.uva.nl</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>Faculty of Medicine, Cairo University</ORGANISATION><CITY>Cairo</CITY><COUNTRY CODE="EG">Egypt</COUNTRY></ADDRESS></PERSON><PERSON ID="z1507270644522416744735676726611" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Selma</FIRST_NAME><LAST_NAME>Mourad</LAST_NAME><POSITION>Resident in Obstetrics and Gynaecology</POSITION><EMAIL_1>Selma.Mourad@radboudumc.nl</EMAIL_1><ADDRESS><ORGANISATION>Radboud University Medical Centre</ORGANISATION><CITY>Nijmegen</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-08-08 10:35:22 +1200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="2" MONTH="9" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="9" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="9" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-11-04 14:39:20 +1300" MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-11-04 14:39:20 +1300" MODIFIED_BY="Helen E Nagels">
<DATE DAY="4" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>Further evidence is unlikely to change the conclusions of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-11-04 14:39:09 +1300" MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-11-04 14:39:06 +1300" MODIFIED_BY="Helen E Nagels">
<DATE DAY="29" MONTH="8" YEAR="2016"/>
<DESCRIPTION>
<P>The revision of evidence and addition of a new comparison have led to a change in the conclusions of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-11-04 14:39:09 +1300" MODIFIED_BY="Helen E Nagels">
<DATE DAY="9" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>New search. The title has been amended to reflect differences in the inclusion criteria and change to moderate or severe OHSS as the primary outcome (previously just severe OHSS). One study added for one new comparison (mannitol versus no treatment; <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>). Exclusion of suspected duplicate data. Extra author added. 'Summary of findings' table added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-09-09 13:51:48 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-09-10 12:26:12 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>The title was changed from Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome to Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-09-03 11:22:27 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Five RCTs were added</P>
<P>New comparisons</P>
<P>1- Between hydroxyethyl starch versus placebo</P>
<P>2- Overall comparison of IV fluid stratified by the nature of intervention</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-09-03 11:22:34 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>The conclusion has changed and a new author was added with change of authors' order</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-18 09:08:14 +1200" MODIFIED_BY="jane clarke">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-11-11 14:25:24 +1300" MODIFIED_BY="Julie A Brown">
<INTERNAL_SOURCES MODIFIED="2008-11-11 14:25:24 +1300" MODIFIED_BY="Julie A Brown">
<SOURCE MODIFIED="2008-11-11 14:25:24 +1300" MODIFIED_BY="Julie A Brown">
<NAME>None specified by review author</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-08-25 15:25:37 +1200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-08-25 15:25:37 +1200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">Intravenous plasma expanders for preventing ovarian hyperstimulation syndrome (OHSS)</TITLE>
<SUMMARY_BODY MODIFIED="2016-08-25 15:25:37 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Researchers in the Cochrane Collaboration reviewed the evidence on different types of volume expanders in women at high risk of OHSS undergoing ovarian hyperstimulation as part of any assisted reproductive technique (ART). Women with very high estradiol levels, high numbers of follicles or oocytes retrieved, and women with polycystic ovary syndrome (PCOS), are at particularly high risk of developing OHSS.</P>
<P>
<B>Background</B>
</P>
<P>OHSS is a serious complication of ovarian stimulation, which affects up to 14% of ART cycles. It is characterised by enlarged ovaries following excessive hormonal stimulation resulting in a shift of fluid from the blood vessels to the extracellular space. It can cause abdominal bloating, blood clots (thrombosis) and reduced perfusion of vital organs like the kidneys and liver. Several clinical studies have reported on the use of intravenous fluids such as albumin and hydroxyethyl starch (HES), as a possible way of preventing OHSS.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We found nine randomised controlled trials (RCTs) which compared the use of volume expanders (albumin, HES and mannitol) for preventing moderate or severe OHSS. Control groups received no treatment or placebo. The studies included 1867 women at high risk of OHSS. The evidence is current to September 2015.</P>
<P>
<B>Key results</B>
</P>
<P>Evidence suggests that plasma expanders (human albumin, HES and mannitol) reduce rates of moderate and severe OHSS in women at high risk.</P>
<P>If the rate of OHSS without treatment is 12%, it will be about 9% (6% to 12%) with the use of intravenous albumin. If the rate of OHSS without treatment is 16%, it will be about 5% (2% to 10%) with the use of HES, and if the rate without treatment is 52%, it will be about 29% (19% to 41%) with mannitol.</P>
<P>Adverse events appear to be uncommon, but were too poorly reported to reach firm conclusions. No studies reported live birth, but there was evidence that human albumin reduces pregnancy rates. While there was no evidence that HES, or mannitol had any influence on pregnancy rates, the evidence of effectiveness was based on very few trials, and better evidence is needed before they should be considered for routine use in clinical practice.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The evidence was very low to moderate quality for all comparisons. The main limitations were imprecision, poor reporting of study methods, and failure to blind outcome assessment.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-08-25 15:17:26 +1200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-08-18 00:23:28 +1200" MODIFIED_BY="[Empty name]">
<P>Ovarian hyperstimulation syndrome (OHSS) is a serious and potentially fatal complication of ovarian stimulation which affects 1% to 14% of all in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles. A number of clinical studies with conflicting results have reported on the use of plasma expanders such as albumin, hydroxyethyl starch (HES), mannitol, polygeline and dextran as a possible intervention for the prevention of OHSS. Women with very high estradiol levels, high numbers of follicles or oocytes retrieved, and women with polycystic ovary syndrome (PCOS), are at particularly high risk of developing OHSS. Plasma expanders are not commonly used nowadays in ovarian hyperstimulation. This is mainly because clinical evidence on their effectiveness remains sparse, because of the low incidence of moderate and severe ovarian hyperstimulation syndrome (OHSS) and the simultaneous introduction of mild stimulation approaches, gonadotropin-releasing hormone (GnRH) antagonist protocols and the freeze-all strategy for the prevention of OHSS.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-06-30 00:36:17 +1200" MODIFIED_BY="Heather Maxwell">
<P>To review the effectiveness and safety of administration of volume expanders for the prevention of moderate and severe ovarian hyperstimulation syndrome (OHSS) in high-risk women undergoing IVF or ICSI treatment cycles.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-06-30 00:36:32 +1200" MODIFIED_BY="Heather Maxwell">
<P>We searched databases including the Cochrane Gynaecology and Fertility Group Specialised Register of controlled trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and trial registers to September 2015; no date restrictions were used as new comparators were included in this search. The references of relevant publications were also searched. We attempted to contact authors to provide or clarify data that were unclear from trial or abstract reports.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-08-10 13:10:55 +1200" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) comparing volume expanders versus placebo or no treatment for the prevention of OHSS in high-risk women undergoing ovarian hyperstimulation as part of any assisted reproductive technique.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-08-10 13:11:23 +1200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently selected the studies, assessed risk of bias and extracted relevant data. The primary review outcome was moderate or severe OHSS. Other outcomes were live birth, pregnancy and adverse events. We combined data to calculate pooled Peto odds ratios (ORs) and 95% confidence intervals (CIs) for each intervention. Statistical heterogeneity was assessed using the I<SUP>2</SUP> statistic. We assessed the overall quality of the evidence for each comparison, using GRADE methods.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-08-25 15:12:46 +1200" MODIFIED_BY="[Empty name]">
<P>We included nine RCTs (1867 women) comparing human albumin (seven RCTs) or HES (two RCTs) or mannitol (one RCT) versus placebo or no treatment for prevention of OHSS. The evidence was very low to moderate quality for all comparisons. The main limitations were imprecision, poor reporting of study methods, and failure to blind outcome assessment.</P>
<P>There was evidence of a beneficial effect of intravenous albumin on OHSS, though heterogeneity was substantial (Peto OR 0.67 95% CI 0.47 to 0.95, seven studies, 1452 high risk women; I² = 69%, very low quality evidence) . This suggests that if the rate of moderate or severe OHSS with no treatment is 12%, it will be about 9% (6% to12%) with the use of intravenous albumin. However, there was evidence of a detrimental effect on pregnancy rates (Peto OR 0.72 95% CI 0.55 to 0.94, I² = 42%, seven studies 1069 high risk women, moderate quality evidence). This suggests that if the chance of pregnancy is 40% without treatment, it will be about 32% (27% to 38%) with the use of albumin.</P>
<P>There was evidence of a beneficial effect of HES on OHSS (Peto OR 0.27 95% CI 0.12 to 0.59, I² = 0%, two studies, 272 women, very low quality evidence). This suggests that if the rate of moderate or severe OHSS with no treatment is 16%, it will be about 5% (2% to 10%) with the use of HES. There was no evidence of an effect on pregnancy rates (Peto OR 1.20 95% CI 0.49 to 2.93, one study, 168 women, very low quality evidence).</P>
<P>There was evidence of a beneficial effect of mannitol on OHSS (Peto OR 0.38, 95% CI 0.22 to 0.64, one study, 226 women with PCOS, low quality evidence). This means that if the risk of moderate or severe OHSS with no treatment is 52%, it will be about 29% (19% to 41%) with mannitol. There was no evidence of an effect on pregnancy rates (Peto OR 0.85 95% CI 0.47 to 1.55; one study, 226 women, low quality evidence).</P>
<P>Live birth rates were not reported in any of the studies. Adverse events appeared to be uncommon, but were too poorly reported to reach any firm conclusions.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-08-25 15:17:26 +1200" MODIFIED_BY="[Empty name]">
<P>Evidence suggests that the plasma expanders assessed in this review (human albumin, HES and mannitol) reduce rates of moderate and severe OHSS in women at high risk. Adverse events appear to be uncommon, but were too poorly reported to reach any firm conclusions, and there were no data on live birth. However, there was evidence that human albumin reduces pregnancy rates. While there was no evidence that HES, or mannitol had any influence on pregnancy rates, the evidence of effectiveness was based on very few trials which need to be confirmed in additional, larger randomised controlled trials (RCTs) before they should be considered for routine use in clinical practice.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-08-25 15:17:23 +1200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-06-30 00:40:37 +1200" MODIFIED_BY="Heather Maxwell">
<P>Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic, serious and potentially fatal complication of ovarian stimulation which affects 1% to 14% of all in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles (<LINK REF="REF-Garcia_x002d_Velasco-2003" TYPE="REFERENCE">Garcia-Velasco 2003</LINK>). OHSS may be associated with massive ovarian enlargement, extracellular exudate accumulation combined with profound intravascular volume depletion, ascites, hydrothorax, haemoconcentration, liver dysfunction and renal failure (<LINK REF="REF-Aboulghar-2003" TYPE="REFERENCE">Aboulghar 2003</LINK>; <LINK REF="REF-Vloeberghs-2009" TYPE="REFERENCE">Vloeberghs 2009</LINK>). It can lead to cancellation of an IVF cycle and prolonged bed rest or hospitalisation, which may have significant emotional, social, and economic impacts (<LINK REF="REF-Delvigne-2002" TYPE="REFERENCE">Delvigne 2002</LINK>; <LINK REF="REF-Engmann-2008" TYPE="REFERENCE">Engmann 2008</LINK>). OHSS can be classified into an early form that is related to the ovarian response and exogenous human chorionic gonadotrophin (hCG) administration, and is detected three to nine days after hCG administration. A late form of OHSS, diagnosed 10 to 17 days later, is due to endogenous hCG (<LINK REF="REF-Mathur-2000" TYPE="REFERENCE">Mathur 2000</LINK>) and is categorised as mild, moderate, severe or life-threatening. The aetiology of OHSS is not completely clear at this moment; however the syndrome is strongly associated with serum hCG and certain vasoactive substances (<LINK REF="REF-Enskog-2001" TYPE="REFERENCE">Enskog 2001</LINK>; <LINK REF="REF-Rizk-1997" TYPE="REFERENCE">Rizk 1997</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-06-30 00:40:46 +1200" MODIFIED_BY="Heather Maxwell">
<P>Many strategies have been tried to prevent OHSS and cycle cancellation such as coasting (withholding gonadotrophins before the ovulation trigger is given) (<LINK REF="REF-D_x0027_Angelo-2011" TYPE="REFERENCE">D'Angelo 2011</LINK>), gonadotropin-releasing hormone (GnRH) agonist as an oocyte trigger in GnRH antagonist cycles (<LINK REF="REF-Kol-2008" TYPE="REFERENCE">Kol 2008</LINK>; <LINK REF="REF-Youssef-2014" TYPE="REFERENCE">Youssef 2014</LINK>), natural cycle IVF (<LINK REF="REF-Edwards-2007" TYPE="REFERENCE">Edwards 2007</LINK>), cabergoline (<LINK REF="REF-Tang-2012" TYPE="REFERENCE">Tang 2012</LINK>), embryo freezing (<LINK REF="REF-D_x0027_Angelo-2007" TYPE="REFERENCE">D'Angelo 2007</LINK>), and in vitro oocyte maturation (<LINK REF="REF-Loutradis-2006" TYPE="REFERENCE">Loutradis 2006</LINK>). Unfortunately, none of the strategies currently employed completely prevent OHSS after hCG administration (<LINK REF="REF-Egbase-2000" TYPE="REFERENCE">Egbase 2000</LINK>). Recently the role of vascular endothelial growth factor (VEGF), as mediator of hCG-dependent ovarian angiogenesis, has emerged (<LINK REF="REF-Cerrilo-2009" TYPE="REFERENCE">Cerrilo 2009</LINK>). VEGF is expressed in human ovaries (<LINK REF="REF-Yan-1993" TYPE="REFERENCE">Yan 1993</LINK>) and levels significantly increase after hCG administration leading to increased vascular permeability (<LINK REF="REF-Foong-2006" TYPE="REFERENCE">Foong 2006</LINK>). It has been proposed that the administration of intravenous fluids such as human albumin, hydroxyethyl starch (HES), dextran or polygeline might result in a restoration of intravascular volume and inactivation of the vasoactive intermediates responsible for the pathogenesis of OHSS (<LINK REF="STD-Asch-1993" TYPE="STUDY">Asch 1993</LINK>; <LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-Isik-1997" TYPE="STUDY">Isik 1997</LINK>; <LINK REF="STD-Kissler-2001" TYPE="STUDY">Kissler 2001</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-06-30 01:07:43 +1200" MODIFIED_BY="Heather Maxwell">
<P>Albumin has both osmotic and transport functions. It contributes about 75% of the plasma oncotic pressure and administration of 50 g human albumin solution will draw more than 800 mL of extracellular fluid into the circulation within 15 minutes (<LINK REF="REF-McClelland-1990" TYPE="REFERENCE">McClelland 1990</LINK>). It has been suggested that the binding and transport properties of human albumin play a major role in the prevention of severe OHSS, as albumin may result in binding and inactivation of the vasoactive intermediates responsible for the pathogenesis of OHSS. The osmotic function is responsible for maintaining the intra-vascular volume in the event of capillary leakage, thus preventing the sequelae of hypovolaemia, ascites and haemoconcentration (<LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>).</P>
<P>Hydroxyethyl starch (HES) is a plasma expander that has gained recent attention as an alternative to albumin in reducing the incidence of severe OHSS. Because HES is a non-biological substance, its use avoids any potential concern about viral transmission that may be present with albumin (<LINK REF="STD-Abramov-2001" TYPE="STUDY">Abramov 2001</LINK>; <LINK REF="REF-Chen-2003a" TYPE="REFERENCE">Chen 2003a</LINK>).</P>
<P>Dextran is a complex, branched glucan composed of chains of varying lengths. It is used as an antithrombotic, to reduce blood viscosity, and as a volume expander in anaemia (<LINK REF="STD-Endo-2004" TYPE="STUDY">Endo 2004</LINK>).</P>
<P>Polygeline is a type of intravenous colloid with 3.5% urea-linked gelatin used to treat OHSS (<LINK REF="STD-Gamzu-2002" TYPE="STUDY">Gamzu 2002</LINK>). It is used in the prevention or treatment of shock associated with reduction in effective circulating blood volume due to haemorrhage, loss of plasma or loss of water and electrolytes from persistent vomiting and diarrhoea.</P>
<P>Mannitol is a naturally occurring sugar alcohol used for its osmotic diuretic purposes; it is used as plasma expander for the protection of renal failure and in cases of intracerebral oedema (<LINK REF="REF-Shawkat-2012" TYPE="REFERENCE">Shawkat 2012</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>OHSS is one of the most common adverse effects of assisted reproductive technology-controlled ovarian hyperstimulation (ART-COH) cycles. OHSS can result in hospital admission and in some cases in critical illness. Therefore the aim of this review is to evaluate the evidence from randomised controlled trials (RCTs) to determine whether volume expanders can reduce the incidence of moderate and severe OHSS in high-risk women undergoing IVF/ICSI treatment This review provides a new evidence base for physicians and stakeholders considering the use of plasma expanders in women at high risk of developing OHSS who are undergoing IVF/ICSI treatment.</P>
<P>This is an update of a Cochrane review first published in 1999, and previously updated in 2002 and 2011. This is the first update that aims to report 'moderate or severe OHSS' as a primary outcome, as opposed to the original primary outcome of 'severe OHSS'.<BR/>
</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-06-30 00:41:11 +1200" MODIFIED_BY="Heather Maxwell">
<P>To investigate the effectiveness and safety of administration of volume expanders in the prevention of moderate and severe ovarian hyperstimulation syndrome (OHSS) in high-risk women undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-08-18 00:29:00 +1200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-06-30 00:41:18 +1200" MODIFIED_BY="Heather Maxwell">
<P>Published and unpublished randomised controlled trials (RCTs).</P>
<P>We excluded non-randomised and quasi-randomised studies (e.g. studies with evidence of inadequate sequence generation such as alternate days, patient numbers) as they are associated with a high risk of bias.</P>
<P>Cross-over studies were not eligible for inclusion, as the design is not valid in this context.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-06-30 00:41:27 +1200" MODIFIED_BY="Heather Maxwell">
<P>Women of reproductive age who were having controlled ovarian hyperstimulation as part of any assisted reproductive technique and were considered to be at high risk of moderate or severe OHSS (as determined by either a diagnosis of polycystic ovary syndrome (PCOS) (criterion new to the 2016 update), a specific threshold serum estradiol level, a threshold number of follicles on day of human chorionic gonadotrophin (hCG) administration or threshold number of retrieved oocytes (as defined in individual studies).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-06-30 00:41:27 +1200" MODIFIED_BY="Heather Maxwell">
<P>All kinds of volume expanders used in the prevention of OHSS versus placebo or no treatment. Administration can be at any time in the cycle (e.g. prior to or after oocyte pick-up).</P>
<P>For example:</P>
<UL>
<LI>Intravenous albumin versus placebo or no treatment</LI>
<LI>Hydroxyethyl starch (HES) versus placebo or no treatment</LI>
<LI>Mannitol versus placebo or no treatment</LI>
<LI>Polygeline versus placebo or no treatment</LI>
<LI>Dextran versus placebo or no treatment</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-08-18 00:29:00 +1200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-08-18 00:29:00 +1200" MODIFIED_BY="[Empty name]">
<P>1. Moderate or severe OHSS (as determined by established clinical criteria, such as <LINK REF="REF-Humaidan-2010" TYPE="REFERENCE">Humaidan 2010</LINK>; <LINK REF="REF-Rizk-1999" TYPE="REFERENCE">Rizk 1999</LINK>; <LINK REF="REF-Navot-1992" TYPE="REFERENCE">Navot 1992</LINK>; <LINK REF="REF-Golan-1989" TYPE="REFERENCE">Golan 1989</LINK>; <LINK REF="REF-Schenker-1978" TYPE="REFERENCE">Schenker 1978</LINK>; <LINK REF="REF-WHO-1973" TYPE="REFERENCE">WHO 1973</LINK>)</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-08-10 13:55:13 +1200" MODIFIED_BY="[Empty name]">
<P>2. Live birth rate per woman randomised</P>
<P>3. Pregnancy rate per woman randomised (as confirmed by &#946;-hCG or pregnancy test or ultrasonic visualisation of fetal heart beat at a certain gestational age (as defined in the separate studies))</P>
<P>4. Adverse effects of treatment (e.g. allergic reaction)</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-08-10 09:16:13 +1200" MODIFIED_BY="[Empty name]">
<P>We searched for published and unpublished RCTs of diverse intravenous fluids versus placebo or no treatment using a systematic search strategy, without date or language restriction and in consultation with the Cochrane Gynaecology and Fertility (formerly Menstrual Disorders and Subfertility Group (MDSG)) Information Specialist.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-06-30 00:45:29 +1200" MODIFIED_BY="Heather Maxwell">
<P>The following electronic databases, trial registers and websites were searched to September 2015.</P>
<UL>
<LI>Ovid Cochrane Central Register of Controlled Trials (CENTRAL) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)</LI>
<LI>Ovid MEDLINE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</LI>
<LI>Ovid Embase: Embase (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>)</LI>
<LI>Ovid PsycINFO (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>)  </LI>
<LI>MEDLINE and Embase search strategies use different filters for identifying randomised trials. The MEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomised trials which appears in the <I>Cochrane Handbook of Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
<LI>The Embase and CINAHL searches were combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<A HREF="http://ttp://www.sign.ac.uk/mehodology/filters.html#random ">www.sign.ac.uk/mehodology/filters.html#random</A>)<A HREF="http://ttp://www.sign.ac.uk/mehodology/filters.html#random "> </A>
</LI>
<LI>Trial registers for ongoing and registered trials including <A HREF="http://www.controlled-trials.com/ , 'ClinicalTrials.gov'">www.controlled-trials.com/</A>,<U> https://clinicaltrials.gov</U> and <A HREF="http://www.who.int/trialsearch/Default.aspx ">www.who.int/trialsearch/Default.aspx</A>
</LI>
<LI>The Web of Knowledge (for conference abstracts, and to check citations of included studies)</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-08-10 09:16:13 +1200" MODIFIED_BY="[Empty name]">
<P>We hand searched the reference lists of all primary studies and review articles retrieved by the search, and checked the citation lists of relevant publications. We contacted known experts in the field and personal contacts regarding any unpublished materials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-08-10 13:56:35 +1200" MODIFIED_BY="[Empty name]">
<P>Thereview authors (MY or SM) independently reviewed the titles and abstracts of studies using the a priori criteria for inclusion. The full-text manuscripts of studies were obtained for the short-listed papers that were considered potentially eligible for inclusion. We sought further information from the authors of study reports that did not contain sufficient information to make a decision about eligibility. Thereview authors independently critically appraised these studies and any disagreements were resolved by discussion. The studies that were determined to be suitable for inclusion were assessed for risk of bias and data were extracted. Subsequently, a detailed 'Characteristics of excluded studies' table was constructed for those studies that did not satisfy the inclusion criteria. A similar 'Characteristics of included studies' table was constructed for those studies considered suitable for inclusion.</P>
<P>The 2016 selection process was documented with a study flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-07-01 11:26:09 +1200" MODIFIED_BY="[Empty name]">
<P>A standardised data extraction form was developed and piloted for consistency and completeness. Two review authors (MY, HG or SM) independently performed data extraction. The two sets of extracted data were compared and discrepancies were resolved by discussion. Where studies had multiple publications, the review authors collated multiple reports so that each study rather than each report was the unit of interest in the review; overlapping data were thus identified and duplicates were excluded.</P>
<P>We requested extra information about the methodological quality of some studies (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; Gokmen 2005; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>; <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>; <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>), however the only response we received was from the authors of <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK> and <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-08-10 13:56:41 +1200" MODIFIED_BY="[Empty name]">
<P>The review authors independently evaluated the included studies for risk of bias using the Cochrane 'Risk of bias' assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess: selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other bias. Disagreements were resolved by discussion. We described all judgements fully and presented the conclusions in 'Risk of bias' tables (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), which were incorporated into the interpretation of review findings by means of sensitivity analyses.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>All data were dichotomous. The numbers of events in the control and intervention groups of each study were used to calculate Peto odds ratios (ORs) for each comparison, with 95% confidence intervals (CIs). </P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-06-13 23:51:58 +1200" MODIFIED_BY="[Empty name]">
<P>The primary analysis was per woman randomised. Only one cycle per woman could be included.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-09-11 09:37:59 +1200" MODIFIED_BY="[Empty name]">
<P>The data were analysed on an intention-to-treat basis as far as possible and attempts were made to obtain missing data from the original trials. Where these were unobtainable, only the available data were analysed.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-06-30 00:48:01 +1200" MODIFIED_BY="Heather Maxwell">
<P>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by visual inspection of the forest plots, and used the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to quantify any apparent inconsistency, interpreted in the broad terms:</P>
<UL>
<LI>0% to 40% might not be important;</LI>
<LI>30% to 60% represented moderate heterogeneity;</LI>
<LI>50% to 90% represented substantial heterogeneity;</LI>
<LI>75% to 100% represented considerable heterogeneity.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-06-30 00:48:17 +1200" MODIFIED_BY="Heather Maxwell">
<P>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, the review authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. Had there been 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small-study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies)</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>If the studies were sufficiently similar, data from primary studies were combined using a fixed-effect model to compare intravenous (IV) intervention fluids versus no treatment or placebo. We considered each type of volume expander in a separate comparison. </P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-08-18 00:29:48 +1200" MODIFIED_BY="[Empty name]">
<P>We considered whether the effect of the intervention on OHSS rates was different in studies that only measured severe (as opposed to moderate or severe) OHSS.</P>
<P>We also considered whether the effect of the intervention on pregnancy rates was different in studies that diagnosed pregnancy by ultrasonic visualisation of fetal heart beat rather than by pregnancy test.</P>
<P>Had we detected substantial heterogeneity, we planned to explore possible explanations in sensitivity analyses and to take any statistical heterogeneity into account when interpreting the results.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-08-10 10:01:26 +1200" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses were conducted for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding eligibility and in the analysis. These analyses included consideration of whether conclusions would have differed if:</P>
<UL>
<LI>the summary effect measure was risk ratio rather than Peto odds ratio;</LI>
<LI>eligibility was restricted to studies without high risk of bias;</LI>
<LI>eligibility was restricted to full-text published studies.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Overall quality of the body of evidence: 'Summary of findings' table</HEADING>
<P>Two review authors working independently prepared a 'Summary of findings' table using Guideline Development Tool software and Cochrane methods (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)This table evaluated the overall quality of the body of evidence for all outcomes for the three review comparisons using GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias). Judgements about evidence quality (high, moderate, low or very low) were justified, documented, and incorporated into reporting of results for each outcome.<BR/>
</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-08-25 15:16:11 +1200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-08-10 10:49:27 +1200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-08-08 09:58:05 +1200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">2016 update</HEADING>
<P>Two hundred and eighty-nine studies were retrieved by the search; a total of 124 duplicates were discarded, leaving 165 studies for screening of title and abstract. Two new studies were identified concerning the infusion of mannitol (<LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>) and calcium gluconate (<LINK REF="STD-El_x002d_Khayat-2015" TYPE="STUDY">El-Khayat 2015</LINK>). However, calcium gluconate has a very different pathophysiological mechanism than the other IV fluids used, which all are volume expanders. We excluded <LINK REF="STD-El_x002d_Khayat-2015" TYPE="STUDY">El-Khayat 2015</LINK>. A discussion on this topic took place between the authors and led to a decision to maintain a focus on volume expanders only; therefore, we amended the protocol and changed the title accordingly.</P>
<P>The data from <LINK REF="STD-Gokmen-2005" TYPE="STUDY">Gokmen 2005</LINK> (conference abstract) were excluded from this update of the review, as there was serious concern that the data overlapped with the <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK> publication, which was published as a full paper. We tried to contact the author to clarify potential duplication of data but did not succeed.</P>
<P>In total, nine studies were included in this review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2014 update</HEADING>
<P>Two hundred and seventy-three records were retrieved by the search and were screened. One unpublished study was deemed potentially eligible and was awaiting classification. The rest were discarded as clearly ineligible based on the title or abstract.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Searches prior to 2014</HEADING>
<P>In earlier versions of the review a total of 43 articles were identified as potentially eligible and retrieved in full text. Of these, 34 articles (32 studies) were further assessed and excluded. Eight studies (nine articles) were included.</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-06-30 00:52:59 +1200" MODIFIED_BY="Heather Maxwell">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="5">Design</HEADING>
<UL>
<LI>The nine included studies (n = 1867 women) were all single-centre studies. Eight studies were parallel-group RCTs comparing a single intervention versus placebo or a no treatment group; the <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK> study had a three-armed design with two different intervention groups versus placebo.</LI>
<LI>Eight studies were published as full papers and one as a 'letter to the editor' (<LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Participants</HEADING>
<P>All the studies used strict inclusion criteria for participant selection (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<UL>
<LI>Two studies used estradiol (E2) as the basic risk factor of ovarian hyperstimulation syndrome (OHSS) (7000 pmol/L in <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>, 11,010 pmol/L in <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>), both in combination with 'multifollicular response'; however no specific number of follicles was mentioned.</LI>
<LI>Two studies used the number of retrieved oocytes as the main risk factor (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>).</LI>
</UL>
<UL>
<LI>Four studies used both E2 level and number of follicles or oocytes as inclusion criteria; high E2 <I>or</I> number of follicles on day of human chorionic gonadotrophin (hCG) administration/number of retrieved oocytes in <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>, <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK> and <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>; high E2 level <I>and</I> number of follicles in <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>.</LI>
</UL>
<UL>
<LI>Where E2 levels were (partly) used to define the 'high-risk' population, cut-off levels varied (1906 pg/mL in <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>, &gt; 2506 pg/mL in <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>, &gt; 3000 pg/mL in <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>, &gt; 1500 pg/mL in <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>, &gt; 3000 pg/mL in <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>, &gt; 4000 pg/mL in <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>, &gt; 9200 pg/mL in <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK> ; where necessary pmol/L was converted to pg/mL).</LI>
<LI>One study included women with polycystic ovary syndrome (PCOS) as their 'high-risk' group (<LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>), without taking E2 levels or number of follicles/oocytes into account.</LI>
<LI>One study excluded women with very high E2 levels and performed cycle cancellation for this extremely high-risk group for E2 &gt; 7000 pmol/L (<LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>).</LI>
</UL>
<UL>
<LI>Mean female age was around 30 years in all studies (mean age range was 27.5 to 32.6 years). The intervention and control groups were largely similar regarding the number of ampoules of human menopausal gonadotropin (hMG) used for controlled ovarian hyperstimulation, number of oocytes retrieved and number of embryos. However, in five studies (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>; <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>), there was no mention of the number of ampoules between intervention and control group.</LI>
</UL>
<P>See the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interventions</HEADING>
<UL>
<LI>Seven studies compared albumin versus placebo (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>; <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>) or no treatment (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>).</LI>
<LI>Two studies compared hydroxyethyl starch (HES) versus placebo (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>).</LI>
<LI>One study made both comparisons (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>).</LI>
<LI>One study compared mannitol versus no treatment (<LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>).</LI>
<LI>Placebo (saline) was used in the control group of five studies (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001302.pub2/full#CD001302-bbs2-0002">Gokmen 2001</A>; <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001302.pub2/full#CD001302-bbs2-0005">Isikoglu 2007</A>; <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001302.pub2/full#CD001302-bbs2-0006">Koike 1999</A>; <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001302.pub2/full#CD001302-bbs2-0007">Konig 1998</A>; <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001302.pub2/full#CD001302-bbs2-0009">Shoham 1994</A>).</LI>
</UL>
<P>The dose and timing of the interventions varied between studies but all were given in a relatively early phase (i.e. day of hCG administration or oocyte retrieval) to try to prevent early onset OHSS: <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK> used 50 g albumin two hours before oocyte retrieval; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK> used 37.5 g albumin just after oocyte retrieval; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK> used 20 g albumin just after oocyte retrieval; and <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK> used 10 g albumin two hours before oocyte retrieval; <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK> and <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK> used 10 g albumin immediately after oocyte retrieval; and <LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK> used 40 g of albumin immediately after oocyte retrieval. In <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>, 6% hydroxyethyl starch (200/0.5) (500 mL) was used immediately after oocyte retrieval, and in <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK> it was used 48 hours after the oocyte retrieval. <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK> used mannitol 3 g/kg bodyweight daily infusions (each 100 mL infusion containing 20 g mannitol and water for injection), starting the day after hCG injection until the third day after embryo transfer (lasting five to seven days depending on day of embryo transfer).</P>
<P>
<B>Outcomes</B>
</P>
<P>All nine studies reported the incidence of severe OHSS and five studies additionally reported on the incidence of moderate OHSS (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>; <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>). Diagnosis of severity of OHSS was done according to the criteria of <LINK REF="REF-Schenker-1978" TYPE="REFERENCE">Schenker 1978</LINK> in three studies (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>), while <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK> and <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK> used the criteria of <LINK REF="REF-Navot-1988" TYPE="REFERENCE">Navot 1988</LINK>, <LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK> used the criteria of <LINK REF="REF-Golan-1989" TYPE="REFERENCE">Golan 1989</LINK>, and <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK> used those of <LINK REF="STD-Ben_x002d_Rafael-1995" TYPE="STUDY">Ben-Rafael 1995</LINK>. <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK> used the criteria of <LINK REF="REF-WHO-1973" TYPE="REFERENCE">WHO 1973</LINK>. <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK> did not explicitly state the reference but describes criteria similar to <LINK REF="REF-Golan-1989" TYPE="REFERENCE">Golan 1989</LINK>.</P>
<P>Eight studies reported pregnancy rates. Diagnosis of pregnancy was determined using serum ß-hCG in all studies except <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK> and <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>, which used "presence at ultrasound of a gestational sac with positive fetal heart rate".</P>
<P>Most studies mentioned adverse events in their results or discussion sections, but none of the studies prespecified adverse events as an outcome, or reported comparative data on adverse effects in all study groups.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-08-10 10:49:27 +1200" MODIFIED_BY="[Empty name]">
<P>We excluded 39 studies which did not meet the inclusion criteria for this review, in most cases because they did not make any comparisons of interest or were not randomised. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-07-01 11:34:04 +1200" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2016-06-30 00:53:26 +1200" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Sequence generation</HEADING>
<P>Seven studies used adequate methods of sequence generation and were rated as at low risk of bias (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>; <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>; <LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>). Two studies did not report details of the methods used and were rated as at unclear risk of bias (<LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>; <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>None of the studies clearly described an acceptable method of allocation concealment and all were rated as at unclear risk of bias in this domain.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2016-07-01 11:34:04 +1200" MODIFIED_BY="[Empty name]">
<P>We considered that lack of blinding might influence outcome assessment for the outcomes of OHSS and adverse events.</P>
<P>One study clearly blinded both participants and outcomes assessors, and was rated as at low risk of bias (<LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>). One study stated that "<I>physicians were blinded to the allocated groups and a nurse performed the protocol" (</I>
<LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>
<I>), </I>and we considered this study also to be at low risk of bias. Four studies did not mention blinding, and were rated as at unclear risk (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>; <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>; <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>). Three studies were unblinded and were rated as at high risk of bias (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>)</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-07-01 11:26:09 +1200" MODIFIED_BY="[Empty name]">
<P>All studies appeared to include all randomised women in analysis. All were rated as at low risk of attrition bias apart from one (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>). An abstract from a conference held in 2005 (Gokmen 2005) appears to relate to the same study but has a larger sample size and reports two additional events. We attempted to contact the study authors to query this but did not receive a reply. We therefore rated this study as at unclear risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-09-10 12:11:59 +1200" MODIFIED_BY="[Empty name]">
<P>Although most studies either stated that no events were observed, or mentioned events in one or both arms, it was unclear whether data on adverse events were collected prospectively or systematically. All studies were rated as at unclear risk of bias in this domain.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-09-04 16:24:23 +1200" MODIFIED_BY="[Empty name]">
<P>No other potential source of bias was identified in any of the studies, and they were rated as at low risk in this domain.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-08-25 15:16:11 +1200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Human albumin versus placebo or no treatment</HEADING>
<P>Seven studies compared albumin versus placebo (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>; <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>) or no treatment (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Moderate or severe OHSS</HEADING>
<P>There was evidence of a difference between the groups, though (Peto OR 0.67 95% CI 0.47 to 0.95, seven studies, 1452 women; I² = 69%, very low quality evidence). Heterogeneity was substantial, and there was no obvious explanation for this (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). This suggests that if the rate of moderate or severe OHSS with no treatment is 12%, it will be about 9% (6% to 12%) with the use of intravenous albumin.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup and sensitivity analyses</HEADING>
<P>Subgroup analysis showed no evidence that findings differed in studies that only reported severe OHSS (test for subgroup differences: Chi² = 0.19, df = 1 (P = 0.66), I² = 0%).</P>
<P>Use of a risk ratio reduced heterogenity to I<SUP>2</SUP>=57%. Sensitivity analysis by study risk of bias was not possible as no studies were at low risk of bias in most domains.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Live birth</HEADING>
<P>None of the studies reported live birth as an outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Pregnancy</HEADING>
<P>Seven studies reported data for this outcome.</P>
<P>There was evidence of a detrimental effect on pregnancy rates for the use of albumin (Peto OR 0.72 95% CI 0.55 to 0.94, I² = 42%, seven studies, 1069 women, moderate quality evidence) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>;<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<P>We examined whether effects differed according to the method used for diagnosing pregnancy (by &#946;-hCG: <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>; <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK>; <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>; <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>) or heartbeat on ultrasound (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK> (only pregnancy data for autologous cycles considered); <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>) and found no evidence of a difference between the subgroups (test for subgroup differences: Chi² = 0.78, df = 1 (P = 0.38), I² = 0%</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Adverse effects</HEADING>
<P>None of the studies explicitly mentioned 'adverse effects' as a prespecified outcome, though most commented (in the results or discussion section) on adverse events related to the interventions. Among women receiving albumin, in one study (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>), a woman developed an anaphylactoid reaction with hypotension and laryngospasm. In a second study (<LINK REF="STD-Isik-1996" TYPE="STUDY">Isik 1996</LINK>), two women developed mild urticaria. Four studies (<LINK REF="STD-Bellver-2003" TYPE="STUDY">Bellver 2003</LINK>, <LINK REF="STD-Isikoglu-2007" TYPE="STUDY">Isikoglu 2007</LINK>, <LINK REF="STD-Shalev-1995" TYPE="STUDY">Shalev 1995</LINK>, <LINK REF="STD-Shoham-1994" TYPE="STUDY">Shoham 1994</LINK>), noted that no side effects or hypersensitivity reactions were detected in association with the intervention. <LINK REF="STD-Koike-1999" TYPE="STUDY">Koike 1999</LINK> did not mention adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Hydroxyethyl starch (HES) versus placebo or no treatment</HEADING>
<P>Two studies compared hydroxyethyl starch (HES) versus placebo (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>; <LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>). Both reported overall rates of moderate or severe OHSS.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Moderate or severe OHSS</HEADING>
<P>There was evidence of a beneficial effect of HES on OHSS (Peto OR 0.27 95% CI 0.12 to 0.59, I² = 0%, two studies, 272 women, very low quality evidence). This suggests that if the rate of moderate or severe OHSS with no treatment is 16%, it will be about 5% (2% to 10%) with the use of HES (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<I>Sensitivity analysis</I>
</P>
<P>Use of a risk ratio did not materially change the main findings. Sensitivity analysis by study risk of bias was not possible as neither studies was at low risk of bias in most domains.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Live birth</HEADING>
<P>Neither of the studies reported live birth as an outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Pregnancy</HEADING>
<P>There was no evidence of a difference in pregnancy rates (diagnosed by serum &#946;-hCG level) between women receiving IV HES and those receiving placebo (Peto OR 1.20 95% CI 0.49 to 2.93, one study, 168 women, very low quality evidence) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Adverse effects</HEADING>
<P>Neither of the studies explicitly mentioned 'adverse effects' as a prespecified outcome. There were two mild cases of urticaria in one study (<LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>) and one case of urticaria in the other (<LINK REF="STD-Konig-1998" TYPE="STUDY">Konig 1998</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Mannitol versus placebo or no treatment</HEADING>
<P>One study compared mannitol versus no treatment (<LINK REF="STD-Saremi-2003" TYPE="STUDY">Saremi 2003</LINK>).This study reported overall rates of moderate or severe OHSS.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Moderate or severe OHSS</HEADING>
<P>There was evidence of a beneficial effect of mannitol on OHSS (Peto OR 0.38, 95% CI 0.22 to 0.64, one study, 226 women, low quality evidence).</P>
<P>This suggests that if the rate of OHSS with no treatment is 52%, it will be about 29% (19% to 41%) with mannitol (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<I>Sensitivity analysis</I>
</P>
<P>Use of a risk ratio did not materially change the main findings.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Live birth</HEADING>
<P>Live birth was not reported as an outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Pregnancy</HEADING>
<P>There was no evidence of a difference in pregnancy rates (diagnosed by ultrasound) between the groups (Peto OR 0.85 95% CI 0.85 to 1.55; one study, 226 women, low quality evidence) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Adverse effects</HEADING>
<P>Adverse events were not mentioned in this study. In private correspondence the authors stated that data on adverse events were collected, but they did not specify what type or report any events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of publication bias</HEADING>
<P>There were insufficient studies to construct a funnel plot to assess the risk of publication bias.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>Nine randomised controlled studies compared the effectiveness of intravenous (IV) administration of the volume expanders human albumin, hydroxyethyl starch (HES), or mannitol versus placebo or no treatment for the prevention of ovarian hyperstimulation syndrome (OHSS) in women at high risk of OHSS. The overall quality of the evidence ranged from very low to moderate (Summary of findings table 1).</P>
<P>There was evidence that intravenous albumin administration around the time of oocyte retrieval has a beneficial effect on the incidence of moderate or severe OHSS. However, there was substantial unexplained heterogeneity between studies for this outcome (I² = 69%).</P>
<P>Our analysis suggested that HES might be associated with reduced rates of moderate or severe OHSS, but this was only based on two studies reporting only 28 events. Mannitol also appeared to have a beneficial effect on the incidence of OHSS, but this finding was based on a single study, so this moderate quality evidence remains to be confirmed in additional, large RCTs.</P>
<P>Live birth rate was not reported in any of the studies.There was moderate quality evidence that administration of human albumin lowered pregnancy rates in women at high risk for OHSS. For HES or mannitol there was no evidence of an effect on pregnancy rates.</P>
<P>Adverse effects were poorly reported and no firm conclusions could be drawn; although uncommon, clinicians should be aware that administration of IV fluids could cause severe morbidity.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>There were no randomised controlled studies (RCTs) that compared other volume expanders such as dextran or polygeline versus placebo or no treatment.</P>
<P>There was significant clinical heterogeneity between the included studies. The criteria for selecting women with a risk of OHSS varied across trials. Some used the number of oocytes at the day of hCG administration or the number of retrieved oocytes. Other studies used E2 level as a basic risk marker, but cut-off levels varied greatly amongst studies; for example, inclusion E2 level for the study matched cycle cancellation (and therefore exclusion level) in another study. The method or criteria of OHSS diagnosis also varied widely between studies. With regard to studies of human albumin, the dosage of gonadotropins used for controlled ovarian hyperstimulation was not stated in most of the studies; the dose and timing of administration of albumin or starch varied between studies, between 10 g albumin immediately after oocyte retrieval to 50 g albumin one or two hour before oocyte retrieval, whilst 52.5 g albumin is required to accomplish a normal plasma albumin level of 4.2 to 4.5 g/100 mL in a well-hydrated patient (<LINK REF="STD-Kissler-2001" TYPE="STUDY">Kissler 2001</LINK>).</P>
<P>All of the plasma expanders were given either on the day of hCG administration or day of oocyte retrieval, therefore implicitly aiming to prevent early onset OHSS. The included studies made no distinction between early and late onset OHSS.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-08-10 12:42:28 +1200" MODIFIED_BY="[Empty name]">
<P>All the studies were at serious risk of bias: none adequately described their method of allocation concealment, none prospectively collected comparative data on adverse events and only one clearly reported blinded outcome assessment.</P>
<P>The quality of the evidence was rated as very low to moderate for all comparisons. The main limitations in the evidence were risk of bias, statistical heterogeneity, imprecision, and lack of data for most comparisons. (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-08-08 01:20:38 +1200" MODIFIED_BY="[Empty name]">
<P>Previous versions of the review included both <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK> and a subsequent study by the same group (<LINK REF="STD-Gokmen-2005" TYPE="STUDY">Gokmen 2005</LINK>). We understand from personal communication with Christos Venetis (first author of <LINK REF="REF-Venetis-2011" TYPE="REFERENCE">Venetis 2011</LINK>) that these two studies overlap and so we have removed the data for Gokmen 2005 from this updated version of the review. However, we have been unable to contact the study authors directly. No other potential biases were identified in the review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-08-10 12:43:00 +1200" MODIFIED_BY="[Empty name]">
<P>Two older systematic reviews of human albumin for the prevention of OHSS reached slightly different conclusions, but both focused on severe OHSS only. Both reviews reported no difference in the occurrence of severe OHSS between those who received intravenous albumin and those who did not (<LINK REF="REF-Venetis-2011" TYPE="REFERENCE">Venetis 2011</LINK>: odds ratio (OR) 0.80; 95% confidence interval (CI), 0.52 to 1.22, eight RCTs, 1199 women; <LINK REF="REF-Jee-2010" TYPE="REFERENCE">Jee 2010</LINK>: risk ratio (RR) 0.80, 95% CI 0.57 to1.12, 9 RCTs, 1613 women). These reviews however included quasi-randomised studies which were not eligible for the current review (for <LINK REF="REF-Jee-2010" TYPE="REFERENCE">Jee 2010</LINK> this was <LINK REF="STD-Panay-1999" TYPE="STUDY">Panay 1999</LINK>; for <LINK REF="REF-Venetis-2011" TYPE="REFERENCE">Venetis 2011</LINK> this was <LINK REF="STD-Ben_x002d_Chetrit-2001" TYPE="STUDY">Ben-Chetrit 2001</LINK>) and <LINK REF="REF-Venetis-2011" TYPE="REFERENCE">Venetis 2011</LINK> also included data from <LINK REF="STD-Gokmen-2005" TYPE="STUDY">Gokmen 2005</LINK>, that we considered possibly biased. The slightly deleterious effect of albumin on pregnancy rate reported by <LINK REF="REF-Jee-2010" TYPE="REFERENCE">Jee 2010</LINK> was confirmed in our review.</P>
<P>We have not identified any other systematic reviews comparing HES or mannitol with placebo or no treatment for prevention of OHSS.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-08-25 15:17:23 +1200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-08-25 15:17:23 +1200" MODIFIED_BY="[Empty name]">
<P>Evidence suggests that the plasma expanders assessed in this review (human albumin, HES and mannitol) reduce rates of moderate and severe OHSS in women at high risk. Adverse events appear to be uncommon, but were too poorly reported to reach any firm conclusions, and there were no data on live birth. However, there was evidence that human albumin reduces pregnancy rates. While there was no evidence that HES, or mannitol had any influence on pregnancy rates, the evidence of effectiveness was based on very few trials which need to be confirmed in additional, larger randomised controlled trials (RCTs) before they should be considered for routine use in clinical practice.</P>
<P>.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-06-30 00:58:28 +1200" MODIFIED_BY="Heather Maxwell">
<UL>
<LI>High-quality, well-designed and adequately powered RCTs are needed to assess the effectiveness of volume expanders in women at high risk of developing OHSS.</LI>
</UL>
<UL>
<LI>Future studies should take into consideration the cost-effectiveness and psychological impact of treatment with volume expanders and should systematically report on adverse events.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-08-10 12:58:15 +1200" MODIFIED_BY="[Empty name]">
<P> Dr Saremi is acknowledged for providing additional information on his publication. Special thanks also to the highly supportive team at the Cochrane office in Auckland, especially editor Jane Marjoribanks and the Information Specialist Marian Showell for designing and running the search strategies.</P>
<P>We thank Professor Johannes Evers, Professor Hesham Al-Inany and Professor Mohamed Aboulghar for their contributions to previous versions of this review. Professor Al-Inany took the lead in writing the protocol and the first version of the full review. Prof Aboulghar screened studies and extracted and interpreted data in the first version of the full review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-08-07 01:51:52 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>Mohamed AFM Youssef</B>: performed searches of databases for new trials for the first review update, was involved in selecting trials for inclusion, performed independent data extraction and quality assessment of the included trials, was involved in writing the review, statistical analysis and interpretation of the data.</P>
<P>
<B>Selma Mourad: </B>contributed to the 2016 update. Performed searches of databases for new trials, selecting trials for inclusion, corresponding with authors of primary studies, performed independent data extraction and quality assessment of the included trials, was responsible for interpretation of the data, adding the summary of findings tables and updating the main review text.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>The original plan for the review was to only study the preventive effect of human albumin administration on OHSS. During the 2010 update process it was decided that the review should be broadened to include all kinds of intravenous fluids being used in the prevention of OHSS. The only other intravenous fluid for which randomised controlled trials with a placebo or 'no treatment' control group could be found at that time, was hydroxyethyl starch (HES).</P>
<P>For the 2016 update, there were two new comparisons found, i.e. calcium gluconate and mannitol. However, calcium gluconate has a very different pathophysiological mechanism than the other fluids used, which all are volume expanders. A discussion on this topic took place between the authors and led to a decision to maintain a focus on volume expanders only. Therefore, we amended the protocol and changed the title accordingly.</P>
<P>The 2016 update also is the first version of the review to include 'moderate OHSS' as part of the primary outcome measure, as this is a clinically relevant degree of OHSS that could easily proceed to severe OHSS. Moreover, other interventional Cochrane reviews on the prevention of OHSS also use 'moderate OHSS' as an outcome.</P>
<P>Also in 2016 we added a subgroup analysis for the outcome clinical pregnancy, to explore whether the effect of the intervention on pregnancy rates was different in studies that diagnosed pregnancy by ultrasonic visualisation of fetal heart beat rather than by pregnancy test.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-11-04 03:30:12 +0000" MODIFIED_BY="Helen Nagels">
<STUDIES MODIFIED="2016-08-08 10:38:32 +1200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-08-08 10:38:32 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bellver-2003" MODIFIED="2014-09-04 12:33:52 +1200" MODIFIED_BY="[Empty name]" NAME="Bellver 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-04 12:33:52 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellver J, Munoz EA, Ballesteros A, Soares SR, Bosch E, Simon C, et al</AU>
<TI>Intravenous albumin does not prevent moderate&#8211;severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>11</NO>
<PG>2283&#8211;8</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777406"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777405"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gokmen-2001" MODIFIED="2016-06-28 03:17:51 +1200" MODIFIED_BY="Heather Maxwell" NAME="Gokmen 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-06-28 03:17:51 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H</AU>
<TI>Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomised placebo controlled study</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>2</NO>
<PG>187-92</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777408"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777407"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isik-1996" MODIFIED="2014-09-04 14:21:12 +1200" MODIFIED_BY="[Empty name]" NAME="Isik 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-09-04 14:21:12 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isik AZ, Gokmen O, Zeyneloglu HB, Kara S, Keles G, Gulekli B</AU>
<TI>Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in vitro fertilisation patients: a prospective randomized and controlled study</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>1996</YR>
<VL>70</VL>
<PG>170-83</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777410"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777409"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isikoglu-2007" MODIFIED="2010-11-21 13:54:36 +1300" MODIFIED_BY="[Empty name]" NAME="Isikoglu 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-21 13:54:36 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K</AU>
<TI>Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>88</VL>
<NO>4</NO>
<PG>982-5</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777412"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777411"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koike-1999" MODIFIED="2010-11-21 13:52:13 +1300" MODIFIED_BY="[Empty name]" NAME="Koike 1999" YEAR="1994">
<REFERENCE MODIFIED="2010-11-21 13:52:13 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koike E, Araki S, Ogawa S, Minakami H, Sato I</AU>
<TI>Does i.v albumin prevent ovarian hyperstimulation syndrome?</TI>
<SO>Human Reproduction</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>7</NO>
<PG>1920</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777414"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777413"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konig-1998" MODIFIED="2016-07-18 03:08:11 +1200" MODIFIED_BY="[Empty name]" NAME="Konig 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-07-18 03:08:11 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konig E, Bussen S, Sütterlin M, Steck T</AU>
<TI>Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study</TI>
<SO>Human Reproduction</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>9</NO>
<PG>2421-4</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777416"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777415"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Saremi-2003" MODIFIED="2016-08-08 10:38:32 +1200" MODIFIED_BY="[Empty name]" NAME="Saremi 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-08-08 10:38:32 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saremi A, Alam M, Motaghi M</AU>
<TI>Administration of mannitol to prevent severe ovarian hyperstimulation syndrome: A randomized controlled trial</TI>
<SO>Middle East Fertility Society Journal</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>159-163</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777418"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777417"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shalev-1995" MODIFIED="2014-09-04 15:14:46 +1200" MODIFIED_BY="[Empty name]" NAME="Shalev 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-09-04 15:14:46 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shalev E, Giladi Y, Matilsky M, Ben-Ami M</AU>
<TI>Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilisation patients receiving intravenous albumin: a prospective study</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>1373-6</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777420"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777419"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoham-1994" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Shoham 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoham Z, Weissman A, Barash A, Borenstein R, Schachter M, Insler V</AU>
<TI>Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an invitro fertilisation program: a prospective, randomised, placebo-controlled study</TI>
<SO>Fertility and Sterility</SO>
<YR>1994</YR>
<VL>62</VL>
<PG>137-42</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777422"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777421"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-01 12:09:18 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abramov-2001" MODIFIED="2016-06-28 03:26:28 +1200" MODIFIED_BY="Heather Maxwell" NAME="Abramov 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-06-28 03:26:28 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abramov Y, Fatum M, Abrahamove D, Schenker JC</AU>
<TI>Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>75</VL>
<PG>1228-30</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777424"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-05 08:28:15 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abramov Y, Fatum M, Fasouliotis S, Abrahamov D, Schenker JC</AU>
<TI>Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility. Abstracts of the 17th Annual meeting of the ESHRE</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>1</NO>
<PG>121</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777425"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-04 19:37:34 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777423"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abuzeid--2010" MODIFIED="2010-12-16 09:48:53 +1300" MODIFIED_BY="[Empty name]" NAME="Abuzeid  2010" YEAR="2010">
<REFERENCE MODIFIED="2010-12-07 18:31:20 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abuzeid M, Abed S, Salem W, Joseph S, Ashraf M, Rizk P.B</AU>
<TI>The effectiveness of 6% hydroxyethyle starch solution in reducing the incidence of severe hyperstimulation syndrome in polycystic ovarian disease patients: A prospective cohort clinical trial</TI>
<SO>Journal of Reproductive Medicine and Endocrinology,</SO>
<YR>IFFS 2010 September 12-16 Munich</YR>
<VL>7</VL>
<NO>4</NO>
<PG>240-383</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777427"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777426"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmadi-2010" MODIFIED="2016-06-28 03:28:21 +1200" MODIFIED_BY="Heather Maxwell" NAME="Ahmadi 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-06-28 03:28:21 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmadi Sh, Rahmani E, Oskouian H</AU>
<TI>Cabergoline versus human albumin in prophylaxis ovarian hyperstimulation syndrome</TI>
<SO>Reproductive BioMedicine Online</SO>
<YR>2010</YR>
<VL>Suppl. 3</VL>
<PG>S41&#8211;S42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777429"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777428"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asch-1993" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Asch 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-07-12 09:59:43 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asch R, Ivery G, Goldsman M</AU>
<TI>The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome</TI>
<SO>Human Reproduction</SO>
<YR>1993</YR>
<VL>8</VL>
<PG>1015-20</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777431"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777430"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ben_x002d_Chetrit-2001" MODIFIED="2016-06-28 03:28:52 +1200" MODIFIED_BY="Heather Maxwell" NAME="Ben-Chetrit 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-06-28 03:28:52 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ben Chetrit A, Eldar-Geva T, Gal M, Huerta M, Mimon T, Algur N, et al</AU>
<TI>The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial</TI>
<SO>Human Reproduction</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>9</NO>
<PG>1880-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777433"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777432"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ben_x002d_Rafael-1995" MODIFIED="2016-06-28 03:29:11 +1200" MODIFIED_BY="Heather Maxwell" NAME="Ben-Rafael 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-06-28 03:29:11 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ben-Rafael Z, Orvieto R, Dekel A, Peleg D, Gruzman C</AU>
<TI>Intravenous albumin and the prevention of severe ovarian hyperstimulation syndrome</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>10</NO>
<PG>2750-2</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777435"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777434"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cambiaghi-2005" MODIFIED="2010-11-21 13:57:52 +1300" MODIFIED_BY="[Empty name]" NAME="Cambiaghi 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-21 13:57:52 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cambiaghi AS, Castellotti DS</AU>
<TI>Oral whey protein for preventing ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility. Abstracts from the annual meeting of ASRM</SO>
<YR>84 Suppl 1</YR>
<VL>84</VL>
<NO>1</NO>
<PG>315</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777437"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777436"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1997" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Chen 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen C, Chen S, Wu M, Ho H, Yang J, Yang Y</AU>
<TI>Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>68</VL>
<PG>287-91</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777439"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777438"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" MODIFIED="2014-09-05 08:33:14 +1200" MODIFIED_BY="[Empty name]" NAME="Chen 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-05 08:33:14 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS</AU>
<TI>Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>80</VL>
<NO>1</NO>
<PG>86-90</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777441"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777440"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costabile-2000" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Costabile 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costabile L, Unfer V, Manna C, Gerli S, Rossetti D, Di Renzo GC</AU>
<TI>Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>3</NO>
<PG>182-5</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777443"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777442"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dmitrieva-2010" MODIFIED="2016-06-28 03:30:28 +1200" MODIFIED_BY="Heather Maxwell" NAME="Dmitrieva 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-06-28 03:30:28 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dmitrieva NV, Yakovenko SA, Zorina IV, Voznesenskaya YV, Apryshko VP</AU>
<TI>Comparison of calcium gluconate and starch solution in the treatment of ovarian hyperstimulation syndrome</TI>
<SO>Reproductive BioMedicine Online</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>S41&#8211;S42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777445"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777444"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egbase-1997" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Egbase 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-11 14:28:28 +1300" MODIFIED_BY="Julie A Brown" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egbase PE, Makhseed M, Al Sharhan M, Grdzinskas JG</AU>
<TI>Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in invitro fertilisation: a prospective randomised study</TI>
<SO>Human Reproduction</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>2603-6</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777447"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777446"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Khayat-2015" MODIFIED="2016-06-28 03:32:24 +1200" MODIFIED_BY="Heather Maxwell" NAME="El-Khayat 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-06-28 03:32:24 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Khayat W, Elsadek M</AU>
<TI>Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2015</YR>
<VL>103</VL>
<NO>1</NO>
<PG>101-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777449"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777448"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Endo-2004" MODIFIED="2010-11-21 14:02:08 +1300" MODIFIED_BY="[Empty name]" NAME="Endo 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-21 14:02:08 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Endo T, Kitajima Y, Hayashi T, Fujii M, Hata H, Azumaguchi A</AU>
<TI>Low-molecular-weight dextran infusion is more effective for the treatment of hemoconcentration due to severe ovarian hyperstimulation syndrome than human albumin infusion</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>82</VL>
<NO>5</NO>
<PG>1449-51</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777451"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777450"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2006" MODIFIED="2015-03-21 03:18:01 +1300" MODIFIED_BY="[Empty name]" NAME="Fan 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-05 08:28:57 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan YH, Qiao J, Chen XN, Wang HY, Ma CH, Liu P</AU>
<TI>Assisted reproductive Intravenous hydroxyethyl starch versus human albumin for prevention of the ovarian hyperstimulation syndrome</TI>
<SO>VIII FIGO World Congress of Gynecology and Obstetrics</SO>
<YR>2006</YR>
<VL>2</VL>
<PG>34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777453"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-21 14:02:55 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan YH, Qiao J, Chen XN, Wang HY, Ma CH, Liu P</AU>
<TI>Intravenous hydroxyethyl starch versus human albumin for prevention of the ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86 Suppl 2</VL>
<PG>136</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777454"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777452"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fluker-2000" MODIFIED="2010-11-21 14:05:25 +1300" MODIFIED_BY="[Empty name]" NAME="Fluker 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-21 14:05:25 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fluker MR, Copeland JE, Yuzpe AA</AU>
<TI>An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2000</YR>
<VL>73</VL>
<NO>4</NO>
<PG>821-4</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777456"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777455"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gamzu-2002" MODIFIED="2010-11-21 14:05:54 +1300" MODIFIED_BY="[Empty name]" NAME="Gamzu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-21 14:05:54 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gamzu R, Almog B , Levin Y, Avni A, Lessing BJ, Baram A</AU>
<TI>Comparative efficacy of hydroxyethyl starch and Haemaccel for the treatment of severe ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>6</NO>
<PG>1302-3</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777458"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gokmen-2005" MODIFIED="2016-07-01 11:26:09 +1200" MODIFIED_BY="[Empty name]" NAME="Gokmen 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-07-01 11:26:09 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gokmen O, Ozcan S, Erman Akar M, Ugur M</AU>
<TI>A randomized prospective placebo-controlled study of intravenous albumin vs. hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme</TI>
<SO>Fertility and Sterility: Abstracts of ASRM</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>Suppl 1</NO>
<PG>308</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4359155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4359154"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graf-1997" MODIFIED="2010-11-21 14:06:28 +1300" MODIFIED_BY="[Empty name]" NAME="Graf 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-21 14:06:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graf AM, Fischer R , Naether ONJ, Baukloh V, Tafel J, Nuckel M</AU>
<TI>Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyethyl starch solution in an in-vitro fertilization programme</TI>
<SO>Human Reproduction</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>12</NO>
<PG>2599-602</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777460"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777459"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halme-1995" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Halme 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-15 04:21:29 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halme J, Toma SK, Talbert LM</AU>
<TI>A case of severe ovarian hyperstimulation in a healthy oocyte donor</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>64</VL>
<NO>4</NO>
<PG>857-9</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777462"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777461"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isik-1997" MODIFIED="2016-06-28 03:34:58 +1200" MODIFIED_BY="Heather Maxwell" NAME="Isik 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-06-28 03:34:58 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isik AZ, Ozgun OD, Kahraman S, Polat G, Vicdan K, Biberoglu K, et al</AU>
<TI>Intravenous albumin combined with low dose human chorionic gonadotrophin and late step-down administration of menotropins are effective in prevention of severe ovarian hyperstimulation syndrome in high-risk patients in an in vitro fertilisation program</TI>
<SO>Middle East Fertility Society Journal</SO>
<YR>1997</YR>
<VL>2/3</VL>
<PG>238-42</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777464"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777463"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isik-2001" MODIFIED="2010-11-21 14:07:18 +1300" MODIFIED_BY="[Empty name]" NAME="Isik 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-21 14:07:18 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isik AZ, Vicdan K</AU>
<TI>Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2001</YR>
<VL>97</VL>
<NO>2</NO>
<PG>208-12</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777466"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777465"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kissler-2001" MODIFIED="2010-11-21 14:07:57 +1300" MODIFIED_BY="[Empty name]" NAME="Kissler 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-21 14:07:57 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kissler S, Neidhardt B, Siebzehnrübl E, Schmitt H, Tschaikowsky K, Wildt L</AU>
<TI>The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2001</YR>
<VL>99</VL>
<NO>1</NO>
<PG>131-4</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777468"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koike--2000" MODIFIED="2016-06-28 03:35:28 +1200" MODIFIED_BY="Heather Maxwell" NAME="Koike  2000" YEAR="2000">
<REFERENCE MODIFIED="2016-06-28 03:35:28 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koike E, Araki S, Ogawa S, Minakami H, Sayama H, Shibahara H, et al</AU>
<TI>Clinical efficacy of peritoneovenous shunting for the treatment of sever ovarian hyperstimulation syndrome</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>1</NO>
<PG>113-7</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777470"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777469"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumbak-2005" MODIFIED="2010-11-21 14:09:22 +1300" MODIFIED_BY="[Empty name]" NAME="Kumbak 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-21 14:09:22 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumbak B, Kahraman S, Karlikaya G, Karagozoglu H, Sen T, Hatirnaz S</AU>
<TI>Intravenous albumin prophylaxis in high risk patients for moderate to severe ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>84 Suppl</VL>
<NO>1</NO>
<PG>264</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777472"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777471"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewit-1996" MODIFIED="2010-11-21 14:09:40 +1300" MODIFIED_BY="[Empty name]" NAME="Lewit 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-21 14:09:40 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewit N, Kol S, Ronen N, Itskovitz-Eldor J</AU>
<TI>Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome?</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>66</VL>
<NO>4</NO>
<PG>654-6</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777474"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777473"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lincolin-2002" MODIFIED="2010-11-21 14:11:21 +1300" MODIFIED_BY="[Empty name]" NAME="Lincolin 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-21 14:11:21 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lincoln SR, Opsahl MS, Blauer KL, Black SH, Schulman JD</AU>
<TI>Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>159-63</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777476"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matorras-2013" MODIFIED="2016-06-28 03:39:21 +1200" MODIFIED_BY="Heather Maxwell" NAME="Matorras 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-06-28 03:39:21 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matorras R, Andrés M, Mendoza R, Prieto B, Pijoan JI, Expósito A</AU>
<TI>Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch</TI>
<SO>European Journal of Obstetrics Gynecology and Reproductive Biology</SO>
<YR>2013</YR>
<VL>170</VL>
<NO>2</NO>
<PG>439-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777478"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milacic-1996" MODIFIED="2016-06-28 04:18:48 +1200" MODIFIED_BY="Heather Maxwell" NAME="Milacic 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-06-28 04:18:48 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milacic D, Radonjic G, Matijasevic S, Kontic O</AU>
<TI>Prevention of ovarian hyperstimulation syndrome with iv albumin</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>216</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777480"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukherjee-1995" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Mukherjee 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-12 09:58:28 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukherjee T, Copperman AB, Sandler B, Bustillo M, Grunfeld L</AU>
<TI>Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilization and embryo transfer</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>64</VL>
<NO>3</NO>
<PG>641-3</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777482"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777481"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Naredi-2013" MODIFIED="2016-06-28 03:41:04 +1200" MODIFIED_BY="Heather Maxwell" NAME="Naredi 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-06-28 03:41:04 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naredi N, Karunakaran S</AU>
<TI>Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome</TI>
<SO>Journal of Human Reproductive Sciences</SO>
<YR>2013</YR>
<VL>6</VL>
<NO>4</NO>
<PG>248-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777484"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777483"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ndukwe-1997" MODIFIED="2010-09-27 15:15:10 +1300" MODIFIED_BY="[Empty name]" NAME="Ndukwe 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-27 15:15:10 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ndukwe G, Thornton S, Fishel S, Dowell K, Aloum M</AU>
<TI>Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>68</VL>
<NO>5</NO>
<PG>851-4</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777486"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777485"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ng-1995" MODIFIED="2010-11-21 14:13:09 +1300" MODIFIED_BY="[Empty name]" NAME="Ng 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-21 14:13:09 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ng E, Leader A, Claman P, Domingo M, Spence JEH</AU>
<TI>Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>4</NO>
<PG>807-10</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777488"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777487"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panay-1999" MODIFIED="2016-07-01 12:09:18 +1200" MODIFIED_BY="[Empty name]" NAME="Panay 1999" YEAR="">
<REFERENCE MODIFIED="2016-07-01 12:08:58 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iammarone E, Panay N, ZosmerA, TozerA, Hussain S, Wilson C, et al</AU>
<TI>Does the prophylactic use of intravenous albumin prevent ovarian hyperstimulation syndrome? A randomised prospective study</TI>
<SO>Human Fertility</SO>
<YR>1999</YR>
<VL>2</VL>
<NO>2</NO>
<PG>179-180</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777490"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-01 12:09:18 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Panay NA, Iammorrone E, Zosmer A, Tozer A, Hussain S</AU>
<TI>Does the prophylactic use of intravenous albumin prevent ovarian hyperstimulation syndrome? A randomized prospective study</TI>
<SO>Abstracts from the 15th Annual Meeting of the ESHRE, Tours, France</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>105</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777491"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777489"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaker-1996" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Shaker 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaker AG, Zosmer A, Dean N, Berik JS, Jacob HS, Tan SL</AU>
<TI>Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian of ovarian hyperstimulation syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<PG>992-6</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777493"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777492"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-1992" MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" NAME="Tan 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan Sl, Balen A, El Hussein E, Campbell S, Jacobs HS</AU>
<TI>The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in invitro fertilisation: a prospective randomised study</TI>
<SO>Fertility and Sterility</SO>
<YR>1992</YR>
<VL>58</VL>
<PG>378-83</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777495"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tehraninejad--2012" MODIFIED="2016-06-28 03:46:06 +1200" MODIFIED_BY="Heather Maxwell" NAME="Tehraninejad  2012" YEAR="2012">
<REFERENCE MODIFIED="2016-06-28 03:46:06 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tehraninejad E, Hafezi M, Arabipoor A, Aziminekoo E, Chehrazi M, Bahmanabadi A</AU>
<TI>Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.</TI>
<SO>Journal of Assisted Reproduction &amp; Genetics.</SO>
<YR>2012</YR>
<VL>29</VL>
<NO>3</NO>
<PG>259-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777497"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777496"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Torabizadeh-2013" MODIFIED="2016-06-28 03:46:22 +1200" MODIFIED_BY="Heather Maxwell" NAME="Torabizadeh 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-06-28 03:46:22 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torabizadeh A, Vahidroodsari F, Ghorbanpour Z</AU>
<TI>Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.</TI>
<SO>Iranian Journal of Reproductive Medicine</SO>
<YR>2013</YR>
<VL>11</VL>
<NO>10</NO>
<PG>837-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777499"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777498"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Yakovenko-2009" MODIFIED="2016-06-28 03:48:14 +1200" MODIFIED_BY="Heather Maxwell" NAME="Yakovenko 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-06-28 03:48:14 +1200" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yakovenko SA, Zorina IV, Dmitrieva NV, Troshina MN, Apryshko VP, Voznesenskaya JV</AU>
<TI>Intravenous administration of calcium in ovarian hyperstimulation syndrome (OHSS) prevention</TI>
<SO>European Journal of Obstetrics Gynecology and Reproductive Biology</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>s20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2777501"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2777500"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-09-07 14:34:30 +1200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-01 11:26:09 +1200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-01 11:26:09 +1200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aboulghar-2003" MODIFIED="2016-06-28 03:51:39 +1200" MODIFIED_BY="Heather Maxwell" NAME="Aboulghar 2003" TYPE="JOURNAL_ARTICLE">
<AU>Aboulghar MA, Mansour RT</AU>
<TI>Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures</TI>
<SO>Human Reproduction Update</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>3</NO>
<PG>275-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cerrilo-2009" MODIFIED="2009-10-07 04:57:49 +1300" MODIFIED_BY="[Empty name]" NAME="Cerrilo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cerrillo M, Pacheco A, Rodríguez S, Mayoral M, Ruiz M, García Velasco JA</AU>
<TI>Differential regulation of VEGF, Cadherin, and Angiopietin 2 by trigger oocyte maturation with GnRHa vs hCG in donors: try to explain the lower OHSS incidence</TI>
<SO>Abstracts of the 25th  annual meeting of the ESHRE</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>1</NO>
<PG>i60</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2003a" MODIFIED="2014-09-05 10:46:14 +1200" MODIFIED_BY="[Empty name]" NAME="Chen 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Chen D, Burmeister L, Goldschlag D, Rosenwaks Z</AU>
<TI>Ovarian hyperstimulation syndrome: strategies for prevention</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>43-9</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Angelo-2007" MODIFIED="2014-09-17 16:09:41 +1200" MODIFIED_BY="[Empty name]" NAME="D'Angelo 2007" TYPE="COCHRANE_REVIEW">
<AU>D'Angelo A, Amso NN</AU>
<TI>Embryo freezing for preventing ovarian hyperstimulation syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-09-17 16:09:41 +1200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-09-17 16:09:41 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002806.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Angelo-2011" MODIFIED="2014-09-17 16:14:29 +1200" MODIFIED_BY="[Empty name]" NAME="D'Angelo 2011" TYPE="COCHRANE_REVIEW">
<AU>D'Angelo A, Brown J, Amso NN</AU>
<TI>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2014-09-17 16:14:29 +1200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-09-17 16:14:29 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002811.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Delvigne-2002" MODIFIED="2010-11-21 14:15:14 +1300" MODIFIED_BY="[Empty name]" NAME="Delvigne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Delvigne A, Rozenberg S</AU>
<TI>Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review</TI>
<SO>Human Reproduction Update</SO>
<YR>2002</YR>
<VL>8</VL>
<PG>559-77</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2007" MODIFIED="2010-11-21 14:17:58 +1300" MODIFIED_BY="[Empty name]" NAME="Edwards 2007" TYPE="JOURNAL_ARTICLE">
<AU>Edwards RG</AU>
<TI>IVF, IVM, natural cycle IVF, minimal stimulation IVF - time for a rethink</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2007</YR>
<VL>15</VL>
<PG>106-19</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Egbase-2000" MODIFIED="2009-10-06 23:01:27 +1300" MODIFIED_BY="[Empty name]" NAME="Egbase 2000" TYPE="JOURNAL_ARTICLE">
<AU>Egbase PE</AU>
<TI>Severe OHSS: how many cases are preventable?</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<PG>8-10</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Engmann-2008" MODIFIED="2010-11-21 14:18:44 +1300" MODIFIED_BY="[Empty name]" NAME="Engmann 2008" TYPE="JOURNAL_ARTICLE">
<AU>Engmann L, DiLugie A, Schmidt D, Nulsen J, Maier D, Benavida C</AU>
<TI>The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study</TI>
<SO>Fertility and Sterility</SO>
<YR>2008</YR>
<VL>89</VL>
<NO>1</NO>
<PG>84-91</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Enskog-2001" MODIFIED="2010-11-21 14:19:26 +1300" MODIFIED_BY="[Empty name]" NAME="Enskog 2001" TYPE="JOURNAL_ARTICLE">
<AU>Enskog A, Nilsson L, Brännström M</AU>
<TI>Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>196-201</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Foong-2006" MODIFIED="2010-11-21 14:19:46 +1300" MODIFIED_BY="[Empty name]" NAME="Foong 2006" TYPE="JOURNAL_ARTICLE">
<AU>Foong LC, Bhagavath BA, Kumar J, Ng SC</AU>
<TI>Ovarian hyperstimulation syndrome is associated with reversible impairment of vascular reactivity</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>78</VL>
<NO>6</NO>
<PG>1159-63</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Velasco-2003" MODIFIED="2010-11-21 14:20:05 +1300" MODIFIED_BY="[Empty name]" NAME="Garcia-Velasco 2003" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Velasco JA, Pellicer A</AU>
<TI>New concepts in the understanding of the ovarian hyperstimulation syndrome</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Golan-1989" MODIFIED="2016-06-28 03:56:31 +1200" MODIFIED_BY="Heather Maxwell" NAME="Golan 1989" TYPE="JOURNAL_ARTICLE">
<AU>Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E</AU>
<TI>Ovarian hyperstimulation syndrome: an update review</TI>
<SO>Obstetrical &amp; Gynecological Survey</SO>
<YR>1989</YR>
<VL>44</VL>
<NO>6</NO>
<PG>430-40</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-09-03 17:49:08 +1200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2011</YR>
<VL>Available from www.cochrane-handbook.org.</VL>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Humaidan-2010" MODIFIED="2016-06-28 03:57:20 +1200" MODIFIED_BY="Heather Maxwell" NAME="Humaidan 2010" TYPE="JOURNAL_ARTICLE">
<AU>Humaidan P, Quartarolo J, Papanikolaou EG</AU>
<TI>Preventing ovarian hyperstimulation syndrome: guidance for the clinician</TI>
<SO>Fertility and Sterility</SO>
<YR>2010</YR>
<VL>94</VL>
<NO>2</NO>
<PG>389&#8211;400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jee-2010" MODIFIED="2016-06-28 03:58:33 +1200" MODIFIED_BY="Heather Maxwell" NAME="Jee 2010" TYPE="JOURNAL_ARTICLE">
<AU>Jee BC, Suh CS, Kim YB, Kim SH, Choi YM, Kim JG, et al</AU>
<TI>Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>2010</YR>
<VL>70</VL>
<NO>1</NO>
<PG>47-54. Epub 2010 Feb 19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kol-2008" MODIFIED="2010-11-21 14:25:42 +1300" MODIFIED_BY="[Empty name]" NAME="Kol 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kol S, Solt I</AU>
<TI>GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>63-6</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Loutradis-2006" MODIFIED="2010-11-21 14:26:41 +1300" MODIFIED_BY="[Empty name]" NAME="Loutradis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Loutradis D, Kiapekou E, Zapanti E, Antsaklis A</AU>
<TI>Oocyte maturation in assisted reproductive techniques</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2006</YR>
<VL>1092</VL>
<PG>235-46</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Mathur-2000" MODIFIED="2010-11-21 14:27:09 +1300" MODIFIED_BY="[Empty name]" NAME="Mathur 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mathur RS, Jenkins JM</AU>
<TI>Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome?</TI>
<SO>BJOG</SO>
<YR>2000</YR>
<VL>107</VL>
<PG>943-6</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-McClelland-1990" MODIFIED="2010-11-21 14:27:32 +1300" MODIFIED_BY="[Empty name]" NAME="McClelland 1990" TYPE="JOURNAL_ARTICLE">
<AU>McClelland DB</AU>
<TI>Human albumin solutions</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>300</VL>
<PG>35-57</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Navot-1988" MODIFIED="2010-11-21 14:28:02 +1300" MODIFIED_BY="[Empty name]" NAME="Navot 1988" TYPE="JOURNAL_ARTICLE">
<AU>Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ</AU>
<TI>Risk factors and prognostic variables in the ovarian hyperstimulation syndrome</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>159</VL>
<PG>210-5</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Navot-1992" MODIFIED="2016-06-28 03:59:16 +1200" MODIFIED_BY="Heather Maxwell" NAME="Navot 1992" TYPE="JOURNAL_ARTICLE">
<AU>Navot D, Bergh PA, Laufer N</AU>
<TI>Ovarian hyperstimulation syndrome in novel reproductive technologies:prevention and treatment</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1992</YR>
<VL>58</VL>
<PG>249-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizk-1997" MODIFIED="2010-11-21 14:28:55 +1300" MODIFIED_BY="[Empty name]" NAME="Rizk 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rizk B, Aboulghar M, Smitz J, Ron-El R</AU>
<TI>The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome</TI>
<SO>Human Reproduction Update</SO>
<YR>1997</YR>
<VL>3</VL>
<PG>255-6</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rizk-1999" MODIFIED="2016-06-28 04:00:44 +1200" MODIFIED_BY="Heather Maxwell" NAME="Rizk 1999" TYPE="BOOK_SECTION">
<AU>Rizk B, Aboulghar MA</AU>
<TI>Classification, pathophysiology and management of ovarian hyperstimulation syndrome</TI>
<SO>In-Vitro Fertilization and Assisted Reproduction</SO>
<YR>1999</YR>
<PG>131-55</PG>
<ED>Brinsden P</ED>
<PB>The Parthenon Publishing Group</PB>
<CY>New York, London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schenker-1978" MODIFIED="2008-11-11 14:25:00 +1300" MODIFIED_BY="Julie A Brown" NAME="Schenker 1978" TYPE="JOURNAL_ARTICLE">
<AU>Schenker JG, Weinstein D</AU>
<TI>Ovarian hyperstimulation syndrome: a current survey</TI>
<SO>Fertility and Sterility</SO>
<YR>1978</YR>
<VL>30</VL>
<PG>225-68</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Shawkat-2012" MODIFIED="2016-06-28 04:01:16 +1200" MODIFIED_BY="Heather Maxwell" NAME="Shawkat 2012" TYPE="JOURNAL_ARTICLE">
<AU>Shawkat H, Westwood M, Mortimer A</AU>
<TI>Mannitol: a review of its clinical uses</TI>
<SO>Continuing Education in Anaesthesia, Critical Care &amp; Pain</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>2</NO>
<PG>82-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2012" MODIFIED="2014-09-17 16:11:13 +1200" MODIFIED_BY="[Empty name]" NAME="Tang 2012" TYPE="COCHRANE_REVIEW">
<AU>Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ</AU>
<TI>Cabergoline for preventing ovarian hyperstimulation syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-09-17 16:11:13 +1200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-09-17 16:11:13 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008605.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Venetis-2011" MODIFIED="2016-06-28 04:03:03 +1200" MODIFIED_BY="Heather Maxwell" NAME="Venetis 2011" TYPE="JOURNAL_ARTICLE">
<AU>Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC</AU>
<TI>Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis</TI>
<SO>Fertility and Sterilility</SO>
<YR>2011</YR>
<VL>95</VL>
<NO>1</NO>
<PG>188-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vloeberghs-2009" MODIFIED="2016-06-28 04:03:21 +1200" MODIFIED_BY="Heather Maxwell" NAME="Vloeberghs 2009" TYPE="JOURNAL_ARTICLE">
<AU>Vloeberghs V, Peeraer K, Pexsters A, D&#8217;Hooghe T</AU>
<TI>Ovarianhyperstimulation syndrome and complications of ART</TI>
<SO>Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>5</NO>
<PG>691-709</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1973" MODIFIED="2016-06-28 04:05:21 +1200" MODIFIED_BY="Heather Maxwell" NAME="WHO 1973" TYPE="OTHER">
<AU>WHO</AU>
<TI>Agents stimulating gonadal function in human</TI>
<SO>World Health Organization Technical Report Series</SO>
<YR>1973</YR>
<PG>514-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yan-1993" MODIFIED="2016-06-28 04:05:38 +1200" MODIFIED_BY="Heather Maxwell" NAME="Yan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J</AU>
<TI>Ascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1993</YR>
<VL>77</VL>
<PG>1723-5</PG>
<IDENTIFIERS MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Youssef-2014" MODIFIED="2016-06-28 04:09:09 +1200" MODIFIED_BY="Heather Maxwell" NAME="Youssef 2014" TYPE="COCHRANE_REVIEW">
<AU>Youssef MAFM, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al</AU>
<TI>Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>10</NO>
<EN>Youssef MAFM, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No.: CD008046. DOI: 10.1002/14651858.CD008046.pub4.</EN>
<IDENTIFIERS MODIFIED="2016-06-28 04:09:09 +1200" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-06-28 04:09:09 +1200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD008046.pub4"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-06-28 04:29:46 +1200" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Youssef-2002" MODIFIED="2016-06-28 04:29:46 +1200" MODIFIED_BY="Heather Maxwell" NAME="Youssef 2002" TYPE="COCHRANE_REVIEW">
<AU>Youssef MA, Al-Inany HG, Evers JHANSLH, Aboulghar M</AU>
<TI>Intra-venous fluids preventing severe ovarian hyperstimulation syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-06-28 04:29:01 +1200" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-06-28 04:29:01 +1200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001302"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Youssef-2011" MODIFIED="2016-06-28 04:26:38 +1200" MODIFIED_BY="Heather Maxwell" NAME="Youssef 2011" TYPE="COCHRANE_REVIEW">
<AU>Youssef MAFM, Al-Inany HG, Evers JLH, Aboulghar M</AU>
<TI>Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-06-28 04:24:17 +1200" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-06-28 04:24:17 +1200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001302.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-08-10 13:40:32 +1200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-08-10 13:40:32 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-06-30 01:09:53 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bellver-2003">
<CHAR_METHODS MODIFIED="2009-08-18 10:18:17 +1200" MODIFIED_BY="jane clarke">
<P>Randomised controlled trial<BR/>Parallel design<BR/>Single centre</P>
<P>Not blind</P>
<P>Power calculation: done</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:09:53 +1200" MODIFIED_BY="Heather Maxwell">
<P>988 women (infertile women n = 605 and donors n = 383) who were all considered to be at risk of moderate or severe OHSS (495 albumin/493 control)<BR/>&gt; 20 retrieved oocytes was the basic risk factor of OHSS<BR/>Age (29.9 versus 29.7years)<BR/>Duration of infertility (not stated)<BR/>No. of FSH and hMG ampoules (not stated)<BR/>No. of oocytes (28.7 versus 27.8)<BR/>No. of embryos (15 versus 19)</P>
<P>No. of transferred embryos (2.8 versus 3.0)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-14 15:00:27 +1200" MODIFIED_BY="Helen E Nagels">
<P>
<B>Study group: </B>40 g human albumin infused intravenously at a slow rate, immediately after oocyte retrieval</P>
<P>
<B>Duration</B>: during 30 min<BR/>
<B>Control group</B>: no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-14 15:00:25 +1200" MODIFIED_BY="Helen E Nagels">
<P>Method of diagnosing severe OHSS: criteria for (<LINK REF="REF-Golan-1989" TYPE="REFERENCE">Golan 1989</LINK>)</P>
<P>Severe OHSS: 25/495 versus 23/493<BR/>Pregnancy: 138/298 versus 166/307<BR/>Method of diagnosing pregnancy: fetal heart rate</P>
<P>Tolerability: yes<BR/>Safety: yes<BR/>Cost-benefit: stated (195 euros/patient)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-28 20:44:00 +1200" MODIFIED_BY="Heather Maxwell">
<P>Two kinds of GnRH agonist were used and only early OHSS was assessed. Placebo was not used in their control group, which eliminates the placebo effect of albumin administration. Serum E2 level, which was previously reported as an independent risk factor for severe OHSS, was not considered a high-risk factor in this study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-30 01:08:23 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gokmen-2001">
<CHAR_METHODS MODIFIED="2016-06-28 20:44:27 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised controlled trial, three-arm trial, parallel design, single centre<BR/>Power calculation: not done</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:08:23 +1200" MODIFIED_BY="Heather Maxwell">
<P>250 infertile women at risk of severe OHSS (82 albumin/83 control/85 HES)<BR/>E2 (the basic risk factor of OHSS) was 3000 pg/mL or the presence of &gt; 20 follicles on the day of hCG.<BR/>Age: albumin 29.6 versus HES 31.2 versus placebo 32.3 years<BR/>Duration of infertility (not mentioned)<BR/>No. of hMG ampoules (not mentioned)<BR/>No.of oocytes (albumin 12.0 versus HES 13.2 versus placebo 11.1)<BR/>No.of embryos ( albumin 3.3 versus HES 3.1 versus placebo 3.0)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-28 21:30:07 +1200" MODIFIED_BY="Heather Maxwell">
<P>
<B>Study group: </B>10 g albumin immediately after oocyte retrieval, or 6% HES (200/0.5) 500 mL<BR/>
<B>Duration of infusion</B>: over 30 minutes<BR/>
<B>Control group:</B> received saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-29 05:07:39 +1200" MODIFIED_BY="Heather Maxwell">
<P>Method of diagnosing severe OHSS: criteria of Schenker and Weinstein, 1978<BR/>Severe OHSS: albumin versus control 0/82 versus 4/83, and HES versus control 0/85 versus 4/83<BR/>Pregnancy: albumin versus control 11/82 versus 10/83, and HES versus control 12/85 versus 10/83<BR/>Method of diagnosing pregnancy: serum &#946;-hCG<BR/>Tolerability: yes<BR/>Safety: one case of anaphylactic reaction with albumin and two cases of urticaria with HES<BR/>Cost-benefit: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-18 10:23:37 +1200" MODIFIED_BY="jane clarke">
<P>Source of funding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-30 01:08:28 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Isik-1996">
<CHAR_METHODS MODIFIED="2016-06-28 20:48:20 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised controlled trial, parallel design, single centre</P>
<P>Power calculation: done</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:08:28 +1200" MODIFIED_BY="Heather Maxwell">
<P>55 infertile women who were all considered to be at risk of severe OHSS (27 albumin/28 control)<BR/>E2 (the basic risk factor of OHSS) was 11010 pmol/L<BR/>Age (31.2 versus 30.8 years)<BR/>Duration of infertility (7.8 versus 7.3)<BR/>No. of hMG ampoules (25.9 versus 26.1)<BR/>No. of oocytes (15.3 versus 16.4)<BR/>No. of embryos (3.2 versus 3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-28 20:48:45 +1200" MODIFIED_BY="Heather Maxwell">
<P>
<B>Study group: </B>10 g albumin 2 hours before oocyte retrieval<BR/>
<B>Duration of infusion</B>: over 1 hour<BR/>
<B>Control group</B>: no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-29 05:07:46 +1200" MODIFIED_BY="Heather Maxwell">
<P>Method of diagnosing severe OHSS: criteria of Schenker and Weinstein, 1978<BR/>Severe OHSS: 0/27 versus 1/28<BR/>Pregnancy: 5/27 versus 5/28<BR/>Method of diagnosing pregnancy: serum &#946;-hCG<BR/>Tolerability: yes<BR/>Safety: 2 urticaria<BR/>Cost-benefit: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 09:36:19 +1200" MODIFIED_BY="jane clarke">
<P>Source of funding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-30 01:08:39 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Isikoglu-2007">
<CHAR_METHODS MODIFIED="2016-06-28 20:49:12 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised, placebo-controlled trial, parallel design, single centre</P>
<P>No sample size calculation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:08:35 +1200" MODIFIED_BY="Heather Maxwell">
<P>
<B>Study group: </B>75 infertile women who were all considered to be at risk of severe OHSS (38 albumin/37control)<BR/>High blood E2 level (&gt; 4000 pg/mL) and &gt; 20 follicles R14 mm on the day of hCG administration have been defined as the basic risk factors for severe OHSS<BR/>Age (29.3 versus 29.1 years)<BR/>Duration of infertility (not stated)<BR/>No. of hMG ampoules ( no significant difference between both groups)</P>
<P>No. of FSH ampoules (no significant difference between both groups)</P>
<P>No.of oocytes (22.6 versus 20.5)<BR/>No.of embryos (3.4 versus 3.2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-28 20:50:03 +1200" MODIFIED_BY="Heather Maxwell">
<P>
<B>Study group: </B>10 g (50 cc, 20% HSA diluted in 100 mL 0.9% NaCl or 100 mL 0.9% NaCl) just after oocyte retrieval<BR/>
<B>Duration</B>: 1 hour<BR/>
<B>Control group</B>: 100 mL 0.9% NaCl</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-30 01:08:39 +1200" MODIFIED_BY="Heather Maxwell">
<P>Method of diagnosing severe OHSS: according to Navot et al, 1992<BR/>Severe OHSS: 8/38 versus 6/37<BR/>Pregnancy: 21/38 versus 23/37<BR/>Method of diagnosing clinical pregnancy: heartbeat at ultrasound 3 weeks after ET<BR/>Tolerability: yes<BR/>Safety: yes<BR/>Cost-benefit: not calculated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-30 01:08:47 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Koike-1999">
<CHAR_METHODS MODIFIED="2016-06-28 20:50:36 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised, placebo-controlled trial, single centre, unpublished</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:08:47 +1200" MODIFIED_BY="Heather Maxwell">
<P>98 infertile women at risk of severe OHSS ( 43 albumin plus saline versus 55 saline alone) undergoing IVF/ICSI/GIFT</P>
<P>&gt; 20 oocytes were retrieved from patients at high risk.The estradiol in their serum was not measured<BR/>Age (32.1 versus 31.0 years)<BR/>Duration of infertility (not stated)<BR/>No. of hMG ampoules (not stated)<BR/>No. of oocytes (27 versus 26.1)<BR/>No. of embryos (19 versus 17)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-28 20:51:27 +1200" MODIFIED_BY="Heather Maxwell">
<P>
<B>Study group</B>: 37.5 g albumin plus 1000 mL electrolyte solution just after oocyte retrieval<BR/>
<B>Duration</B>: consecutive 3 days<BR/>
<B>Control group</B>: 1000 mL electrolyte solution for consecutive 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-29 05:08:03 +1200" MODIFIED_BY="Heather Maxwell">
<P>Method of diagnosing severe OHSS: marked haemoconcentration (haematocrit &#8805; 45) and/or hypoproteinaemia (serum total protein &lt; 6.0 g/dL) in addition to marked ascites on the upper abdomen at least 4 days after oocyte retrieval (Orvieto and Ben-Rafael,1998)<BR/>Severe OHSS: 13/43 versus 21/55<BR/>Pregnancy: 14/43 versus 24/55<BR/>Method of diagnosing pregnancy: serum &#946;-hCG<BR/>Tolerability: not stated<BR/>Safety: not stated<BR/>Cost-benefit: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-14 15:00:03 +1200" MODIFIED_BY="Helen E Nagels"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-18 03:14:50 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konig-1998">
<CHAR_METHODS MODIFIED="2016-06-28 20:52:12 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised, placebo-controlled, double blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:08:51 +1200" MODIFIED_BY="Heather Maxwell">
<P>104 infertile women at risk of severe OHSS (53 HES/51 control)<BR/>E2 the basic risk factor of OHSS) was &gt; 1500 pg/mL and more than 10 follicles on the day of hCG injection<BR/>Age (HES 32.6 versus placebo 30.7 years)<BR/>Duration of infertility (not mentioned)<BR/>No. of hMG ampoules (not mentioned, similar in both groups )<BR/>No. of oocytes (not mentioned, similar in both groups)<BR/>No. of embryos (not mentioned)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-18 03:14:50 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>Study group: </B>1000 mL of 6% HES solution shortly after embryo transfer (48 hr after the oocyte retrieval)</P>
<P>originally 104 pt randomised: HES 53 control 51; data presented only for 51 and 50 patients respectively. dropout 2.9% (3 women; 2 missing data, 1 allergic reaction)<BR/>
<B>Duration of infusion</B>: over 2 hours<BR/>
<B>Control group</B>: 1000 mL NaCl 0.9% solution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 12:32:16 +1300" MODIFIED_BY="[Empty name]">
<P>Method of diagnosing severe OHSS: criteria of WHO, 1973<BR/>Severe OHSS 0/53 versus 1/51<BR/>Pregnancy: not stated but similar between both group<BR/>Method of diagnosing pregnancy: not stated (clinical pregnancy)<BR/>Tolerability: yes<BR/>Safety: one case of urticaria<BR/>Cost-benefit: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 15:12:01 +1200" MODIFIED_BY="jane clarke">
<P>Commercially funded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-10 10:44:21 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saremi-2003">
<CHAR_METHODS MODIFIED="2015-11-30 14:27:12 +1300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial; simple randomisation per random number table</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-28 20:54:29 +1200" MODIFIED_BY="Heather Maxwell">
<P>226 patients with endocrine and sonographic evidence of PCOS.</P>
<P>110 women study group, 116 women control group</P>
<P>E2 : no threshold for inclusion. Exclusion and cancelling when E2 &gt; 6000 pg/mL<BR/>Age ( mannitol 27.5yr vs control 28.6yr))<BR/>Duration of infertility not mentioned<BR/>No. of hMG ampoules not mentioned<BR/>No. of oocytes (mannitol 25.5 vs control 23.6) similar in both groups<BR/>No. of embryos (not mentioned)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-10 10:44:15 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>Study group (A):</B> 3 gr/kg bodyweight mannitol (20 g mannitol/100 mL water for injection) daily starting on the day after hCG injection until third day after embryo transfer ( lasting 5-7 days depending on day of transfer)</P>
<P>
<B>Duration of infusion:</B> 30-60 minutes</P>
<P>
<B>Control group (B): </B>no drugs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-08-10 10:44:21 +1200" MODIFIED_BY="[Empty name]">
<P>Incidence of OHSS (mild, moderate and severe), pregnancy rates (defined as heartbeat at ultrasound 3 weeks after ET), blood pressure, Hb levels, white blood cell count, vital sign per 4 hrs after administration, serum osmolality and osmolar gap, intake and output volumes before and during mannitol administration &amp; renal functionality, serum electrolytes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-28 20:56:47 +1200" MODIFIED_BY="Heather Maxwell">
<P>Funding not stated; additional information from correspondence with author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-30 01:09:02 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Shalev-1995">
<CHAR_METHODS MODIFIED="2016-06-28 20:57:35 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised, placebo-controlled trial, parallel design, single centre</P>
<P>No power of calculation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:09:02 +1200" MODIFIED_BY="Heather Maxwell">
<P>40 infertile women who were all considered to be at risk of severe OHSS (22 albumin/18control)<BR/>E2 (the basic risk factor of OHSS) was 9200 pmol/L<BR/>Age (29.7 versus 28.3 years)<BR/>Duration of infertility (not stated)<BR/>No. of hMG ampoules (not stated)<BR/>No. of oocytes (21 versus 19.3)<BR/>No. of embryos (19 versus 17)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-28 20:57:53 +1200" MODIFIED_BY="Heather Maxwell">
<P>
<B>Study group: </B>20 g albumin just after oocyte retrieval<BR/>
<B>Duration</B>: not stated<BR/>
<B>Control group</B>: no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-29 05:08:28 +1200" MODIFIED_BY="Heather Maxwell">
<P>Method of diagnosing severe OHSS: according to Navot et al, 1992<BR/>Severe OHSS: 0/22 versus 4/18<BR/>Pregnancy: 6/22 versus 2/18<BR/>Method of diagnosing pregnancy: serum &#946;-hCG<BR/>Tolerability: yes<BR/>Safety: yes<BR/>Cost-benefit: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 12:34:18 +1300" MODIFIED_BY="[Empty name]">
<P>Source of funding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-30 01:09:08 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Shoham-1994">
<CHAR_METHODS MODIFIED="2016-06-28 20:58:13 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised, placebo-controlled trial, parallel design, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 01:09:08 +1200" MODIFIED_BY="Heather Maxwell">
<P>31 infertile women who were all considered to be at risk of severe OHSS (16 albumin/15control)<BR/>E2 (the basic risk factor of OHSS was 7000 pmol/L)<BR/>Age (32.5 versus 29.7 years)<BR/>Duration of infertility (6.9 versus 7)<BR/>No. of hMG ampoules: (23.3 versus 22.7)<BR/>No. of oocytes: (13.4 versus 12.6)<BR/>No. of embryos: (3.4 versus 3.2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-28 21:00:19 +1200" MODIFIED_BY="Heather Maxwell">
<P>
<B>Study group: </B>50 g albumin 2 hours before oocyte retrieval<BR/>
<B>Duration</B>: over 1 hour<BR/>
<B>Control group</B>: 500 mL of 9% NaCl</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-29 05:08:34 +1200" MODIFIED_BY="Heather Maxwell">
<P>Method of diagnosing severe OHSS: criteria for Schenker and Weinstein, 1978<BR/>Severe OHSS (0/16 versus 4/15)<BR/>Pregnancy: (4/16 versus 2/15)<BR/>Method of diagnosing pregnancy: serum &#946;-hCG<BR/>Tolerability: yes<BR/>Safety: yes<BR/>Cost-benefit: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 15:13:59 +1300" MODIFIED_BY="[Empty name]">
<P>Source of funding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ET: embryo transfer<BR/>FSH: follicle-stimulating hormone <BR/>GIFT: gamete intra-fallopian transfer<BR/>GnRH: gonadotropin-releasing hormone<BR/>Hb: haemoglobin<BR/>hCG: human chorionic gonadotrophin<BR/>HES: hydroxyethyl starch<BR/>hMG: human menopausal gonadotropin<BR/>ICSI: intracytoplasmic sperm injection<BR/>IVF: in vitro fertilisation<BR/>NaCl: sodium chloride<BR/>OHSS: ovarian hyperstimulation syndrome<BR/>PCOS: polycystic ovary syndrome</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-07-01 11:27:55 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-09-27 15:14:14 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abramov-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 15:14:14 +1300" MODIFIED_BY="[Empty name]">
<P>Case control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-07 18:31:52 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abuzeid--2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-07 18:31:52 +1300" MODIFIED_BY="[Empty name]">
<P>Prospective cohort clinical trial </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-16 09:49:09 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmadi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-16 09:49:09 +1300" MODIFIED_BY="[Empty name]">
<P>RCT, compared human albumin with cabergoline as prophylaxis of OHSS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-12 10:00:09 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asch-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-12 10:00:09 +1200" MODIFIED_BY="[Empty name]">
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:36:52 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ben_x002d_Chetrit-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:36:52 +1300" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-12 09:49:00 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ben_x002d_Rafael-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-12 09:49:00 +1200" MODIFIED_BY="[Empty name]">
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 04:32:17 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cambiaghi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 04:32:17 +1200" MODIFIED_BY="Heather Maxwell">
<P>RCT compared oral whey protein versus albumin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:37:01 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:37:01 +1300" MODIFIED_BY="[Empty name]">
<P>Prospective non-randomised trial with historical control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-30 01:03:19 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Chen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-30 01:03:19 +1200" MODIFIED_BY="Heather Maxwell">
<P>Retrospective study, compared coasting versus intravenous albumin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:37:18 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Costabile-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:37:18 +1300" MODIFIED_BY="[Empty name]">
<P>Albumin infusion versus intra-muscular progesterone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-07 20:10:52 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dmitrieva-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-07 20:10:52 +1300" MODIFIED_BY="[Empty name]">
<P>RCT, compared starch solution versus calcium gluconate in prevention of OHSS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:37:24 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Egbase-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:37:24 +1300" MODIFIED_BY="[Empty name]">
<P>Non-controlled randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-30 14:27:12 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El_x002d_Khayat-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 14:27:12 +1300" MODIFIED_BY="[Empty name]">
<P>RCT, excluded because calcium gluconate is not a volume expander</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:37:36 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Endo-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:37:36 +1300" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised study, comparing human albumin versus dextran</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 04:32:49 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Fan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 04:32:49 +1200" MODIFIED_BY="Heather Maxwell">
<P>Randomised, placebo-controlled trial comparing human albumin versus hydroxyethyl starch versus placebo. Abstract and the data were not reported clearly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-05 19:17:38 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fluker-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-05 19:17:38 +1300" MODIFIED_BY="[Empty name]">
<P>Prospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:38:25 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gamzu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:38:25 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study, comparing hydroxyethyl starch versus Haemaccel</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-01 11:27:55 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gokmen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-01 11:27:55 +1200" MODIFIED_BY="[Empty name]">
<P>Data appear to overlap with <LINK REF="STD-Gokmen-2001" TYPE="STUDY">Gokmen 2001</LINK>. Attempts to obtain clarification from author were unsuccessful</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-11 17:58:28 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graf-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-11 17:58:28 +1200" MODIFIED_BY="[Empty name]">
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-12 09:44:59 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halme-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-12 09:44:59 +1200" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:38:33 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Isik-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:38:33 +1300" MODIFIED_BY="[Empty name]">
<P>Non-controlled randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:38:39 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Isik-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:38:39 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study, used combined approach for OHSS prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:38:49 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kissler-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:38:49 +1300" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:39:06 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koike--2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:39:06 +1300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial comparing human albumin versus continuous autotransfusion system of ascites (CASTA)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-12 08:51:19 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumbak-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-12 08:51:19 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-15 02:26:26 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewit-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-15 02:26:26 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-05 19:53:01 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lincolin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-05 19:53:01 +1300" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-30 14:27:12 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matorras-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-30 14:27:12 +1300" MODIFIED_BY="[Empty name]">
<P>comparison of HES vs cabergoline and HES</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-06 03:06:24 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Milacic-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-06 03:06:24 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was unclear </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-12 09:58:41 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mukherjee-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-12 09:58:41 +1200" MODIFIED_BY="[Empty name]">
<P>Case reports</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 04:34:33 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Naredi-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 04:34:33 +1200" MODIFIED_BY="Heather Maxwell">
<P>Quasi-randomised study (patients appointed to groups by odd/ even registration numbers)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-12 09:54:08 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ndukwe-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-12 09:54:08 +1200" MODIFIED_BY="[Empty name]">
<P>Retrospective review and data analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-12 08:33:46 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ng-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-12 08:33:46 +1200" MODIFIED_BY="[Empty name]">
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-23 12:39:27 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panay-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-23 12:39:27 +1300" MODIFIED_BY="[Empty name]">
<P>RCT, quasi-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 23:03:40 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaker-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 23:03:40 +1300" MODIFIED_BY="[Empty name]">
<P>Compared albumin infusion versus embryo cryopreservation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 04:35:13 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Tan-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 04:35:13 +1200" MODIFIED_BY="Heather Maxwell">
<P>The trial did not study the relevant intervention, instead it studied the use of glucocorticoids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 04:34:55 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Tehraninejad--2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 04:34:55 +1200" MODIFIED_BY="Heather Maxwell">
<P>Comparison of cabergoline with albumin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 04:35:35 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Torabizadeh-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 04:35:35 +1200" MODIFIED_BY="Heather Maxwell">
<P>Comparison of cabergoline versus albumin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-28 04:35:45 +1200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Yakovenko-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-28 04:35:45 +1200" MODIFIED_BY="Heather Maxwell">
<P>Comparison of calcium gluconate versus HES</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>HES: hydroxyethyl starch<BR/>OHSS: ovarian hyperstimulation syndrome<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-09-07 14:34:30 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-07-12 08:51:05 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>os</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-08-10 13:40:32 +1200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-06-28 20:56:53 +1200" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-28 20:44:05 +1200" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Bellver-2003">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:37:38 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gokmen-2001">
<DESCRIPTION>
<P>Random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-27 15:12:06 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isik-1996">
<DESCRIPTION>
<P>Random table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-17 16:16:29 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isikoglu-2007">
<DESCRIPTION>
<P>Methods unclear: "Patients were randomised by third-party sealed envelope entry"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:52:41 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koike-1999">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:09:07 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konig-1998">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-28 20:56:53 +1200" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Saremi-2003">
<DESCRIPTION>
<P>Simple randomisation per random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:26:47 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-1995">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:56:30 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoham-1994">
<DESCRIPTION>
<P>Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-06-28 20:56:58 +1200" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:07:25 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bellver-2003">
<DESCRIPTION>
<P>Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:37:43 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gokmen-2001">
<DESCRIPTION>
<P>Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:29:00 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isik-1996">
<DESCRIPTION>
<P>Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-17 16:16:29 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isikoglu-2007">
<DESCRIPTION>
<P>Methods unclear: "Patients were randomised by third-party sealed envelope entry"<BR/>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 13:55:12 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koike-1999">
<DESCRIPTION>
<P>Methods not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 13:55:21 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1998">
<DESCRIPTION>
<P>Methods not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-28 20:56:58 +1200" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Saremi-2003">
<DESCRIPTION>
<P>Methods not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 13:55:25 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shalev-1995">
<DESCRIPTION>
<P>Methods not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:58:34 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoham-1994">
<DESCRIPTION>
<P>Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-06-28 20:57:02 +1200" MODIFIED_BY="Heather Maxwell" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 15:53:55 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Bellver-2003">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 15:54:30 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gokmen-2001">
<DESCRIPTION>
<P>Blinding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 15:54:42 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Isik-1996">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 14:40:59 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isikoglu-2007">
<DESCRIPTION>
<P>"The outcome assessors were blind to the interventions. The patients were also blind to the infusions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 15:55:05 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koike-1999">
<DESCRIPTION>
<P>Blinding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 15:44:45 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1998">
<DESCRIPTION>
<P>Double blinded; both patients and physicians blinded, but outcome assessors not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-28 20:57:02 +1200" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Saremi-2003">
<DESCRIPTION>
<P>Physicians were blinded to the allocated groups, nurse performed protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 15:55:20 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shalev-1995">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-04 15:55:45 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoham-1994">
<DESCRIPTION>
<P>Blinding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-06-28 20:57:07 +1200" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-04 14:06:30 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellver-2003">
<DESCRIPTION>
<P>966/988 (98%) randomised women included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-04 16:23:41 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gokmen-2001">
<DESCRIPTION>
<P>250 women randomised and all included in analysis - but later unpublished report (Gokmen 2005) apparently refers to same study and includes a larger sample and two additional events. Attempts to contact the study authors were unsuccessful.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-04 15:43:51 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isik-1996">
<DESCRIPTION>
<P>All randomised women included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-04 14:42:46 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isikoglu-2007">
<DESCRIPTION>
<P>All randomised women were included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-04 14:53:19 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koike-1999">
<DESCRIPTION>
<P>All randomised women included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-04 15:08:21 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konig-1998">
<DESCRIPTION>
<P>101/104 (97%) randomised women were included in analysis </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-28 20:57:07 +1200" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Saremi-2003">
<DESCRIPTION>
<P>All randomised women included in analysis, no drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-04 15:26:17 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-1995">
<DESCRIPTION>
<P>All randomised women were included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-17 16:16:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoham-1994">
<DESCRIPTION>
<P>All randomised women included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-08-10 13:40:32 +1200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 16:56:48 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bellver-2003">
<DESCRIPTION>
<P>Unclear whether data on adverse events were collected prospectively as it was not a prespecified outcome, though mentioned in the discussion section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-28 21:30:23 +1200" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Gokmen-2001">
<DESCRIPTION>
<P>Unclear whether data on adverse events were collected prospectively as it was not a prespecified outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 16:00:12 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isik-1996">
<DESCRIPTION>
<P>Unclear whether data on adverse events were collected prospectively as it was not a prespecified outcome, though mentioned in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 16:00:08 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isikoglu-2007">
<DESCRIPTION>
<P>Unclear whether data on adverse events were collected prospectively as it was not a prespecified outcome, though mentioned in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:55:42 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koike-1999">
<DESCRIPTION>
<P>Adverse effects not reported as an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 16:00:00 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1998">
<DESCRIPTION>
<P>Unclear whether data on adverse events were collected prospectively as it was not a prespecified outcome, though mentioned in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-10 13:40:32 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saremi-2003">
<DESCRIPTION>
<P>Data on adverse events were collected though not explicitly mentioned what kind of events.</P>
<P>"mannitol protocol, all of the lab tests and patient's signs and symptoms were recorded; including vital sign Q4h, serum osmolality and osmolar gap, intake and output volumes before and during mannitol administration &amp; renal functionality, serum electrolytes and etc&#8230; " (private correspondence)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:59:53 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shalev-1995">
<DESCRIPTION>
<P>Unclear whether data on adverse events were collected prospectively as it was not a prespecified outcome, though mentioned in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:59:27 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoham-1994">
<DESCRIPTION>
<P>Unclear whether data on adverse events were collected prospectively as it was not a prespecified outcome, though mentioned in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-06-28 20:57:25 +1200" MODIFIED_BY="Heather Maxwell" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:11:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellver-2003">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 16:23:54 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gokmen-2001">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:43:23 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isik-1996">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:43:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isikoglu-2007">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 14:55:50 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koike-1999">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:11:25 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1998">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-28 20:57:25 +1200" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Saremi-2003">
<DESCRIPTION>
<P>No other potential bias detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:26:59 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-1995">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-04 15:59:38 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoham-1994">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-08-18 00:55:54 +1200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-08-10 13:46:39 +1200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-08-10 11:09:56 +1200" MODIFIED_BY="[Empty name]">Human albumin versus placebo or no treatment for the prevention of OHSS</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Human albumin versus placebo or no treatment for the prevention of OHSS </B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Population: </B>women at high risk of OHSS<BR/>
<B>Setting: </B>ART clinics<BR/>
<B>Intervention: </B>Human albumin<BR/>
<B>Comparison: </B>placebo / no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo / no treatment</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Human albumin</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Moderate or severe OHSS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>122 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>85 per 1000<BR/>(61 to 117)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>OR 0.67<BR/>(0.47 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1452<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW <SUP>1 2 3</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Live birth</P>
</TD>
<TD COLSPAN="5">
<P>Not reported in the included studies</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Pregnancy rate</P>
<P>assessed with: serum &#946;-hCG or heartbeat on ultrasound</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>396 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>321 per 1000<BR/>(265 to 381)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>OR 0.72<BR/>(0.55 to 0.94)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1069<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse effects</P>
</TD>
<TD COLSPAN="5">
<P>No reliable data as none of the studies specified adverse effects as an outcome</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded one level for serious risk of bias: associated with lack of blinding, inadequate reporting of allocation concealment, unclear risk of attrition bias</P>
<P>
<SUP>2</SUP> Downgraded one level for serious imprecision: number of events &lt; 300</P>
<P>
<SUP>3</SUP> Downgraded one level for serious inconsistency: I<SUP>2</SUP>= 69%</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-08-10 13:45:23 +1200" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2016-08-10 11:30:15 +1200" MODIFIED_BY="[Empty name]">HES versus placebo or no treatment for the prevention of OHSS</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>HES versus placebo or no treatment for the prevention of OHSS</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Population: </B>Women at high risk of OHSS<BR/>
<B>Setting: </B>ART clinics<BR/>
<B>Intervention: </B>HES<BR/>
<B>Comparison: </B>placebo / no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo / no treatment</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with HES</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Moderate or severe OHSS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>164 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>50 per 1000<BR/>(23 to 104)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>OR 0.27<BR/>(0.12 to 0.59)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>272<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW <SUP>1 2</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Live birth</P>
</TD>
<TD COLSPAN="5">
<P>Not reported in the included studies</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Pregnancy rate</P>
<P>assessed with: serum &#946;-hCG or heartbeat on ultrasound</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>120 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>141 per 1000<BR/>(63 to 286)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>OR 1.20<BR/>(0.49 to 2.93)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>168<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW <SUP>1 2</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse effects</P>
</TD>
<TD COLSPAN="5">
<P>No reliable data as none of the studies specified adverse effects as an outcome</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded two levels for very serious risk of bias: associated with inadequate reporting of allocation concealment and blinding, and unclear risk of attrition bias</P>
<P>
<SUP>2</SUP> Downgraded one level for serious imprecision: number of events &lt;300</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-08-18 00:55:54 +1200" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2016-08-10 11:45:55 +1200" MODIFIED_BY="[Empty name]">Mannitol versus placebo / no treatment for the prevention of OHSS</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mannitol versus placebo or no treatment for the prevention of OHSS</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Population:</B> women at high risk of OHSS<BR/>
<B>Setting: </B>ART clinics<BR/>
<B>Intervention: </B>Mannitol<BR/>
<B>Comparison: </B>placebo / no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo / no treatment</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Mannitol</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Moderate or severe OHSS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>517 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>289 per 1000<BR/>(191 to 407)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>OR 0.38<BR/>(0.22 to 0.64)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>226<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<SUP>1,2</SUP>
<BR/>LOW</P>
</TD>
</TR>
<TR>
<TD>
<P>Live birth</P>
</TD>
<TD COLSPAN="5">
<P>Not reported in the included studies</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Pregnancy rate<BR/>assessed with: serum &#946;-hCG or heartbeat on ultrasound</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>276 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>245 per 1000<BR/>(152 to 371)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>OR 0.85<BR/>(0.47 to 1.55)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>226<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<SUP>1,2</SUP>
<BR/>LOW</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse effects</P>
</TD>
<TD COLSPAN="5">
<P>No reliable data as none of the studies specified adverse effects as an outcome</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1 Downgraded one level for risk of bias: inadequate reporting of allocation concealment, </P>
<P>
<SUP>2 </SUP>Downgraded one level for serious imprecision: number of events &lt; 300</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-10-07 00:38:28 +1300" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-08-25 15:26:43 +1200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-08-25 15:26:43 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Human Albumin vs placebo / no treatment</NAME>
<DICH_OUTCOME CHI2="19.101963785103607" CI_END="0.9472961077994356" CI_START="0.4719090198371275" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6686086880434307" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="89" I2="68.58961692368503" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.023514247097533802" LOG_CI_START="-0.32614172168638833" LOG_EFFECT_SIZE="-0.17482798439196107" METHOD="PETO" MODIFIED="2016-08-25 15:26:43 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00399486179154751" P_Q="0.6588493588715738" P_Z="0.023540702320424448" Q="0.19492433788743288" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="723" TOTAL_2="729" WEIGHT="100.0" Z="2.2645435835824412">
<NAME>Total OHSS</NAME>
<GROUP_LABEL_1>Albumin</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo/ no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours albumin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.64230839189554" CI_END="1.0779984925302328" CI_START="0.4621827812470747" DF="2" EFFECT_SIZE="0.7058557511685917" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="54" I2="81.2070847192977" ID="CMP-001.01.01" LOG_CI_END="0.0326181535350805" LOG_CI_START="-0.33518623832180927" LOG_EFFECT_SIZE="-0.15128404239336443" MODIFIED="2016-08-25 15:26:38 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00488712187044571" P_Z="0.10688985634807036" STUDIES="3" TAU2="0.0" TOTAL_1="604" TOTAL_2="604" WEIGHT="67.69909856121026" Z="1.6123313429166202">
<NAME>Studies reporting moderate or severe OHSS</NAME>
<DICH_DATA CI_END="1.735215321675374" CI_START="0.6481694979296556" EFFECT_SIZE="1.0605251736051216" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="33" LOG_CI_END="0.23935337377428517" LOG_CI_START="-0.18831141019446507" LOG_EFFECT_SIZE="0.025520981789910073" MODIFIED="2016-08-10 12:17:57 +1200" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.9311740890688256" SE="0.2512124110780667" STUDY_ID="STD-Bellver-2003" TOTAL_1="495" TOTAL_2="493" VAR="15.845933040623189" WEIGHT="50.07370516142515"/>
<DICH_DATA CI_END="0.6627340775098082" CI_START="0.10271665704726332" EFFECT_SIZE="0.26090961836066795" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.17866069759365646" LOG_CI_START="-0.9883591233245956" LOG_EFFECT_SIZE="-0.583509910459126" MODIFIED="2016-08-10 09:41:44 +1200" MODIFIED_BY="[Empty name]" ORDER="33" O_E="-5.9393939393939394" SE="0.4756208633462024" STUDY_ID="STD-Gokmen-2001" TOTAL_1="82" TOTAL_2="83" VAR="4.420569329660239" WEIGHT="13.969154400158958"/>
<DICH_DATA CI_END="0.7413299466077403" CI_START="0.01937934129230855" EFFECT_SIZE="0.11986027717939031" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.12998845585586086" LOG_CI_START="-1.7126609887907938" LOG_EFFECT_SIZE="-0.9213247223233273" MODIFIED="2016-07-25 01:53:56 +1200" MODIFIED_BY="[Empty name]" ORDER="35" O_E="-2.4545454545454546" SE="0.9296696802013684" STUDY_ID="STD-Isik-1996" TOTAL_1="27" TOTAL_2="28" VAR="1.1570247933884295" WEIGHT="3.656238999626149"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.26473105532064" CI_END="1.1017045428489831" CI_START="0.32328676156374925" DF="3" EFFECT_SIZE="0.5967968614677179" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="35" I2="63.70117817604397" ID="CMP-001.01.02" LOG_CI_END="0.042065140237436856" LOG_CI_START="-0.49041207917294216" LOG_EFFECT_SIZE="-0.22417346946775268" MODIFIED="2016-08-25 15:26:43 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04084595219505427" P_Z="0.09888286012003002" STUDIES="4" TAU2="0.0" TOTAL_1="119" TOTAL_2="125" WEIGHT="32.30090143878974" Z="1.6502937982312502">
<NAME>Studies reporting severe OHSS</NAME>
<DICH_DATA CI_END="4.341867461598236" CI_START="0.43184704579311184" EFFECT_SIZE="1.369314659425085" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6376765621918566" LOG_CI_START="-0.3646700470055405" LOG_EFFECT_SIZE="0.13650325759315812" MODIFIED="2016-08-10 12:18:00 +1200" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.9066666666666663" SE="0.5887833599382878" STUDY_ID="STD-Isikoglu-2007" TOTAL_1="38" TOTAL_2="37" VAR="2.8846222222222226" WEIGHT="9.115507574552387"/>
<DICH_DATA CI_END="1.6268299661874266" CI_START="0.30691922210947203" EFFECT_SIZE="0.7066154454345189" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" LOG_CI_END="0.21134216350509857" LOG_CI_START="-0.5129759111945942" LOG_EFFECT_SIZE="-0.15081687384474785" MODIFIED="2016-08-10 12:18:03 +1200" MODIFIED_BY="[Empty name]" ORDER="37" O_E="-1.9183673469387763" SE="0.4254680225108944" STUDY_ID="STD-Koike-1999" TOTAL_1="43" TOTAL_2="55" VAR="5.52415874828787" WEIGHT="17.45653573806819"/>
<DICH_DATA CI_END="0.699677968287373" CI_START="0.011589222359243147" EFFECT_SIZE="0.09004845114906664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.15510180109409558" LOG_CI_START="-1.9359457043660058" LOG_EFFECT_SIZE="-1.0455237527300507" MODIFIED="2016-07-25 01:56:05 +1200" MODIFIED_BY="[Empty name]" ORDER="38" O_E="-2.2" SE="1.046076524101413" STUDY_ID="STD-Shalev-1995" TOTAL_1="22" TOTAL_2="18" VAR="0.913846153846154" WEIGHT="2.8877859544959334"/>
<DICH_DATA CI_END="0.7951399816265319" CI_START="0.012735581751501504" EFFECT_SIZE="0.10063086126975215" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.09955640858071622" LOG_CI_START="-1.894981212011996" LOG_EFFECT_SIZE="-0.9972688102963561" MODIFIED="2016-07-25 01:56:05 +1200" MODIFIED_BY="[Empty name]" ORDER="39" O_E="-2.064516129032258" SE="1.0546414170316463" STUDY_ID="STD-Shoham-1994" TOTAL_1="16" TOTAL_2="15" VAR="0.8990634755463058" WEIGHT="2.841072171673229"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.343244523799976" CI_END="0.938096649688896" CI_START="0.5481111650653788" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7170643259881985" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="215" I2="41.99112293832075" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.02775241507058136" LOG_CI_START="-0.2611313512266553" LOG_EFFECT_SIZE="-0.1444418831486183" METHOD="PETO" MODIFIED="2016-08-10 11:28:44 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11092188169341832" P_Q="1.0" P_Z="0.015261858701474007" Q="0.0" RANDOM="NO" SCALE="430.55" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="526" TOTAL_2="543" WEIGHT="100.00000000000001" Z="2.4261048875559967">
<NAME>Pregnancy rate</NAME>
<GROUP_LABEL_1>Favours albumin</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours albumin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatm</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0085354971239104" CI_START="0.5333790578470019" EFFECT_SIZE="0.7334382818350902" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="166" LOG_CI_END="0.003691188551495957" LOG_CI_START="-0.2729640400897767" LOG_EFFECT_SIZE="-0.1346364257691403" MODIFIED="2016-08-10 10:59:19 +1200" MODIFIED_BY="[Empty name]" ORDER="48" O_E="-11.738842975206609" SE="0.1625086507693518" STUDY_ID="STD-Bellver-2003" TOTAL_1="298" TOTAL_2="307" VAR="37.8657907690053" WEIGHT="71.16157415288207"/>
<DICH_DATA CI_END="2.8155622145580157" CI_START="0.453566975048268" EFFECT_SIZE="1.130064616169041" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4495651282462757" LOG_CI_START="-0.34335857465404324" LOG_EFFECT_SIZE="0.05310327679611632" MODIFIED="2016-08-10 10:59:19 +1200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.5636363636363644" SE="0.4657673081192789" STUDY_ID="STD-Gokmen-2001" TOTAL_1="82" TOTAL_2="83" VAR="4.609586776859504" WEIGHT="8.662844339808016"/>
<DICH_DATA CI_END="7.073039746163109" CI_START="0.0027812306593088722" EFFECT_SIZE="0.14025603372596518" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8496060985590221" LOG_CI_START="-2.5557629917503686" LOG_EFFECT_SIZE="-0.8530784465956733" MODIFIED="2016-08-10 10:59:19 +1200" MODIFIED_BY="[Empty name]" ORDER="50" O_E="-0.4909090909090909" SE="2.000330660496597" STUDY_ID="STD-Isik-1996" TOTAL_1="27" TOTAL_2="28" VAR="0.2499173553719008" WEIGHT="0.46967228348356715"/>
<DICH_DATA CI_END="4.341867461598236" CI_START="0.43184704579311184" EFFECT_SIZE="1.369314659425085" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6376765621918566" LOG_CI_START="-0.3646700470055405" LOG_EFFECT_SIZE="0.13650325759315812" MODIFIED="2016-08-10 10:59:19 +1200" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.9066666666666663" SE="0.5887833599382878" STUDY_ID="STD-Isikoglu-2007" TOTAL_1="38" TOTAL_2="37" VAR="2.8846222222222226" WEIGHT="5.421100523740904"/>
<DICH_DATA CI_END="1.4230137854834441" CI_START="0.2789994655100187" EFFECT_SIZE="0.6300952987947691" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" LOG_CI_END="0.15320910734387017" LOG_CI_START="-0.5543966287202083" LOG_EFFECT_SIZE="-0.2005937606881691" MODIFIED="2016-08-10 10:59:19 +1200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="-2.6734693877551017" SE="0.4156511120689242" STUDY_ID="STD-Koike-1999" TOTAL_1="43" TOTAL_2="55" VAR="5.78818104140457" WEIGHT="10.87778879096779"/>
<DICH_DATA CI_END="0.699677968287373" CI_START="0.011589222359243147" EFFECT_SIZE="0.09004845114906664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.15510180109409558" LOG_CI_START="-1.9359457043660058" LOG_EFFECT_SIZE="-1.0455237527300507" MODIFIED="2016-08-10 10:59:19 +1200" MODIFIED_BY="[Empty name]" ORDER="52" O_E="-2.2" SE="1.046076524101413" STUDY_ID="STD-Shalev-1995" TOTAL_1="22" TOTAL_2="18" VAR="0.913846153846154" WEIGHT="1.7174005750456813"/>
<DICH_DATA CI_END="0.7951399816265319" CI_START="0.012735581751501504" EFFECT_SIZE="0.10063086126975215" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.09955640858071622" LOG_CI_START="-1.894981212011996" LOG_EFFECT_SIZE="-0.9972688102963561" MODIFIED="2016-08-10 10:59:19 +1200" MODIFIED_BY="[Empty name]" ORDER="53" O_E="-2.064516129032258" SE="1.0546414170316463" STUDY_ID="STD-Shoham-1994" TOTAL_1="16" TOTAL_2="15" VAR="0.8990634755463058" WEIGHT="1.6896193340719972"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-08-10 11:56:43 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>HES vs placebo / no treatment</NAME>
<DICH_OUTCOME CHI2="0.14120026916251227" CI_END="0.5920652240762428" CI_START="0.12370566051950882" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2706322590065394" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.22763044716885547" LOG_CI_START="-0.9076104274837138" LOG_EFFECT_SIZE="-0.5676204373262845" METHOD="PETO" MODIFIED="2016-08-10 11:56:43 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7070908051068168" P_Q="1.0" P_Z="0.0010671364876307019" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="134" WEIGHT="100.0" Z="3.2722010831355743">
<NAME>Total OHSS</NAME>
<GROUP_LABEL_1>Favours HES</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo / no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14120026916251227" CI_END="0.5920652240762428" CI_START="0.12370566051950882" DF="1" EFFECT_SIZE="0.2706322590065394" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.22763044716885547" LOG_CI_START="-0.9076104274837138" LOG_EFFECT_SIZE="-0.5676204373262845" MODIFIED="2016-07-25 02:24:51 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7070908051068168" P_Z="0.0010671364876307019" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="134" WEIGHT="100.0" Z="3.2722010831355743">
<NAME>studies reporting moderate or severe OHSS</NAME>
<DICH_DATA CI_END="0.7366993680843466" CI_START="0.11893573070505555" EFFECT_SIZE="0.296006550017165" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.13270970266798682" LOG_CI_START="-0.924687654911177" LOG_EFFECT_SIZE="-0.5286986787895819" MODIFIED="2016-07-25 02:11:30 +1200" MODIFIED_BY="[Empty name]" ORDER="388" O_E="-5.625" SE="0.46521176950174015" STUDY_ID="STD-Gokmen-2001" TOTAL_1="85" TOTAL_2="83" VAR="4.620602544910179" WEIGHT="73.71673136694292"/>
<DICH_DATA CI_END="0.9691433867809854" CI_START="0.04571336958037332" EFFECT_SIZE="0.21048232661269659" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.013611963423032246" LOG_CI_START="-1.339956765229437" LOG_EFFECT_SIZE="-0.6767843643262346" MODIFIED="2016-07-25 02:11:30 +1200" MODIFIED_BY="[Empty name]" ORDER="105" O_E="-2.5673076923076925" SE="0.7791015020937383" STUDY_ID="STD-Konig-1998" TOTAL_1="53" TOTAL_2="51" VAR="1.6474487634285055" WEIGHT="26.283268633057084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.928943496521267" CI_START="0.49011330551017906" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1981294499062194" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.46671099360521834" LOG_CI_START="-0.30970350717679707" LOG_EFFECT_SIZE="0.07850374321421064" METHOD="PETO" MODIFIED="2016-08-08 01:37:37 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.691849572555243" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="83" WEIGHT="100.0" Z="0.3963463052183055">
<NAME>Pregnancy rate</NAME>
<GROUP_LABEL_1>HES</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo / no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatm</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.928943496521267" CI_START="0.490113305510179" EFFECT_SIZE="1.1981294499062194" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.46671099360521834" LOG_CI_START="-0.3097035071767971" LOG_EFFECT_SIZE="0.07850374321421064" MODIFIED="2016-07-25 02:22:22 +1200" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.8690476190476186" SE="0.4560697210731189" STUDY_ID="STD-Gokmen-2001" TOTAL_1="85" TOTAL_2="83" VAR="4.8077017733241" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-08-10 11:06:32 +1200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Mannitol vs placebo / no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6416067571878596" CI_START="0.2219851152300252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3773952171486939" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.19273107085552102" LOG_CI_START="-0.6536761453249805" LOG_EFFECT_SIZE="-0.42320360809025076" METHOD="PETO" MODIFIED="2016-08-10 11:06:32 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="3.194795974574188E-4" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="116" WEIGHT="100.0" Z="3.5989703586224246">
<NAME>Total OHSS</NAME>
<GROUP_LABEL_1>Mannitol</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo / no treatmen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mannitol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatm</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6416067571878596" CI_START="0.2219851152300252" DF="0" EFFECT_SIZE="0.3773952171486939" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.19273107085552102" LOG_CI_START="-0.6536761453249805" LOG_EFFECT_SIZE="-0.42320360809025076" MODIFIED="2016-07-25 02:26:21 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="3.194795974574188E-4" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="116" WEIGHT="100.0" Z="3.5989703586224246">
<NAME>studies reporting moderate or severe OHSS</NAME>
<DICH_DATA CI_END="0.6416067571878596" CI_START="0.2219851152300252" EFFECT_SIZE="0.3773952171486939" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" LOG_CI_END="-0.19273107085552102" LOG_CI_START="-0.6536761453249805" LOG_EFFECT_SIZE="-0.42320360809025076" MODIFIED="2016-07-25 02:08:02 +1200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="-13.292035398230091" SE="0.2707614184582782" STUDY_ID="STD-Saremi-2003" TOTAL_1="110" TOTAL_2="116" VAR="13.640379042994752" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5459504611688457" CI_START="0.4726041483672777" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8547646466242638" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.18919557316205146" LOG_CI_START="-0.32550247058957743" LOG_EFFECT_SIZE="-0.068153448713763" METHOD="PETO" MODIFIED="2016-08-06 22:56:37 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6037223671514156" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="116" WEIGHT="100.0" Z="0.5190550324517349">
<NAME>Pregnancy rate</NAME>
<GROUP_LABEL_1>Mannitol</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo / no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mannitol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/no treatm</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5459504611688457" CI_START="0.4726041483672777" EFFECT_SIZE="0.8547646466242638" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" LOG_CI_END="0.18919557316205146" LOG_CI_START="-0.32550247058957743" LOG_EFFECT_SIZE="-0.068153448713763" MODIFIED="2016-07-25 02:27:21 +1200" MODIFIED_BY="[Empty name]" ORDER="58" O_E="-1.716814159292035" SE="0.30233617869611373" STUDY_ID="STD-Saremi-2003" TOTAL_1="110" TOTAL_2="116" VAR="10.940061433506495" WEIGHT="100.0">
<FOOTNOTE>pregnancy rate was provided in the publication as percentages, from which numbers were calculated. It is unclear if the percentages were per woman randomised or per woman receiving a transfer.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-08-25 15:26:44 +1200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-08-08 09:57:49 +1200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAgsAAAK8CAYAAABhkPwDAABZ9ElEQVR42u2dD2QdS///H6qqqqpU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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-08-10 13:40:34 +1200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-08-10 13:40:34 +1200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARsAAAIoCAIAAADWSdjoAAAZPElEQVR42u3dsW4ltxXGcQEBghQq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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-08-25 15:26:44 +1200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Human Albumin vs placebo / no treatment, outcome: 1.1 Total OHSS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5IAAAIgCAMAAADA2qbqAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-08-19 10:10:34 +1200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Human Albumin vs placebo / no treatment, outcome: 1.2 Pregnancy rate.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3IAAAFwCAMAAADKXrnxAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-08-19 10:10:34 +1200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 HES vs placebo / no treatment, outcome: 2.1 Total OHSS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4cAAAFwCAMAAAA8O/4sAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-08-19 10:10:40 +1200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 HES vs placebo / no treatment, outcome: 2.2 Pregnancy rate.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4IAAAEQCAMAAADS5joyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2016-08-19 10:10:40 +1200" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Mannitol vs placebo / no treatment, outcome: 3.1 Total OHSS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5MAAAFgCAMAAAARqN0lAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAABG7ElEQVR42u29C2Ac1Xk2/GpXO7Ozq9uMpGBxMZblkHwlIakxtmVZ
ENYG4jgtbf/k+2nS8AP9PiBfCLT9aJqQtKS5/MEEmpIGEnCIQ+5QQiDBMS22AkgyWIDpRwx/AMmy
ZVsySJqRZK1Wu7OS/nOby+7OrnZ1W0l+H3s1l/Oec945c955z5mZZ94SFRAIxCKCD5sAgUCbRCAQ
aJMIBNrkzBCJRExoJX+zJUON4t7Kr8x89+uyl1xNyDN7a3iBGkSWbjaz6NIalqSQmXI4KUdFckvS
tlo7t5J3o831QUhSuMPWOvUgakMksTbnQQRkpdbd7sU4CPexKG0uFTKUUYNS2NKbnJ0ClV2MfvIM
+NOsaS0tcEHj/FXdEPDae8FGT+HbNyxMe7TEQ4dUb136tk6cjEKZmSt3oiIetXM3siYsAloSyoZL
7ZZLOQhzGKInJ0f6cuU29zaOutu9OAdhH8tw49ZcKkQ3nTxm6b2xolBlF6FNyglIUHfVEZICoRi5
yGgheRdZ7FKCKlkQqyGXnQpZqsznkqbKCrs6m2FJVlpBr5ADYRP0WyV5SqcXNHoZgwpJruAZ/rqU
5wrLMacOidYYiZQpVj5TkSVFk/nuqrBcVRUk8qRs6Vbd0ndOcRgSom6mC0zJEld4RdPTWmCwqQrM
kEzNtkMJVgnvqdheaQBMcfziSABula0jXjh0EzV4G/GDsHVQNw8GtP9sWgG6so0ehDiWWoV4T/tq
0wyTqe2ebx+YFyhEG6KC085m8Hq2ZDpJm+FjmktvIin6X+oxLR2bbE3CRCtZXjKYGNtIT85EV9On
yeJvyjbF6NGTqw9UrtsdvrAqj8ImdjeygUPlnsRo449h1brdVRsqof5g2dNbVtHk8MZSqFoXVtbx
7nEf95OToaZbnDoStEaA/hNWvgo9Hm0ci/PdU0NNa6dOEfn6dU+XHax39J1TlNC6Q1tWMV0qt+wO
r2PdMQjnA8QgCaUbQxP0ctL45CRZXLbh5NHGS+wBKwTE8YsjgcqDod3rFr4/X0Pbn7QRPwhbB5Mc
ATmOG+DHjS9Q7cWxnGrsq9xgKxkjXTWl3fPvA/PRR8EP7nY2y6++d72tk9XMXO+gq/+lHtPSscnA
JnMTNY3YS7dWAD053XVAT1V3P1swxKGii57JaXGkAtgIc8xXUQEPEfNa298yBuPQ+T5qanCkE2RS
TtdhuIhNJ5Nv8Et6P5FNryOmWfli51TcZOvSTXQdCDD5YCeRsPWdO+j1UErr7mI6A6yDtV2sJpgC
cj3WyEKGriNkewOspYtJOPOpR2PWWOGCjmHr+AXGoauC6LugIAdxP9G/grcRPYWWDpP8IH4In4Ou
bjpQ4sfSBH+VfHTMOojtB0ZS2z3/PjAPM8rbX3gW3O1cvqkx4KUT0fv5AVf/cx9TVviVRWaR9dDy
2ODZLY9B996vPh4+49zuergR6lc6C/ofSs69bUf9sQm6mruwG3fWt04SMfUPx7seW9l9MSmFHvXK
Rx6BI2T/jbSU0pVk0Uat/wfJr/NctCpRB9vRzXZa+ao++On7z2C6cFno4fJ7H4GeCZF7Dhuk/uaJ
z/5wh61zN5xYeaPQzL/y5R2gP3Js4hJ6KLRt2GL0naZX/6Z8nDfncBcM7BDHz1Xu9q8k7XJkciHP
av3NybeSftZG/Lw5OgT4QfRYByEWQ4fPrDvYHeMH8aOv+cf9Ke3uOj8L3kN/9FX/11ztXA9Hj+9h
I9LUfkkku1+PvD3h9L+dd1jHtLT8ZF272V5Hltvh2BtZLyWg62Q8Nz1MnY8yotBD56j7QecjwUdb
WmgjklKm+II1hPkZV9atmXWIfGPwqTe8dCKJiXm5pRC/RXN0pidN1y1f8Rqd3JRCO9+1ny+Uk/+1
b5N1OdaVRtU6fnsQScS2LvB9kURJgLeR5aAtHQKwBshxxK2DEAujb/eVndbdqebQhi+ktfvWfPvA
3KO5bOMqcLdzhbyx1btfCp8n2n9r3+4DnaNL8L5rYLO4+xlv8EpeQ+xKgoMNfKA+DaoP8aGED95z
kN2uOVgbCZGcDX0Rej9+1Ro65ISG1cB6bPIHrqztdh1tIExA5LsGzmvgfcddFSt7/h6PiLrbUo7+
ZPvD+qDWFiLqN6xisxc2ow19zJ90usbQfrlWHP8arvLD0HCQ2O/CQ7QRbbmgrYPRFhvUH24/SYyT
HYQ4FuVjQ//LdRDPf9tMbff2fPvAPMB4Pma623lgoPUKcXxpOsW4iYn2J8d0jDuJJWaTfqB3PyG8
ZpXnwOTRtnPgyEvboy8N5XNf+bIXDLoM7R/+Czp/3Ld9+MAwdL8UXUUWAG9HX0hC99rohS8NM5t8
yj0VJXW8zOq4v+1sMXfk+RrbP0B7Raj97JSpKy17aN5ahdX9DNPlyEvfiL7MFK4r37WiriTaD4Py
GD3VLz7/DXpGh983XPZCuXOt3jwmjp+2HS9rOz/iBYZoo3DbWS4dAtGSuhW7yuug5fkxqv2gHKXH
MnJgVfiFMud2/Oaq1HZ3zk8xLi7NVSntHJA31gid3P0yEqh6YcTV/549sGrFC9Ndt0uW9TvoEWgB
BGJpYXnbpFQSx1OMWGIoXdZHl8ATjFhywHfQEQi0SQQCgTaJQKBNIhCImcD1bp1+b4n/Q++076yZ
SrolIvVZ3xPreGDridLgmH96yWkRqafwzJ+mj5d868MmFKBEjspaHzFnrb2rjDRtIm/69W9dcqJ/
h3nZezvTJcSa61h4ySf8StSfrS1Yzd2eB23vNH3yhw6/uFN/kclWTZbFoawsJsrz+5NJ/2zO3LQt
s6T1p6jdWF9/aiz1kKT9O50+c7LnQ/1tO93pgfLx7N0tkrX3ZdjkmaNDp16/9CvJjeekyOd4p/Rn
zT+9c/TSD788veS0oK8GdntnT9OHo7ub5rC2jp7dDQUokaMyV0kFIF9t6k+Nf/QwrDx/V03d8wkr
a5psqgak3InydXoiW1uwQwHPg7Hr9m0ZuufEHfEH6g68SQWP3DXR8eAp3tunAie2HR00Z3Pmpm3q
Ja0/RXAFQO94yiGNRr5iX1z61h4/cduFXzNd6f3fuuj1QNbuxo85r7Hr5yAJSst4wKKnMdZXUAVQ
IrVgRtgbQ5zzxriEtEngj0iOByxpgMptigkdoWBVhBYRClkcNyEQieySQzn8UE2EvrZRFqmh/EBd
8BiZPll5Z5yvxkTCkhSsyb+lY+w9uHBE5ZxIzs9k3LyaUCCnmtnBeI2sDMGXS8cEfBTayW8CArpV
L5GVVdZ8Nco2jXMLU8DYk5TjKYiHmbzBSKRWCoKuBEwuZ/EoOWQYWEuKmKTtRFSom4Kt4kpctTmo
NbdE53ksttT1T8ABSOsOiov5s6JJ0fSWFLKHFoaamdfnc6+upb3IdJG/SjeEdPoSnwk/Zi+E2py3
/hPMycIfp/a7qRca74OLNj7JryGDxzI4brdQvmJWDDy/3gRz/fOJLaHhdfS9TcpjZPpk4525+Gqj
cuLoplP5H7myf0MfmBv+aJLxEoHzMxk3b3Tj2xUby2fQmJzXyMoQfLl0XE1OcIA0ZwJer7fqheoN
4gowPhIfc3PvbJRA/bpweJ1gT3rxBvuDm/aubgwFuJzFo7Ry67TmJETlsA6+Wp+Z6OIpSXhzQWZI
S1v/CRiAtCF3q+ul1iBkEhLegE/OiU2O7IfG251vpvArVOeLACdJF7qJXaRs3l2M0aifTc9xpAt+
TXSsMLgnqs7gkzG+YpaZB0EQqsk/+SLoirFqGI+RIhvvzFV+zFdxHSN55DXNIVDgblLZhTYv0eZn
TsJZyUfHZ9CYDq8xja9oof11c7Ktp23C3NRW5/AhSav2sOSegBfxUl9FzJjIdJJWSDtmcSh0sXf/
9jG525ITPEpxZYU1CtWlvS204RxQhoO18mrpft6s2vx36SWvf2O70r6pI6X33P78XnvLSwkt9dxH
0r4vFcn5hR7XfNL/zue7zzn7q0lBTwPOZNtZD8d7J4//y3H6Kq3gvNVzFiLsfOcfjrhyMPJe24Tv
3Nv8fCuFT2YJeDPe+Ji79+DL4/7Ib26mVMGjEw5lEjx4Z2wO4Spf/eDxdwS5Lr/5ZO/fvPD8A8d2
3mVzKa3KKrs21d1SUZhRsmoFr5Fp4/AV3b75rKOXnPyq0jh05smEw4dk/E1wMURTyq3/7OTJHs6e
fHbCxR11z03I7p1lG1Ye+ArYcqxILvP2/x4P98CEObGz95GjE+MTvTuO9bXvowX0UubiLO8ETNcu
S1t/2stX9JnBs++KuXvP8EXOfPKEUMLdFSildS7mk6AN9b4CvKh2NoalxCD6In5g87s3s7F8Ou9O
G+49SC7tbSBYS4w85gfdHn0LPlmrJdCh5zx87ZGmqqZHNF8GEzEb78zFV4tCT2EDGU3efAmZj7h4
idaFse+VfU1jMzh7Dq8xja/oXPFl8qPfDCh18yFB78heaIsZHxXsSd4k3rxBPSa3x01Lbr+jCTnQ
aCI25ZoyNEhaZ2CK63PevLuZpa4/sYgNkQ1pg1fdNaCR4D0Zecpn89KqyyaDEU37NR0oAG2yvho2
zFhDZzy/hfV8zJzGuwtGYtpvSI5roGYVvwI0kGFKDA6WOvoyPpkfarnA1jVZx64MXe0b2rtIrtVm
xP7cINUnG+9MlE8ZdT4oP1jg3dLWxrZuh0spLkY6ZcXp8P/MoDFTtHmPhzYB2Az95N9msubUK0PD
Ra7xLXhdt2QqrbC2ELzBtOHPw00vhJpKLTnBo+QyoetNlVxTFbmPt378DWg3r2EpbeN6LLIQn8Rc
wvqb8ErLf6Xd5Gl1dUZF+pKuRVK+jqmrMDDzCl1j19hg3N/d8bud3Z33mKf6Xz15BnQnB8bvfRW6
P/3llfuZe+77XOxn74zYQ4X9/2/k+I9PDvlv+q6pnEEHX++MHX9mp/G3fQN1bfz7B32f+1HinWE4
NZD4j99RgZPRPsOfZYxDH9rcmVx98msk17o+UqwY8VJ99n/9X+7qDY9ljBZF+ZWd30pWdAWq+yDP
sSurbMff9Z38Kj2me/qe2Skqqzj8r+aYPnb3iTZ/Qe0otDnc2T8MtIyKw+O/PDNDm7ETK+XD4H/v
RNvRHU69o4OJ8rp2a4BPjyXzgUBfZ9u/9j7Lzg09ZlIL/1oJT6+HU4PPnxp/78rRLi734lePnqwj
1TOZlt3HJ/qHQE1+K/HOkR1QY94B5SV//STV55mH7gq+Neafz7Hr0taf3mJa+dDOkTU9/Tuc3nPi
RyeetZ9Hjv0+8Bnz5O92unrXzR96KZnR3fJ5usgrzIOrpcOZm17N3+6l0OHOzx/wukGNdEZvHxLs
jn/yhUIHy7WnxudEplhY6vrP40UgD5uUp3whPf8iWy+fgECo33Nsh+Qpr4ltbKLEPxwoMFco3D+t
TDjUv2iPeqnrX1ybRCAQCMTpi//rND/+UvSTiMWG07xPIlcLgUCbRCAQedlkbUiWQtbr7CH7iW44
5dluWszFSGQmkQBpDMX8s3lLZokJWTCs2IesFvKnY2pLQA6b9hKBKJ5Njk2URzfy99fMkBUg0Ayl
BlnMjLk4g0iANIbibAMIZokJWSgyYh9euuUn5tCGcnuJQBTPJqPxgTPEe4hX2DvttVpFJv5EdpEr
BceNrOmc7+jwDiORsOLEY+QxIHnMRMqqtKIgijiPgm/JsmmKXKHKQc2KCSnqsLmGZYrgSbIyRL0U
Fk8zrHBvzuICsvQMnqQTR5LeTtgc5LEPbSNlnNBxe4lAFHM+ef0H9zNeJHQct3Z1HBMrf944Wrlh
NO5i9zkct1Wc7+jmHT513BWPcXfjRVBhxUwcHHYogizOo823JEiONK2bGN00xmNCVlp12PEi+08I
niQrY5XFs3Q4eU8xzUVcQJa+Ip0n6cSRZCbYyWMfWrA4oRncUASiCDZ5x8FNLJwEjNqMsNFqsdIF
FeYdKWQph+Mm+I5u3uH51U48xiMVsJXICG5hzPXCCuNH2nxLKhpgv0keE3KdVYcdLzKmuXmSNs/S
4eSdz/QVcQF5ejpP0okjCa7YhxapzeKEPpvJJkUgFgKp7/HoH2sXH/N3Xk0Va2psE7QPKXRL/JyF
tJkItCW0aBO0hwwrT6CZ7WViraa0mSz4VloBgeYWUYmrcLnJFrcqaDWZlPrHHcELeGZRL9C6iFx7
3NI6VrkZ9isGTz955mTb5pK+Fa4yRHnkj9z0qEYO26WYXh/fBM/H7CVioRE5zd+KzvtZiNH7qY4m
/vWNNjKkBXBx3ATfMY13aMdj1GkMSF/WaIFuvqX7+kAJT6ION9fQxZN0eJZpcf9EXECe7sGTdNbt
2Ic2BCfUXiIQRbPJIOWnuXltKQ8hlI/9fQ/p+pTdtwVqKa9ZcNwALL5jGu/Qjse4isaAdEfma0uh
CLr5lo4yNCakZNXh5jgKniSPw2jxLNPi/om4gCI9kyfprBttMVO/rP2knfUmwQm1lghE8Wyy3L9q
NHtQwmcPjJxxoIzF/jtQcopSS5M81iGdBb50YbhjGIY7Ruqev9fOYcdjZDEgnZiJrniO3AM/f7dK
fW8KWEzIESueoh0vktpbe/gpUYaoFzLi/om4gCJduwUkzYrfyEu3ywu0lIRX+Cvq7KxXd3w0sLXj
d/YSgSjqfHJeZgfTkSaz8y0ROJ9Em5wHBHzTxIDMzrdEoE2iTSIQaJNFBt7EQMwaIxl7KrBRZg7k
hSAQ6CcRiKUD8+uHHtx4/rv/fL21/fLZlUPHzlW0bOkFymfC9S1JBGJmyLyJJ8+muHkNXFcoXjj4
QPnR1Y8n/r8vPsa2B7583ye+UfXdvwx98U7P9ELlceyKQBSEH/y35yAB5PeDP/kJM7HfAyQ66U8e
8EovVB5tEoEoCIP3wMUg8d+vTLItr3v1na98sPLvYN2rMd0jvUD56W3SIJhOS8MWzbqYW1iFGtMo
BHOhwawPZBptDO9a7B05jjOzRTILosvsqZ55WYXzcd6WBf6NeLSLn4PnyC/R+U8AbwGsPO+xn+15
8CuwsiqWmV6o/LT3eAzV+pMDqi1Kfp6LOTZJUWh+JjlLDWZ9INNoY3jX4uww1Onr9cpn1aPmTPXI
y3VS0Sa9ceji56TnLn6GGpH03LsBzn91ZRW8vrIq2TlUBUcz0wuVn9Ym3V2HnTF6Rq1VerrBPqNq
dnOdY6hWZzKydFAjV/LMK5yhTadro3okw8Koqk4rlP+h5v540uMFyi+ddwIe3EjnfgBsDvgaiLnh
U3/62N91sltb6emFyudnk6rLNakpq+IiXByoM+54hTo6dfZaqllKU/Ox6gVrUq5cfteJQq1o2byJ
Q+Z9z+yH6sH9PuLZAIi3I57v75794f+gy/KM9ILlp5tPqmI+qWZ2ITWzR3n1HmM+upSxkP1UnUtX
VmBpKjvSguZ2LAc9b2ouC/dMndtDXab4a+LVPuSDQZ+PzAPJWPMY8XA9cOfg/2DLzPRC5af3k9Z8
0siYIOXtJ+bBfhbSPatFLU20fwGHq858+qsutF9eitj2Fp//AZ3//dmj8G46P7R+hxoz0guVz+8e
T5pZqotgkHUaYW5nnEYedmfgqcyB9z9H538+Pv/7UgD8K+n8sAxK6TzxvMz0QuWnHbuCt3s08jXJ
eRkK4fhqxm2Tj0mqqgpoklmx/jfO88T/Q0xIU9a9OrQOqofWrXs1Xp2ZXqi8J1K4WtZkksz+rSGU
4XXXR/QG1UpOW8x5x1Nzda2UnjdbDWZ9INNok7Lf1bauY5z+LlNGPiPlEZWVKs6RkTL+z6xzDh5h
zTEvZFFxtX7yJxc/R4ea8Mvr2PYgvTMz1HMBxGs80wuVn84mEUt+6DuTJECbzAH9V3sevPjd599s
fVRVn3jrHDI3PK86W3qB8miTy30wO7P5/+yeAC1vm1x4IFdrOWGm7wfM/sL83imYemfwv0FJyR/w
NMwSyNVCzA7mj54JycGj/f1TgzAwQBYXgFpVfnzHzEtcVFwttEnEUkLfg6X+DYd+MXQqSr+0bX0y
/u3R4aHB7/zPN4JDA3ejTc4ArmchepksbXEiZIgvLrviPLpiT4pETYGOMkm61QQzQgFV0v0A94jY
N63bpC1lHVQ2qM3fEYj4mGVk0VG2hepSTIi4nUypqm1SZhggl57mrZJUxtrbnJLkMh1UqYoI5AyH
4OSpDUtyqBY6wmSHCGYWYedwim3RuJpkP40wZp9TV/tYuplbIlaklIJufMSqQrIR7D7W+6S3wOCO
Y0fHg75gWG3V8eI1Yz955ujQqdcv/YoV46oe2OVq49n2Veuos8oT9QMn4j9frwdgKJ44b9+R7m64
un3fRN+fPMCvomuPn7jtwq+ZRDb835/eMT/6m+UbqSp939tAFg803/bE1FC8iOM4rk2tj2qjrn25
5cGfp14iUvRUS/THD3+BRlT4B2UwsO7WxFT02pdNKfeM0c7jMyv0D3VO/GTj79+1dtBk56QF7mge
kDexFpicPLqL7P9FMtp34OtCCad9iG5G6c/Ibq2O6NMtznV+x/i7hxTf3yeHTo0CVIvrR7Zl6J0R
475/rpRCu/eMoZ+cgZ/8HCRZxEURXpJcS4NKB4vzyGNHstiTJrk62xf/hvhuSIBOw1Wt4PcJHgpM
wXvFhx9WNCma3sLOhb9z9TzpL+JjfpIF9lBgbScU0SQtbd7Prmtmm74+kfYp6RQ9E9C5Ftg18TvQ
1QXNMBV4CKpzfzbDyTOaGHgBSmEClAEeIoziI3C4k2+Nx+veABNiiYAM1nXBaR+iWyBBTk1HIa2l
t1bcKvtHLx/qe5veyCe/wbyWb/cevfxN//VllbXoMgu0SR+sTR1qTf5nY4TFeaxksSNZ7MnKPYnR
xh8LgTj8EVxDY39MEXOOSeFBcrKv0eOHeWoQ3rBK6oT5GlGK+JhXsriZV4OmFbU1RdzOA7307ydK
QnI4rRem6DlFF1eDtXYOXGOCftXhnDU4eUgD3/58D3wTWmscm9xHk6fExmp+dg+Sc8ThtE+iRJGo
bhflGYHejH03VFrzvqNfPDkAg3RoWvBvYMexI2/WBJR7NIxHn79NjqRHXDwSBB4pfZ0VOxJgzFdR
AQ8JgQlyLQyCsob2gpLRsg3nghK+cLVcL9PorNAELgOZrxMh4mPeonHTZ722eBBxO6Ncm6Z7wxvO
SRVI0bOJjSx4UxH8EC4MK/UPr5aqctTg5AHofaXxXGjcf/sFJXZM3c2uFmgdYw619SPQaF8ardTN
TfeVEd1qQ/l6rrO6pkoGZ90+gzDVhTZXgE0Geg/uhw2XODu09fAcP7uO/1H/afIw7xji9N7dURFv
L4HovgAdNA0lPj4+EK9g9uuKnqV5R7mba7BAQCWLp3Gv7IRkDj3bbRNp5/tvSBxODIwfzRWwvd1l
dFoXGalcumn3q1OqRwvUbtl80CDnbuvmV671aB+m21i+JhnQ74qZU8H6H62oEcPSQn81dWetWj1l
jn9bD6DV5W2ToA31vkJ8X7vl1VgESC5kRZqk0R+dCU8JsbrAqBmd8lnbAGtKA5v6J+iWBO+xZyIL
dMMqa4zLYqA9q9cWevrsFi6ha1to640FNtVN5jxfeofrpPnJqSLzSXtWuMVuAX3Et3uInMnL4FUj
s32Ebhu2R6b7JoC7fyhDt8QntIZzzqRl0LniYF7Ld50VWv3u/vGxYUNDgyvMJoMRTfs1lJKT1sdf
l111iAxYeZxHFt2Rxp70wXsO2jlKyWlV5FptswKh62vWsK96xgzY38dKVaQv6RqP8lgOC3JxDEDD
GpAWS9PKcFBxxcTM1FOChgb4Fr2fJsOag/Bb2npJaK/15T7EK2AHzaNItYdIRj/EapzWbadnSqLJ
D0M5HblWXz1Kv2HIH3aIelmFB18jurW0tBT8TYABfTQ2MXXo5bMD1daANOuyZkXVy4cGzLFRYwDN
cSY2eepAVPpyxzNgtF/Hz7H/8udfFHEeWexIGnsytH/4L+wc34EQhH3D0U/pEP7pyB/vO0KGSv4A
yKvYjcH+Xz21IkrKI0guzDt8ezuio2sHF0vTjry0vXLfYA49B9ZGox0Xsn6+b3R7Bx1o+gKgDOe6
8zpI87D5YVlg+LKXhuHZjsqRDjtq6JGO7VFe5982vZ8+dox3XsGePramtg/Rbcu+WbSU1rw1Gp98
q76q7gNZJD5w1rmr3+qPl2xtRmssELN6B10/UxrJS7Aq1odnZr6RK9Bn3+rYTLNO2wkaJhOT6/ir
A9XUzGsCserX5Fmcb4x1N5vc2nh+j4KD370WbWbex8pTzjORdJTtac6RU4KS2T7VrTUTk4kSn1T6
5MZZT1PQJrEzIxaZwz/NbRJjEyAQaJMIBAJtEoFAm0QgEGiTCATaJAKBmFu43q8Rr0W6w6Klr3lj
fr+jPd33XeejMgPwQ8SIRWCT6qL8Sv108SfnozJDxQ/2IxbV2JVF1zLA8ArxKyIJGyKksLfkXEJd
CF/sUSECUXw/meos1OwhftNiFagL4VkWylIMtEnEIvSTuQxBNdy2py6E2Szd+JMIxNz4yRSvkWXD
yDTVebNJFQeuCLRJ93DVs7+qHp0Z74ogEPM9ds1wiNQb2nNKyOE353KCh0Cc7n7SGoeyuZUzvXIP
T9OGqnwWNj9uUl3IZ4WiMhWfTyKKB+RPIhYbkD+JQCDQJhEIBNokAoE2iUAg0CYRCLRJBAIxXzZp
uP6mruUJw+Mdg3xLNDJTjRmqgUCgnxRQvSxtNtkRCLRJYUppvEg3RdIwOInSxaB0iznyzMyMjBLT
81pFCG6mqziwU+aPnolALDZ4voOeyaB0Vul/SGNQOvRJksfw8nlOiRl5rYUll1krIPEfcbrapJHf
sNJNMcw0FGqWqnsra2GqZxFqhgACcdrapGqPIKc3UyPPeaOXUU47DjVmNS9FIJbd2BXUHH7QM6Eg
jzbtJ68yBdBjIk4b+KZ3VVmdVhZXmeYZPT+mYbhyGF6lGxkp6CoRp7GfTGFQ2tM+m1vI1lIohq4t
YZBGWqJdIthFsKWzsGTVDAEkNCJOJ8yIPznNLdA875BmWi8CAcifLC3YHqed3aGRIRALaZPqHEik
yKEFIxBu4DvoCATaJAKBQJtEINAmEQjETJA9/qS1VzyxKOhejJEeT8BIeQrpKteqNr1W53lnRkRI
8Zp7hj7Z8rgXeE8YsZRsMhf3YpZ92chhDapH8Q4PJDMipKEWlidloaJRIpbi2NVwkRgFWTKNSglZ
olFmEh2tQtIYmJxqmdXiZ/EyLeQwfQRiafnJNIfjdixpVErIEY0y1cJSmJhuviXdlTle9R6Sqtk9
tlGovaGjRCxBm5zGuaipPTw1GmWeHV71GhirnpboOey1XyYqaJKLvhKxVG1SOJ/83/s2PFczt438
56qqp6XOaiCKd3gQS9YmnZfe8uzEaupYNav1qHlYdmFmY8zcRBGIJTV2NfJ0Kqqhpjs7I6cfdGaj
GcnqNK5zdg4TfSRi6dpkWhBGI5U/CZlbqSTLFA5zSiYXA5OVa/DHhh5PG4UkvQ+UHhEy602abHlS
F2iaiMWOpRd/cnZWhTa5+IHxJ5caVANNEoE2ubiMskh5EQi0SQQCbRKBQKBNIhAItEkEAm0SgUCg
TSIQaJMIBAJtEoFAm0QgEGiTCATaJAKBQJtEINAmsQkQCLRJBAKBNolAoE0iTiOY6pRc6pOVqlYd
G2OWKEGWL2J21viTvzHNyQGA6kG+4wPvSL7AG9rMSzzdv/3hV7BXIWaIvgdL/RsO/WLoVHSMbMXE
3rdHh4cGv/M/3wgODdw9o2Lru3Hsal2eGKytmpArgS20IJhlkjylQweXrJSrAKbEqahRJOlWk8oG
F9b1hrl2ZWTRUbaF6lBMhCKOUlXbJKU1XcClp3mrJJV1MF8zJcllOqgSadCyWE6vZOepDUtyqBY6
wmSHKc4f6GWyNMW2akNsfytJDneIzK72sXQzt0R4zsKgx6pCshHsPtb7pLfA4I5jR8eDvmBYxcHs
LPxkd3c9tNiXqI1n26v1QFf13j/E1Yt2PbrphpJfrrjyu93dUFIxljTDJUymdiRw4h/LB00iG4q/
s2PhRk7lG6l2fd/bQBYPNN/2xNRQvIjjOK5NrY9qo659ueXBn6deIlL0VEv0xw9/gbbfPyiDgXW3
Jqai175sSjlrcPL4zAr9Q50TP9n4+3etHTTZaWqBO5oH5E2sBSYnj+4i+3+RjPYd+LpQwmkfoptR
+jOyW6sj+nTzM5znMf7uIcX398mhU6NkuCquH9mWoXdGjPv+uVIK7d4zhn5yFvd4bpXlCiA9IwKm
IkuKNTFY3emHcWjugo/ABHyZ7pnsn4DqIE+NbQ5qSkuUru7e1LBw+l/BF5+cpH8VWNsJRTRJS5v3
J1nnbdPXJ6KpAil6JqBzLbBr4negqwuaYSrwEFTLOWtw8owmBl6AUnIulAGyV+AjcLiTb43H694A
E2KJgAzWdcFpH6JbIEHMpKOQ1tJbK26V/aOXD/W9XU0Nj3jDvJZv9x69/E3/9WWVtegyZ2aTlQdD
u9dVkvPaAhV6PNpoXeBM6IQSIK26D74CH5dDOvj6fHrisJX6plXAHy2kWXQcY4srT9C/V4OmFbU1
O46zxYFe+vcTJSE5nNYLU/ScoourwVo7B64xQb/qcM4anDwAwduf74FvQmuNY5P7aPKUdRXlZ/cg
XCN2OO2TKFEkqttFoTydY+y7odKa9x394skBoLdyCv8N7Dh25M2agHKPZqLVFWqTceiqEFYVO6fi
Jpi0bVKDAKx5gqx+sf3e0MZzILhKWS39O50DATSBbQ0l5Nq9YBitZotbWO2dvNcWD6O8EaJcm6Z7
wxvOSRVI0bOJLh7irUfwQ7gwrNQ/vJo3aBY4eQB6X2k8Fxr3335BSdJK3uxqgdYx5lBbPwKNItVp
n81N95UR3WpD+Xqus7qmSgZn3T6DMNWFNle4TZIr8XphVVUXfPUxfpqZqQH0XBn9TDvpevFAFyRh
KH44duTm6H+nqe1gn12taGbRZum5SHBlJyRz6Nlum0g7339D4nBiYPzoeI4i211Gp3WRa+elm3a/
OqV6tEDtls0HDWKSWze/cq1H+zDdxvI1yYB+V8ycCtb/aEWNGJYW+qupO2vV6ilz/Nt6AK2u4Pkk
6DpsZStj8Kk3XLaqg3ZLfGwqYG2TYZGsNQXYVTsA59nZi2YWfqr6orHJ9qxeW+jpowsftxOytoWs
rBkLbKqbzHm+9A7XSfOT4QuZT9qThS12C+gjvt1DZHRzGbxqZLaP0G3DdnrXNd8D0pShW+ITWsM5
Z9Iy6FxxMK/lu84KrX53//jYsKGhwc3IJoPQcBD2k2uqTuYh5zm3a+j9wJBkPrdZBkWuUdi46E9k
WMOnB8qacT0WCdPV8mkCzc4fAtCwBqTF0rQyHFQgmENPCRoa4Fv08RFpxoPwWzpbSEJ7rS/3IV4B
O2geRao9RDL6IVYDAec6cLCBlEuSH4Zyeoaqrx4dAOtxlqiXVXjwNaJbS0sLvW9QEAb00djE1KGX
zw5UWwPSrMuaFVUvHxowx0aNATTHWdhk90vR7S8Nw/1tZ0Nj+wd0V29YA//hD33jFR2e9Y9Uru0m
Te7rp3Mgmtr/2MSKypeG6GoSvlOkg9nbER1dO7hYmnbkpe2V+wZz6DmwNhrtuJD1832j2zvoQNMX
AGU4153XQZqHzQ/LAsOXkfP0bEflSMewlXykY3uU1/m3Te+njx3jnVewp4+tqe1DdNuybxYtpTVv
jcYn36qvqvtAFokPnHXu6rf64yVbm9EaC0T+79bpdcHhvAQrEr14GoqASA6P17c6NtOs0/aLhsnE
5Dr+6gB7va4mEKt+TcZ36xbAJqH18lhecqEgPoYqylh5ynkmko6yPc05ckpQMtvHV7VmYjJR4pNK
n9w463s4aJPYmRGLzOFj/EkEAoE2iUAg0CYRCLRJBAKBNolAoE0iEIg5hOs1OPFapPVwxLCfkhjT
PC8x5vV5iiFUMhbiqY2ozHCaAYEonk2qC9TvC7QSoZaxgJUZi7MpEKfv2NUwDGoDhlhL2w1OApHx
lJxLqAvhiz0qRCCK7ydTnYWa7i/cG7bzUr0kl7KlGGiTiEXoJ3MZgmq4bU9dCLMxFnAYSa8w2CkQ
i81PpniNLBtGpqnOm02qOHBFoE26h6ue/VX16Mx4VwSBmO+xa4ZDpN7QnlNCDr85lxM8BOJ095PW
OJTNrZzplXt4mjZU5bOw+XGT6kI+KxSVqfh8ElE8IH8SsdiA/EkEAoE2iUAg0CYRCLRJBAKBNomY
WxhFKOGXS0FJtEkE4rT0k0baJaPgi4fh8Y5BviUamanGIryGIRBLyk+qsxsT4KNSBCLb+67sPRbG
ADHEq6z2KmUzifdgeYKLmE+3DFuemZnrTTxRIqTltYqwXq918/xt5hS+WFOsKWQx5mrG/FeRuwR1
8dlkJoPSWeXGmZZg0ydVQ7yMp2YrMSOvtbDkMmsFJP4vJNT0EzfL3q7Oe45iKLlQNmnkd57cFMPM
Y1FtJ5niKD0KUz2LUDMEEIjTduxqDSzzuSuT7wjHyyinHWoYcz84QSCW9HxSnX5krc58AD7tJ68y
BdBjIk4b+KZ3VVmdVhZXmeYZPT+mYbhyGF6lGxkp6CqLPrlcoBLUpaDkQvvJFAalPe2zuYVsLeVO
qGvLUNMnzW5xcSOIG6q44aq6vkvF19MEkNBYDLhO6QwbP6WEAooo9IbL7DuHsajMckb8yWkaLc82
zbRexCIySftW90xvervyFZS90E8HzsFNeWPx+8nZXVLQyHD4OoseYRT65cAF1m8R2qQ6Z22kLsKh
PGKex8GLc2q3uKZGpdhhEPPuSOb7lY/Frl9hQF4IYgmMfk8r/dAmEUttvrXk9EObRCy2Lm+c3voV
CtezEMPTkVt3s6Gwe2dpDWWkPIVMaUjvd9bTH44Z7sCYhueAI1se9wLvCRfSUQUNYKbDO7uEAu+h
FHiSZqyfV9dZZDbp3RrGTAKyptukkWkN6ekZiSkPx1KfdRlqAXmyMFAQiCU0dhWxJJ0wlO4Qk4b1
8ptXNMrMOJRWIe5Eq1wj66VgFi/TLtX7DAiEQNb4kymUxzQqJeSIRplqYSlMTDffku5SvUb1HkPS
HK7cKNTeVHSUiKVnk9M4FzW1h6dGo8yzw6tew1jV0xI9x5v2y0Tz+c4WArHIxq5q/uHQXZKeY9ds
iTmm9HZsVk87UgkKH71iuNdFCX3xalEc1Uqze7H8X25QU8eqWT3iNO/JzmDeN5M8iNkhQv/kH2ZH
+dcbAO6/ZTxLYS1wlntjxtV4FZFtd0dzPEPik17Zzlo0fhI8v+yYe3qWB93StWF4uUlVtd1f3g7N
lScv60XMAVoI8pdufFkH/eZN2coiAnNSTSH4sMcFIu6p+2KxSTpoVe2F3Zmt7cwt17pqpBOaXTuc
gnm5grdsGBljWiFpZCiThSKdK0/qAm/xzBVaQ1KwCoImdChglklhk7s28otUyRCTAttaueD9a2AN
NYJaRZI1kqoGJbqo3Ca1UnH6T+T3Qk1QJrm2mVC7DfSQHNKdaiqD0CpJwRruCTWW5tRTu02OAZjh
QJnJdiodYNWTVKmONLkjJNH9Qg+it5DnZYidcizGdC2OTaqW83EWqn0vRWw7HsrO4UpRVXGrR3WL
qe4SwCpXdTydmun/IC2POt0YOFserxIQs8bl/5FQYiA/C5dLUBpIPOGaBf26D6p+az52Gd/SkjCx
jyz/73AiHCXLyd4yuoCf7vsx95Qt6fndGH06PvQxaH8XJPfDSjke/LGT5O+FLWUJY5RvDfYFH2Yr
op7Y/664BaC6x5SqqRs8Eb4IrHqS5DfZN1QFcFEwEbzI0oLqLeR5GWznZN9ebYXQtahj10WMWd2p
QTc5FxPKCPVUsWYwmuDkryH5JAS7oEJ2BN6nQelTsZgYIb5jQuIvyfI7A6A3kWW3JhbNnVaGtPzu
asabQemE3QkwA7ChCzp/7Qh0ahC4fZdVTVLrfJStiHoSa/sfALiqGnQ6LB3UBoJWPfrEmwBHNIUI
BTuhK+jWW8hburKczY1uXecffmXJdQmlSHkRHPUt3d30RskjAd853af+csK3Ey65EXaWTkA92U9+
9TcCvP2X8l3aGBPvKY0FRshus9pfeg5PrXcW7L8rf3o1ZvWOZ8/pvvubE1tepXl2nEipZqz9ibuP
382rsdJEPaRMgsr6+vpjEzQVfJOingcnvmZVT3bsIPvBLlDIW7p2s5xCGP0kYnHj4hLpFBmYBipv
AmjTQZ9ie62nB9pY3/0jYr20lI1LK6cGyrKU5eTPQOXk2hFaTRWZ0LUTsZKUagLRk8p1fNW00kQ9
bUymvaWlhfrJGtD9Vj1JZ5hMS0wxASGfQ1e0ScRixVSgk/btxy/8AZmtrYGDpCe3xvRV1oBE0666
1LLJGwJscDkQi2cxSJHfC381eD6dDwbW9gPcqcAaUpSk2dXc1Kr17RM3g/idJLseqcG8HkAeBDVE
R9rwmmTpmfTbpQcUaOC51nAzF/KijDYdbRKxdBBet4LM16Cijcy0knHpyiRAS+XHrf70nxukyg6x
/pvO39DFcPnHPXvbjSus/F5oLK+jud5pj5H1amm8hYyaoyssq/rFZXLlMF8tkeIvgqseI/aZT5HZ
4LlSjNpkaNuHj1h6mv9hl95SLcf5/YmfreCzRy4vygisKEbLluBND8SyuPHUsmwOxXXlMgyPJ4X2
h5Fzf7i8oDotQokBxkzuoWJQS4THCHj5HIrrqVCuJ+pz/QxhVmTGgrLhOOD0QGL5HMrs+JNOwB+b
GWmkSQtnZXtEw3p7J4VTmbqaUqKRWhu4nlC6NEzL7VRopBflVgW9JWJR+0m3GyqIPwmuuJGGs5WZ
Ds63JED1DDWZEtIy4yMBGNQScRrAV/DAzzPmlpqyouYsSJ2mJtVb0C1hZC8Ag1oilp+ftB1Zrv47
Z1F1DMh5s8ZbFwxqiTi9bDIv/uRcDfzUvLyymlfgIAxqiVi+Y9dp+ZNpjyKM7L4nI5Kkka+rNLLr
gkEtEaeTn3QCTYL7m42eESdTI0VaW9nSIUUkvdSMCtR0XTCoJeI0wJy/x+M5xFy425sY1BKxHOeT
MzcInKQhEIvOTyIQiFkBeSEIBNokAoFAm0Qg0CYRCATaJAKxvGwyQiAr4tu5YleaeEz+rrM34lFe
ZPoqI9jqCESefrKlpaVPrsgVpaEy/GmXODYfAjHvY1ft8CTzZDH7o+9VFfSvHpIVHSKbP8j2mUHx
Kfo+RQruBWgNWNJgfwC+Q5GrIuzj8Ey2MhhopVv0u/QIBCL/+WQD31NZlniaffS9ymSf6VTluLKS
f6ydbvU+Vc1WrtMTynZiceWJp09ZJVQbCekL9LPvffRjttVDpkxlp3pbtpAt6eQgNjoCka9N0vlk
gn8pN3B76/n0w5fqXx1j28Eu6HSirPRozVexlT0K/UA9SInW8+3vc8YDYPwbzaHRT0dfFQCdyh7R
mjeTtC4NqRgIRC64362LtEBMfW49WzGrzOb/MwCRAxufCog0CJjii330rxynC33VNQ9sYtIl5QMi
id7DaUsQO7W32pks/YmdCAQiz7GrooiPVweiJ79Ax67Rl/kgNfUj7qb1cfizfD85xaWVUSuxraWl
hZieT2dC1sfhOa7RF0lYXgRiqcwnLXJhMKbJLLbJUIINWQP8s/ACFfAaD4M0yT9QH2zVfjNhJQZN
UMMAsQZY1Ur8aR//OLzI2IDEEQSiIJuEnnHmyMpVaQsPxPB0FdtdLY332EIjNz3Ob9UMjX6e3kct
e/jDP7YitsBg1fXjxAqNuPwYKb17jTTeZWe87brr8b4rApHvfHLOseszY9jCCMSMbXLh3q/BmzwI
RHH8JAKBmP18EoFAoE0iEAi0SQQCbXKuoC94RgRiAeFXXBtqaaKjq77+TT+UDfMXBCL19fWX/aHn
bo+cke4iqXxP0rtubawkt4bf9s4o9qUnlZXFsHsgiuwn9Y0GXEGWtQA9qnAqLS0td/ivW1Qqb/J+
mKKPJafJ2JjzKUx6krEB/Sqi2DbZ0B4g47sO+ulkTWpw/M+RfQA1QZm+gROpCspkoSsyfYZicSOr
5OtjsW2UHwmUSylTLqVI00Pb1Ah/9hlhLMxwB8sgxygLk5bSEZJDvPfroeDeiM2/jFQqUqubf0l0
kIgOEfaPSLl5mVT7WMDicYo8TENWlkm1FhmJDiFHByZksUFbQ4Eg0aiVcUcDv23A7oEosk0mdgOE
QAI6nN3tikXdUAow+nS8MUrWJ3vDZLFS6aOvt5YGTIm+7jrZ95hW91PKj6SmVx6nXErBm1w5+NO/
dkpa+Ux84CKWYaiSDJWD5RuJ/DPxQRHAQ+p9Cmz+JcCJ4YjDv/T3Eh0SRAfB4awu5XVzXiZBvNbm
cVZ38jw0d0ImZVUp5WNWxpXBuByxdaAo7R3g0pcPmqExgC1hxh2tTWD3QBTZJpPng97YprdvGgQ4
X5AlI5GIZB4DGG+Ga5uA0iB1sjA7Nfq+6w2HoesGshzUBhoPM34kgcy5lII3aca0bzg1mOtBCbJS
FCJsHh7Y4+wDUA4zWcG/hG5NaXb4l52arQPDVaLuI1a9E2/aPM6r6ngeVpZOykp2DYzbOnRCl2nr
wEapmsKZKzEF6NF99ssxyh19M4ndA1EEuN/jCZgQ294xevOhT13L+JEgKJWnAqQn1yab4y1pNEiH
R2n/iGRVwlc+YPEmA6Yt6VArrS1OxuT7eP0eQmDzLx0dMusGppPgcTp5XGWBK6OUcGV0dnRcNpHc
ZHNHmT4IRDH9pE+HM2B95BDc4n5uoDxJzbZyas8PUiQZN9KLDRmIvq1cZPMm/TqInm2RKZ0RYTvL
7Ozzcdm2VCGHf5miQ0bdJbrN43TyiLLaXaI0Y+oN2lrQr2Erl5RIgg1KuaM6PrtFFNsmS1+DCdjd
8inyFxQn4NbWyRgZ/Q2c73ogQrmRZDG+BhrG00ukXMq9Nm9SUoDODdtjOrXsQAdozsOXQEPNNve+
8dXwhTabfyng4l8KHbiBZdTtf83mccq1Vp6beVmla2rJ8LiNZQy85maCUkRBqeDD30BnNT8Cyh19
rRS7B6LINikd0k0ohb+CTxKH+YSzf/jvdRgur/u+s8dIBB+jri8uJTIcZdnDEuVSCt7kkRqZ5huq
YjzLnkvlT5Q5pXz81GN834goVf5+ic2/FHDxL4UOd9YxA02vW95s8zi7x6w83+BlDY2doteHz9Nd
PVfILiYoKzdYcxtb2TtaR9uj/DLGHd0sYfdAFHk+qX/y15YD6WjumzvucQEf4NFiM35Qr595KjCX
LWOW9yL9GlFkmwTVnmjdc70yd3XI8fzkKuLgG5m5Xanm6Fy2zBR+YQ9RfJtEIBCLaj6JQCDQJhEI
BNokArGcbXIeuRN68VVAIIpsk2oZfb1VCveBzR3UIvSBQCTrV+3Omt337nLlPVNoUDZNnjNzRsJM
T7oHH3Aglo5NUv4ktCQqNlzn8Cfja3OzIxrn78uQm7hSYz3TyxVAi2wcQ7+KWDI2SfmTBAOwz+ZP
6snbTLsP6yFJ0WnMSUo85FxDi5OopHESicyu9NiTPJ/YJ/iY1JHtJZm0YCpXkshHuItrkDWiTUAh
yXpYspmWjIdZq0ixrHxKUh+VjoDgXYImS0oM1ksH8awjFjPc3/7w79lVD91Qc0Z/HPY+xF4d/+jP
vxpseALqu+n/O8qjFXcl4H4pVDIBP9d9FWMT3fUtNOXe4Gj5DxJQf+L4P1ayuCFE5pcT4AuPlcVL
oL732Ee2TIh8qgHlwThMPr3zpl9NsIKjT2x71N+zLTIJ6lt30jQuT4umSr0TgInQ2Kl/T8IdY9Dy
nhJW3+++N7KrBHzSUGVSqKD63XUR1N927HvfTNCkyae/T+uaDEUrLuuEod8gLxKxVPxk8nzqtiIX
vPAHmz+5TQLps1a6iEH5icPEZmGccw05zE4endLmJHKZG1I4jnyf4EO6uJC3ac2Ufdns8B5tTiQt
mvjWbyZjsXEAJQDN/BIiOJeJwwH7NfQMPiVldfKDEHWV6lrnHoDYJ/CsIxYz0viTETL/im2X94gX
4vSPTxGRf9cymIdgcQ1zcBIhjePo0CXb46lcSA+upC1P9ej4UBJaNrPkVjMHLTKFT+noJOrSz56Y
quznREsEYkn4SR+frClkPikeMLz2fEtLy35reCuYh5zyJLiGKSkOuEwqx7HNpkvG0/mYVjEpsSqt
WSzA+rGT4S082bQFPWiRqRn7LAakqEsb6yv7c3x0glhKNln6GlvUQKnFn9x2L/lzX63lR3kMSqnB
lAEmSlnkySycRC6TynHk+wQfMpWPKeDwHoWVUaXWEGU0rZc47HETdvHrg+BcBlabwax8SlgD5/Eb
TqKubZoGD5HdSMFCLBmblA7RIZ/0FweOAedP6skryd8rk8K19FTL8R4AI/aZIYC90To67M3CSTTG
qUwqv5LnE3zIVD6mgMN7pOA8ySeSAIdjUlUZKaBS/jRnWgoe5lvxsqez8ilhSBnjzA5R14uxQJQo
kHwczzpiqcwn54s/OSvoZz63fi7L67gYaZGIJWOT88WfnB1iD9wyl8WV9St41hFLxiYRCMSimk8i
EAi0SQQCgTaJQKBNFgn6NNsIxGK3SbUMahTp+qlBmz9J+ZRKrQeBMhujMnaPx05NrpiJblkYkDmF
U9b+KU3mnwpiWmL8SUTRbVLfaNSO+E/es2WlO/7kySB/hy6Do+gZBFJt9NgbHRqZhYoz52e+nrld
ANPSbgMEolg22dAe+NLmoKa0RN3xJzVjyvaMnB+ph+S9Ykel4D1er3Ivc1BeD5EYi/ko4kqSPJGm
7TSPwraCEFHloNoq0ziWtQpbZIlHCbUhhTMghZzgUQLlRkrBva76JfEegFjj/ErKq9TDrDTG57SY
lmF3fMvs9WjyauwfiOLaZGI3fA7e5Ouu+JOuCB9W3Mi+p6w9vftojMjSO4QV/dmTtIufDFS74kr2
0cCPqhxXVpKNkl5iMX2h+Ef7aBzLU+H40Chki0cJ8eNlfE3IjYZM/TK24zo9oWx36n/i5CDPUS2x
NR7nktU7FL93FcC75Yob7ciVUiLA4k2y+JY56nkS42ohimyTyfOhCYTDccWf/KAjwfmRSqd2m9jR
zXmP3dY3wz9BKZg92uG4E1fyMCtRcC+hS6PxHvWN3SyO5fgAMMKldzxKUno/XxNygkdJsEcBo8mp
f61Vf7yLrbliWgbg2oTF3bRkgOon4lvmqOd8tElEEZDGn9wy9agwSjv+JNScirs4iuTnxJQUO6is
EwTSIi5CeqzJgJkSqpIyG2uSFztRLdPjUboYkFxO8Cjp4HTVNQ9syl6/U7fDuYQ8AlCm1ZNvUAUE
Yp78pE+HF+A8cbPG2T2QnseJKWnf2rHldb51jUesSY94jpUw8Gtwy0BKvlqLlSnkBI+S4CzfT055
1X+NnhbnUnAu21J5nGk3b7LUg7d4EMW2ydLXYKhtXG+NhFPiT6r+tDyxBqhJ2SHXw6o2tibRuecq
WF2REWtSSY/6yEbLT8eqXX46LR4ljMF5sltO8CjpBDTQ6YoOKa9m4TAJKhrAFeeyzbQ4l5y72cYu
JcE1sDqYokaWehQMQIkosk1KhyBQkVyx9aUesONPRiJSfDgtjxGXU11ed1L2XcPWHj+D+tHrk7e5
40pS9FRL45kfhRz+Ud1jrnLT4lFCpxI74pYTPEqCodHPuxhX3aYszOe26653xbkMlIFRKVHOJedz
Bljm7vj15mCKGlnqccfgRCCKMZ+cDX9STURZEXWt6yMty6NpkGmJKLpNzpg/ORWcDAxzc9YSo8vl
G1SLiEOKOG1tEoFALKr5JAKBQJtEIBBokwjE6WWT+oySCs2iu5Pw4T5iGcEdwwfU0s319Sc+3RmD
MnEbNdKdZzmO4LeTWYWiHbMsTfMnnP33JC1ZUq6XomJfepJ1bAjEoveTPP7kyV0frJkNd7Axe9Lr
syzNFYuy0YpPSbkeyItELFOb5PEntU6IufmTgmdo0liPlHtYZvKYkbtijLsYaWVsRKARIOkapSiK
OJLgyNNyeJISVJ14laokazWckxm2WJMkjT6fceJbCq4kwWpJc/az8ioVUS7yIhHL0SYTu9lChmQK
f5LzDFU5qjLuYSl9I/Spvr2frutl/MNtJyX+zmq1kZC+wEiK1Z2mLPYJeeGwKI+ybCPASiUepHn1
k0PjCc6d5DxHgpX39dH4kZcNmqExlsXmSoL5tms/Y0P6T4hyAXmRiGVokyz+JPEmMJnCHeQ8Qx7r
0eIe3qY1bzrM+Yc9WtdV3AICYPwbW7PiSDryNgRHUsSrNDRlo+Bkcp4jlbhSo2+jOvEtLa4kj0WZ
EvcSOl1vvyEvErEs4BF/Uv9Ye9zFn0wlN6ZyD1PiPqaSFtvjmfK5igHGcwSbAunEtxRcSRCxKNPj
XkZakBeJWK5+UsSfjNNYdxm3QTi5MZN76HAX21JIi7zbO/K6u5iMeJWu2JI+nsWJb+niSuppcS9T
gLxIxLKzSR5/Ul8BT3lwB3msx0zuIajQwMmHQRPUMPF2Ha44kkK+tVWnk8U20+JIpserdMWWjDUw
MqQT39LhStJYlM5+JyIs8iIRy9QmefzJFZ/9r2YP7iCP9TiYwT0ETUrwPYNV148TS5Q3u+JICvmR
LYyXSPmMnCOZHq/S4jnStUSQyjrxLcM2V5LGonT287iTAMiLRCzb+eSM+JMLyZacm1iUyItELGq4
3+PZMRi3Jnnv+/d/ybOAExMLp+yOU3/81OxLyf/YEIgi+0kEArG45pMIBAJtEoFAoE0iEMvWJvUF
yDG7fAjEkkMmf5Kgu0zEXjQrfP5w3w4rPZ2JmIW3mAPfTnrn0MZKZpIvC0Pyng4MHYlYFn6S8ycJ
wNjAHVPFv/S1WZ8Y98DrBQeHbMwStnIsOaN8AulJjWPoVxHLwiY5f5Ii8FtOn5z4uLZ+ZNyK58is
JyOeo1ILpuLiP1JOo5AX3Eo9JInYk4LpaMexDO7lrKqGWGBG+YgeIc6QrAnK9Avomixti8F66SCe
WcRyGLv69+yqBz4MrI3zV0j/LXTKPwFw7+++N7KrBOq74Y6xqQc+HIf7pdAvJ7rrW8guUx6vKYmL
/QT1//DADkv+zhP3BuNwR3m04q4E1J/suZHlgPoTx/+xcgLuKOvZ1cfq81WNzShf/W3HvvfNBE2a
fHrnTb+agMlQVL+sE4Z+k8BTi1gGfpLxJyMEAG/yseSxoUSI+MGc8RzbEvBlycV/hCs1W95g3Ep3
7EkOwZk8rH2Db0+8ObN8MKgNcDbJeDNc2wRQqsc69wDEPoFnFrFU4cGfZLADDHRc3rgnZzxHvS6+
bY+L/8j4i7a84FZmkiidOJbghK0sNJ+LIVmbbI63gH72xFRlv0t9BGIp+0mf6+uM/DaorMP6ob25
4zlqd1a1uvmPlhSVF9EgM9iSdn0iS4k+s3zQZ0W1rJza8wOqzFhf2Z/joxPEcrFJzp9kOI9TDMdX
63ql7I4J6RHP8Z/X9rv5j8zjCnnOrXTFnmx3W8v4avhCW0rNheaDNXAef+yRHDj/brLYFtPgIbJb
wjOLWA42yfmTbD6Z4J3amKz7fPKoHc8RwCue41vtMTf/kcKS1yTKaOypluOCLelwHmlZCfn73A9K
22eWD4aUfzTYynB53ffJ4kUtMEoUSz6OZxaxHOaTDn/SLJ8TiuH03EotxtycfuapwEzyZQEyJBHL
xCad+JNTmjEXhU9zp6UiDr4RbouqOTqjfN4o68fIkYjlYZMIBGJRzScRCATaJAKBQJtEIJa+TeIz
eARioeDFn+y2+Yexcv+n796VnfaYhb+IQCDmxE9a/Embf9hW9XT8F1trc8aUpGjBdkQg5sMmbf6k
xT+8ItwMA+EvcfJi7HpXnMhIFaeJePMXEQjEnNikiD9J8PafsUXybbr+OR7g8Yw73HEiS3qZxHtO
hFayldGn441RgGgoceAvsFURiLmxSYs/afMPm6jfDEzx1NQ4kYLTmIW/iEAgZgr3PR7fN6AeWrq7
AXb8nkUcWP3yDjJaPdDNOP43Al1cXF9ff2SSbRHU95ASJuh+s7p0y0Q3vP0d+S5tDJsVgZgTP+nw
J8XKC2vInzV/6pZP5Ulm4y8iEIi5sEmHPyn4h0PRWqj52P9iMSUFUnmS2fiLCARiLmyS8Se5hXH+
YWDvqHzVpwIspqRAKk8yG38RgUDMFJ78SeQfIhCLwiZt/iTyDxGIxWGTCARiUc0nEQgE2iQCgUCb
RCDQJhEIBNokAoE2iUAg0CYRCLRJBAKBNolAoE0iEAi0SQQCgTaJQKBNIhCIXPj/AXj0eMnD+QG3
AAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2016-08-10 13:40:35 +1200" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-003.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Mannitol vs placebo / no treatment, outcome: 3.2 Pregnancy rate.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5kAAAEQCAMAAAANqEAtAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-07-14 22:42:39 +1200" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-06-14 15:22:56 +1200" MODIFIED_BY="Helen E Nagels" NO="1">
<TITLE MODIFIED="2016-06-14 15:22:35 +1200" MODIFIED_BY="Helen E Nagels">CGF database search (formerly MDSG)</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-14 15:21:57 +1200" MODIFIED_BY="Helen E Nagels">
<P>
<B>MDSG search strategy iv fluids for OHSS </B>15.09.15</P>
<P>Keywords CONTAINS "ovarian hyperstimulation" or "ovarian hyperstimulation syndrome " or "OHSS" or Title CONTAINS" ovarian hyperstimulation" or "ovarian hyperstimulation syndrome " or "OHSS"</P>
<P>AND</P>
<P>Keywords CONTAINS "human albumin" or "human serum albumin" or "human sera" or "albumin" or "hydroxyethyl starch" or "hydroxyethyle starch" or "intravenous albumin" or "intravenous fluids" or "intravenous" or "Calcium" or "calcium gluconate" or "starch solution" or "mannitol" or Title CONTAINS "human albumin" or "human serum albumin" or "human sera" or "albumin" or "hydroxyethyl starch" or "hydroxyethyle starch" or "intravenous albumin" or "intravenous fluids" or "intravenous" or "Calcium" or "calcium gluconate" or "starch solution" or "mannitol"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-06-14 15:22:56 +1200" MODIFIED_BY="Helen E Nagels" NO="2">
<TITLE MODIFIED="2009-09-21 20:55:29 +1200" MODIFIED_BY="[Empty name]">Cochrane Central Register of Controlled Trials</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-14 15:20:48 +1200" MODIFIED_BY="Helen E Nagels">
<P>Database: EBM Reviews - Cochrane Central Register of Controlled Trials &lt;02.09.2015&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 exp Ovarian Hyperstimulation Syndrome/ (143)<BR/>2 Ovarian Hyperstimulation Syndrome.tw. (309)<BR/>3 OHSS.tw. (227)<BR/>4 or/1-3 (408)<BR/>5 exp Serum Albumin/ (1044)<BR/>6 Albumin$.tw. (6084)<BR/>7 human sera.tw. (24)<BR/>8 colloid$.tw. (1276)<BR/>9 exp starch/ or exp hetastarch/ (1018)<BR/>10 hydroxyethyl$.tw. (1018)<BR/>11 (starch or hetastarch).tw. (1567)<BR/>12 HES.tw. (583)<BR/>13 haemacel.tw. (1)<BR/>14 Haemaccel.tw. (52)<BR/>15 exp Calcium Gluconate/ (43)<BR/>16 Calcium.tw. (13188)<BR/>17 intravenous fluid$.tw. (533)<BR/>18 iv fluid$.tw. (204)<BR/>19 exp Infusions, Intravenous/ (8755)<BR/>20 exp Fluid Therapy/ (1127)<BR/>21 exp mannitol/ (375)<BR/>22 mannitol.tw. (782)<BR/>23 (osmitrol or osmofundin).tw. (0)<BR/>24 or/5-23 (32416)<BR/>25 4 and 24 (41)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-06-14 15:22:56 +1200" MODIFIED_BY="Helen E Nagels" NO="3">
<TITLE MODIFIED="2010-11-21 13:46:01 +1300" MODIFIED_BY="[Empty name]">Ovid MEDLINE®</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-14 15:20:54 +1200" MODIFIED_BY="Helen E Nagels">
<P>Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) &lt;1946 to Present&gt;02.09.2015<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 exp Ovarian Hyperstimulation Syndrome/ (1881)<BR/>2 Ovarian Hyperstimulation Syndrome.tw. (2167)<BR/>3 OHSS.tw. (1288)<BR/>4 or/1-3 (2789)<BR/>5 exp Serum Albumin/ (71943)<BR/>6 Albumin$.tw. (126452)<BR/>7 human sera.tw. (6398)<BR/>8 colloid$.tw. (41622)<BR/>9 exp starch/ or exp hetastarch/ (33340)<BR/>10 hydroxyethyl$.tw. (12274)<BR/>11 (starch or hetastarch).tw. (27745)<BR/>12 HES.tw. (4360)<BR/>13 haemacel.tw. (6)<BR/>14 Haemaccel.tw. (249)<BR/>15 exp Calcium Gluconate/ (937)<BR/>16 Calcium.tw. (311984)<BR/>17 intravenous fluid$.tw. (4082)<BR/>18 iv fluid$.tw. (1017)<BR/>19 exp Infusions, Intravenous/ (49843)<BR/>20 exp Fluid Therapy/ (15810)<BR/>21 exp mannitol/ (11611)<BR/>22 mannitol.tw. (15517)<BR/>23 (osmitrol or osmofundin).tw. (1)<BR/>24 or/5-23 (649695)<BR/>25 4 and 24 (178)<BR/>26 randomized controlled trial.pt. (411031)<BR/>27 controlled clinical trial.pt. (91630)<BR/>28 randomized.ab. (334732)<BR/>29 placebo.tw. (173207)<BR/>30 clinical trials as topic.sh. (178556)<BR/>31 randomly.ab. (241080)<BR/>32 trial.ti. (147726)<BR/>33 (crossover or cross-over or cross over).tw. (66041)<BR/>34 or/26-33 (1021994)<BR/>35 exp animals/ not humans.sh. (4113129)<BR/>36 34 not 35 (941700)<BR/>37 25 and 36 (36)</P>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-08-18 10:26:44 +1200" MODIFIED_BY="jane clarke">EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2016-08-19 10:05:08 +1200" MODIFIED_BY="[Empty name]">
<P>Database: Embase &lt;1980 to 2015 Week 37&gt; 02.09.2015<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 exp ovary hyperstimulation/ (6927)<BR/>2 Ovarian Hyperstimulation.tw. (5643)<BR/>3 OHSS.tw. (2090)<BR/>4 or/1-3 (8564)<BR/>5 exp Serum Albumin/ (28111)<BR/>6 Albumin$.tw. (147231)<BR/>7 colloid$.tw. (42324)<BR/>8 exp starch/ or exp hetastarch/ (25916)<BR/>9 exp starch/ (20467)<BR/>10 exp hetastarch/ (5626)<BR/>11 hydroxyethyl.tw. (10802)<BR/>12 (starch or hetastarch).tw. (31085)<BR/>13 HES.tw. (6162)<BR/>14 haemacel.tw. (32)<BR/>15 Haemaccel.tw. (436)<BR/>16 exp gluconate calcium/ (4508)<BR/>17 calcium.tw. (353894)<BR/>18 intravenous fluid$.tw. (5388)<BR/>19 iv fluid$.tw. (2002)<BR/>20 exp infusion fluid/ (22326)<BR/>21 exp mannitol/ (25703)<BR/>22 mannitol.tw. (17118)<BR/>23 (osmitrol or osmofundin).tw. (63)<BR/>24 or/5-23 (647541)<BR/>25 4 and 24 (270)<BR/>26 Clinical Trial/ (850170)<BR/>27 Randomized Controlled Trial/ (382698)<BR/>28 exp randomization/ (67925)<BR/>29 Single Blind Procedure/ (20923)<BR/>30 Double Blind Procedure/ (123268)<BR/>31 Crossover Procedure/ (44330)<BR/>32 Placebo/ (262629)<BR/>33 Randomi?ed controlled trial$.tw. (123047)<BR/>34 Rct.tw. (18107)<BR/>35 random allocation.tw. (1447)<BR/>36 randomly allocated.tw. (23181)<BR/>37 allocated randomly.tw. (2054)<BR/>38 (allocated adj2 random).tw. (736)<BR/>39 Single blind$.tw. (16320)<BR/>40 Double blind$.tw. (154326)<BR/>41 ((treble or triple) adj blind$).tw. (482)<BR/>42 placebo$.tw. (220002)<BR/>43 prospective study/ (305847)<BR/>44 or/26-43 (1499732)<BR/>45 case study/ (33720)<BR/>46 case report.tw. (290494)<BR/>47 abstract report/ or letter/ (936759)<BR/>48 or/45-47 (1254488)<BR/>49 44 not 48 (1459953)<BR/>50 49 and 25 (76)</P>
<P>
<BR/>
<BR/>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-06-14 15:22:54 +1200" MODIFIED_BY="Helen E Nagels" NO="5">
<TITLE MODIFIED="2010-11-21 13:45:24 +1300" MODIFIED_BY="[Empty name]">Ovid PsycINFO</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-14 15:21:02 +1200" MODIFIED_BY="Helen E Nagels">
<P>Database: PsycINFO &lt;1806 to September Week 1 2015&gt; 02.09.2015<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 Ovarian Hyperstimulation Syndrome.tw. (4)<BR/>2 OHSS.tw. (6)<BR/>3 or/1-2 (8)<BR/>4 exp Serum Albumin/ (210)<BR/>5 Albumin$.tw. (1205)<BR/>6 colloid$.tw. (193)<BR/>7 (starch or hetastarch).tw. (286)<BR/>8 hydroxyethyl.tw. (47)<BR/>9 HES.tw. (436)<BR/>10 haemacel.tw. (0)<BR/>11 Haemaccel.tw. (0)<BR/>12 calcium/ or calcium.tw. (11395)<BR/>13 intravenous fluid$.tw. (103)<BR/>14 iv fluid$.tw. (35)<BR/>15 Intravenous Infusion$.tw. (531)<BR/>16 mannitol.tw. (127)<BR/>17 or/4-16 (14271)<BR/>18 3 and 17 (0)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-06-14 15:22:53 +1200" MODIFIED_BY="Helen E Nagels" NO="6">
<TITLE MODIFIED="2016-06-14 15:22:42 +1200" MODIFIED_BY="Helen E Nagels">CINAHL</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-14 15:21:16 +1200" MODIFIED_BY="Helen E Nagels">
<P>CINAHL search strategy for PMA481 02.09.15</P>
<TABLE COLS="3" ROWS="23">
<TR>
<TD>
<P>
<B># </B>
</P>
</TD>
<TD>
<P>
<B>Query </B>
</P>
</TD>
<TD>
<P>
<B>Results </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>S22</P>
</TD>
<TD>
<P>S4 AND S21</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>S21</P>
</TD>
<TD>
<P>S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20</P>
</TD>
<TD>
<P>45,131</P>
</TD>
</TR>
<TR>
<TD>
<P>S20</P>
</TD>
<TD>
<P>TX Fluid* N2 Therap*</P>
</TD>
<TD>
<P>4,743</P>
</TD>
</TR>
<TR>
<TD>
<P>S19</P>
</TD>
<TD>
<P>(MM "Infusions, Intravenous")</P>
</TD>
<TD>
<P>1,111</P>
</TD>
</TR>
<TR>
<TD>
<P>S18</P>
</TD>
<TD>
<P>TX iv fluid*</P>
</TD>
<TD>
<P>291</P>
</TD>
</TR>
<TR>
<TD>
<P>S17</P>
</TD>
<TD>
<P>TX intravenous fluid*</P>
</TD>
<TD>
<P>1,060</P>
</TD>
</TR>
<TR>
<TD>
<P>S16</P>
</TD>
<TD>
<P>TX Calcium or (MM "mannitol")or TX mannitol</P>
</TD>
<TD>
<P>26,628</P>
</TD>
</TR>
<TR>
<TD>
<P>S15</P>
</TD>
<TD>
<P>(MM "Calcium")</P>
</TD>
<TD>
<P>3,739</P>
</TD>
</TR>
<TR>
<TD>
<P>S14</P>
</TD>
<TD>
<P>TX Haemaccel</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P>S13</P>
</TD>
<TD>
<P>TX haemacel</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>S12</P>
</TD>
<TD>
<P>TX hetastarch</P>
</TD>
<TD>
<P>73</P>
</TD>
</TR>
<TR>
<TD>
<P>S11</P>
</TD>
<TD>
<P>TX starch</P>
</TD>
<TD>
<P>1,393</P>
</TD>
</TR>
<TR>
<TD>
<P>S10</P>
</TD>
<TD>
<P>TX hydroxyethyl</P>
</TD>
<TD>
<P>696</P>
</TD>
</TR>
<TR>
<TD>
<P>S9</P>
</TD>
<TD>
<P>(MM "Hydroxyethyl Starch")</P>
</TD>
<TD>
<P>388</P>
</TD>
</TR>
<TR>
<TD>
<P>S8</P>
</TD>
<TD>
<P>TX colloid*</P>
</TD>
<TD>
<P>1,185</P>
</TD>
</TR>
<TR>
<TD>
<P>S7</P>
</TD>
<TD>
<P>TX human sera</P>
</TD>
<TD>
<P>89</P>
</TD>
</TR>
<TR>
<TD>
<P>S6</P>
</TD>
<TD>
<P>TX Albumin*</P>
</TD>
<TD>
<P>10,636</P>
</TD>
</TR>
<TR>
<TD>
<P>S5</P>
</TD>
<TD>
<P>(MM "Serum Albumin")</P>
</TD>
<TD>
<P>836</P>
</TD>
</TR>
<TR>
<TD>
<P>S4</P>
</TD>
<TD>
<P>S1 OR S2 OR S3</P>
</TD>
<TD>
<P>278</P>
</TD>
</TR>
<TR>
<TD>
<P>S3</P>
</TD>
<TD>
<P>TX OHSS</P>
</TD>
<TD>
<P>79</P>
</TD>
</TR>
<TR>
<TD>
<P>S2</P>
</TD>
<TD>
<P>TX Ovarian Hyperstimulation Syndrome</P>
</TD>
<TD>
<P>265</P>
</TD>
</TR>
<TR>
<TD>
<P>S1</P>
</TD>
<TD>
<P>(MM "Ovarian Hyperstimulation Syndrome")</P>
</TD>
<TD>
<P>140</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2016-06-14 15:22:15 +1200" MODIFIED_BY="Helen E Nagels" NO="7">
<TITLE MODIFIED="2016-06-14 15:22:15 +1200" MODIFIED_BY="Helen E Nagels">Pubmed</TITLE>
<APPENDIX_BODY MODIFIED="2015-11-30 14:27:12 +1300" MODIFIED_BY="[Empty name]">
<P>search up to 29.07.2015</P>
<P>ohss and albumin (16 hits)</P>
<P>ohss and calcium (5 hits)</P>
<P>ohss and intravenous (18 hits)</P>
<P>ohss and starch (4 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2016-06-14 15:22:21 +1200" MODIFIED_BY="Helen E Nagels" NO="8">
<TITLE MODIFIED="2016-06-14 15:22:21 +1200" MODIFIED_BY="Helen E Nagels">ICTRP</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-14 15:21:37 +1200" MODIFIED_BY="Helen E Nagels">
<P>search up to 29.07.2015</P>
<P>ohss and albumin (4 hits)</P>
<P>ohss and calcium (3 hits)</P>
<P>ohss and mannitol (0 hits)</P>
<P>ohss and intravenous (1 hits)</P>
<P>ohss and starch (2 hits)</P>
<P>ohss and fluid* (1 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2016-06-14 15:22:27 +1200" MODIFIED_BY="Helen E Nagels" NO="9">
<TITLE MODIFIED="2016-06-14 15:22:27 +1200" MODIFIED_BY="Helen E Nagels">Clinicaltrials.gov</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-14 15:21:49 +1200" MODIFIED_BY="Helen E Nagels">
<P>search up to 29.07.2015</P>
<P>ohss and albumin (4 hits)</P>
<P>ohss and mannitol (0 hits)</P>
<P>ohss and calcium (3hits)</P>
<P>ohss and intravenous (2 hits)</P>
<P>ohss and starch (1 hits)</P>
<P>ohss and fluid* (13 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-07-14 22:42:39 +1200" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;48 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;165 records screened&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;165 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;289 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;duplicates n = 124&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;117 records discarded because of ineligibility based on title and/or abstract&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;39 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>